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  Abstract 
Head and neck cancer is the 6th most common cancer and is generally 
treated with surgery and post surgical radiotherapy (RT) alone or in combination 
with chemotherapy (CT). Over 50% of the patients fail to respond to such treatment 
while suffering the undesirable side effects of radio-chemotherapy. This highlights 
the need for new strategies to be able to select patients who could benefit from a 
specific treatment type to spare cost and suffering to the patients.  Furthermore, 
there is need for targeted and effective therapeutics for this disease. TRAIL and 
Smac mimetics are novel promising anticancer agents. However, their effect on 
head and neck cancers so far has not been tested.  
The main objective of this research was to investigate biomarkers which 
could predict response of head and neck squamous cell carcinoma (HNSCC) to 
novel and conventional therapies. This has been conducted using two different 
approaches: 
The first was to test the sensitivity of HNSCC cell lines to two novel 
anticancer therapeutic agents, TRAIL and Smac mimetics, and further to identify 
the biomarkers which could predict response of HNSCC cell lines to these drugs. 
Furthermore, the underlying mechanisms by which these two agents induce 
apoptosis in HNSCC cell lines were examined. Nine HNSCC cell lines were tested 
for their sensitivity to either recombinant TRAIL (h-IZTRAIL) and/or Smac 
mimetic (Smac59). The pathways involved in their apoptotic response were studied 
using western blotting, enzyme linked immunosorbent assays and FACS analysis. 
Overexpression and knockdown experiments were used to examine the importance 
of certain apoptotic regulators in response to TRAIL and Smac59 treatment. All 9 
HNSCC cell lines were found to be successfully killed with either TRAIL or 
Smac59. TNF-α, caspase8, bcl2 and EGFR expression levels correlated with 
TRAIL/Smac59 sensitivity. There was no correlation between the expression of 
inhibitor of apoptosis proteins (IAPs) or TRAIL receptors with Smac59/TRAIL 





The second part of the study was a retrospective study to assess response of 
HNSCC to treatment (surgery and/or radiotherapy) by selecting patients who have 
been treated with surgery and/or radiotherapy and for whom 5 years follow up data 
was available. For this part of the project, paraffin embedded formalin fixed 
biopsies from HNSCC patients were used to construct tissue microarray blocks. The 
expression of a number of genes involved in the DNA damage repair pathway and 
tumour hypoxia including PTEN, Ku80, Rad51, XRCC1, ERCC1 and HIF-1α was 
tested using immunohistochemistry staining IHC. The tested genes were found to be 
expressed at varying levels in HNSCC patients. Associations between the level of 
the expression and gender, site of origin, tumour differentiation, TNM stage, lymph 
node metastases, overall and disease free survival and treatment outcome were 
investigated using statistical analysis programme SPSS. Using univariate analysis, 
ERCC1 expression was significantly associated with poor outcome to treatment. 
HIF-1α high expression was significantly associated with short disease free survival 
and poor treatment outcome. Using multivariate analysis, PTEN expression was 
significantly associated with poor treatment outcome.   
In summary, it could be concluded that HNSCC cell lines could be killed 
effectively using TRAIL and Smac59 and their sensitivity could be predicted by 
level of caspase-8, TNF-α, Bcl-2 and EGFR proteins. TRAIL and Smac59 induce 
caspase-dependent apoptosis in HNSCC cell lines which consequently results in 
depletion of XIAP. Smac59 induces TNF-α autocrine secretion in Smac59 sensitive 
cell lines and adding rhTNF-α sensitised Smac59 resistant cells to Smac59. miRNA 
expression could be a marker for sensitivity of HNSCC cell lines to TRAIL and 
Smac59, however more investigation is required to validate this finding.  
In conclusion, these findings suggest a potential molecular signature that 
may be able to predict response of head and neck cancers to TRAIL and Smac59 for 
the treatment of HNSCC.  Expression of genes involved in DNA damage repair and 
tumour response to hypoxia could be potential biomarkers for patient’s prognosis 
and response to treatment. 




Table of Contents 
 
Abstract ................................................................................................................................. 2 
List of figures ........................................................................................................................ 9 
List of tables ........................................................................................................................ 11 
Acknowledgments ............................................................................................................... 12 
List of abbreviations ........................................................................................................... 13 
1 Introduction ................................................................................................................... 17 
1.1 Head and neck squamous cell carcinoma (HNSCC) ........................................ 17 
1.1.1 Definition and incidence ................................................................................... 17 
1.1.2 Pathogenesis ...................................................................................................... 18 
1.1.3 Risk factors ....................................................................................................... 19 
1.1.4 Histopathological features................................................................................. 19 
1.1.5 Prognosis ........................................................................................................... 19 
1.1.6 Treatment .......................................................................................................... 20 
1.2 Cell death ......................................................................................................... 22 
1.2.1 Necrosis............................................................................................................. 22 
1.2.2 Apoptosis .......................................................................................................... 23 
1.2.3 Inhibitor of apoptosis protein (IAPs) family ..................................................... 26 
1.2.4 Caspases (cysteine-aspartate proteases) ............................................................ 28 
1.2.5 Cellular FLICE inhibitory protein (cFLIP) ....................................................... 32 
1.2.6 Bcl-2 family proteins ........................................................................................ 32 
1.2.7 Nuclear factor kappa-light-chain enhancer of activated B cells (NF-κB) ......... 35 
1.2.8 Tumour necrosis factor-related apoptosis inducing ligand (TRAIL) ................ 36 
1.2.9 Second mitochondria-derived activator of caspases, direct IAP-binding protein 
with low PI (Smac/DIABLO) ........................................................................... 42 
1.2.10 TNF-alpha ......................................................................................................... 45 
1.3 DNA damage repair ......................................................................................... 46 
1.3.1 Excision repair cross complementation group 1 (ERCC1) ............................... 47 
1.3.2 Hypoxia inducible factor -1alpha (HIF-1α) ...................................................... 48 
1.3.3 Ku80 .................................................................................................................. 48 




1.3.4 Phosphate and tensin homolog deleted on chromosome 10 (PTEN) ................ 49 
1.3.5 Rad51 ................................................................................................................ 50 
1.3.6 X-ray repair cross complementing 1 (XRCC1) ................................................ 50 
1.3.7 Human papilloma virus (HPV) ......................................................................... 51 
1.3.8 Cancer stem cells .............................................................................................. 52 
1.4 Aims of the current study ................................................................................. 54 
2 Materials and Methods ................................................................................................. 56 
2.1 Materials .......................................................................................................... 56 
2.1.1 Chemicals and solutions.................................................................................... 56 
2.1.2 Antibodies ......................................................................................................... 66 
2.1.3 Cell lines ........................................................................................................... 71 
2.1.4 Plasmids ............................................................................................................ 73 
2.2 Methods............................................................................................................ 74 
2.2.1 Cell culture ........................................................................................................ 74 
2.2.2 MTT cell viability assay ................................................................................... 75 
2.2.3 Western blotting ................................................................................................ 76 
2.2.4 Enzyme Linked ImmunoSorbent Essay (ELISA) ............................................. 78 
2.2.5 Transformation of plasmid DNA into competent bacterial cells ...................... 79 
2.2.6 Plasmid mini-prep ............................................................................................. 79 
2.2.7 Plasmid midi-prep ............................................................................................. 80 
2.2.8 Transfection using X-tremeGENE HP DNA Transfection Reagent ................. 80 
2.2.9 Transfection using X-tremeGENE siRNA Transfection Reagent ..................... 81 
2.2.10 Cloning of cells ................................................................................................. 81 
2.2.11 Flow cytometric analysis (FACS) for TRAIL receptor expression .................. 82 
2.2.12 Gene and mi-RNA expression profiling ........................................................... 83 
2.2.13 Patient selection ................................................................................................ 83 
2.2.14 Tissue Microarray construction (TMA) ............................................................ 84 
2.2.15 Immunohistochemistry (IHC) ........................................................................... 85 
2.2.16 Scoring of the immunohistochemistry staining................................................. 86 
2.2.17 P16 immunostaining and HPV in situ hybridization (ISH) .............................. 87 
3 Results I .......................................................................................................................... 90 




3.1 Effect of TRAIL and Smac mimetics on the viability of HNSCC cell lines ... 90 
3.1.1 TRAIL and Smac59 titration in HNSCC cell lines ........................................... 90 
3.1.2 Sensitivity of HNSCC cell lines to combined TRAIL and Smac59 treatment . 92 
3.1.3 Sensitisation of TRAIL resistant cell lines to TRAIL using Smac59 ............... 93 
3.1.4 Sensitivity of normal human keratinocytes to TRAIL and Smac59 ............... 100 
4 Results II ...................................................................................................................... 104 
4.1 Expression analysis of target proteins ............................................................ 104 
4.1.1 Inhibitors of apoptosis proteins (IAPs) ........................................................... 105 
4.1.2 Smac/DIABLO ............................................................................................... 110 
4.1.3 Bcl-2 family .................................................................................................... 110 
4.1.4 Caspases .......................................................................................................... 115 
4.1.5 Cellular FLICE-inhibitory Protein (c-FLIP) ................................................... 116 
4.1.6 Epidermal growth factor receptor (EGFR) ..................................................... 116 
4.2 Tumour necrosis factor alpha (TNF-α) and TRAIL/Smac59 sensitivity ....... 121 
4.3 TRAIL receptors and TRAIL/Smac59 sensitivity. ........................................ 122 
4.4 Gene and miRNA expression profiling .......................................................... 126 
4.4.1 Gene expression profiling ............................................................................... 130 
4.4.2 miRNA expression profiling ........................................................................... 133 
5 Results III ..................................................................................................................... 138 
5.1 Role of TNF-α in TRAIL/ Smac59 induced apoptosis .................................. 138 
5.1.1 Effect of TRAIL and Smac59 treatment on TNF-α secretion in HNSCC cell 
lines ................................................................................................................. 139 
5.1.2 Effect of adding recombinant TNF-α in HNSCC cell lines ............................ 139 
5.1.3 Effect of antagonizing TNF-α in HNSCC cell lines ....................................... 140 
5.2 Role of Bcl-2 in TRAIL/Smac59 induced apoptosis ..................................... 146 
5.2.1 Effect of Bcl-2 overexpression on Smac59 sensitivity in Smac59 sensitive cell 
lines ................................................................................................................. 146 
5.2.2 Effect of Bcl-2 overexpression on TRAIL sensitivity in TRAIL sensitive cell 
lines ................................................................................................................. 147 
5.3 Role of IAPs in the TRAIL/Smac59 induced apoptosis ................................ 150 
5.3.1 TRAIL and Smac59 induce Caspase dependant cell death ............................. 150 
5.3.2 Effect of TRAIL and Smac59 on IAPs expression in HNSCC cell lines ....... 151 




5.3.3 Effect of Caspase inhibitor treatment on IAPs expression .............................. 154 
5.3.4 Effect of XIAP knockdown on TRAIL and Smac59 induced apoptosis ......... 156 
6 Results IV ..................................................................................................................... 161 
6.1 Patients and carcinomas ................................................................................. 162 
6.1.1 Clinical and pathological characterization ...................................................... 163 
6.2 Immunohistochemical staining ...................................................................... 167 
6.2.1 ERCC1 Immunostaining ................................................................................. 168 
6.2.2 HIF-1α immunostaining .................................................................................. 168 
6.2.3 Ku80 immunostaining ..................................................................................... 168 
6.2.4 PTEN immunostaining .................................................................................... 168 
6.2.5 Rad51 immunostaining ................................................................................... 169 
6.2.6 XRCC1 immunostaining ................................................................................. 169 
6.3 Survival analysis ............................................................................................ 173 
6.3.1 Clinical and histopathological features and survival ...................................... 173 
6.3.2 DNA damage repair genes expression and survival ....................................... 179 
6.4 Association analysis ....................................................................................... 187 
6.4.1 Association analysis in relation to treatment .................................................. 188 
6.4.2 Association analysis in relation to  treatment ................................................. 189 
6.4.3 HPV status in tonsil and pharyngeal carcinomas ............................................ 191 
7 Discussion ..................................................................................................................... 196 
7.1 TRAIL and Smac59 killed HNSCC cell lines effectively.............................. 197 
7.1.1 Smac59 sensitised TRAIL resistant cell lines to TRAIL ................................ 198 
7.1.2 TRAIL but not Smac59 was toxic to normal human keratinocytes ................ 198 
7.1.3 Protein biomarkers could predict response of HNSCC to TRAIL and     
Smac59 ............................................................................................................ 199 
7.1.4 miRNA biomarkers could predict response of HNSCC to TRAIL and    
Smac59 ............................................................................................................ 204 
7.1.5 Smac59 increased the levels of secreted TNF-α in sensitive cell lines and  
TNF-α sensitised resistant cells to Smac59..................................................... 205 
7.1.6 Bcl2 overexpression induced TRAIL resistance in TRAIL sensitive cells but 
could not protect Smac59 sensitive cells against Smac59-induced   apoptosis206 
7.1.7 TRAIL and Smac59 depleted XIAP and cIAP-1 in HNSCC .......................... 207 




7.1.8 TRAIL and Smac59 mediated XIAP depletion was Caspase dependent, while 
Smac-59 mediated depletion of cIAP-1 was caspase independent. ................ 209 
7.1.9 XIAP knockdown could not sensitise TRAIL and Smac59 resistant cell      
lines ................................................................................................................. 210 
7.1.10 Biomarkers for response of HNSCC to treatment ........................................... 211 
7.1.11 TNM stage, lymph node metastases, site of tumour and treatment were 
associated with survival and patient’s outcome. ............................................. 212 
7.1.12 ERCC1 expression was not associated with patients survival but was 
significantly associated with treatment outcome ............................................ 213 
7.1.13 HIF-1α expression in HNSCC tissues was significantly associated with disease 
free survival and patients response to treatment ............................................. 214 
7.1.14 PTEN expression in HNSCC tissues was significantly associated with overall 
survival and response of patients to treatment ................................................ 215 
7.1.15 Ku80, Rad51 and XRCC1 expression in HNSCC tissues were not significantly 
associated with survival or response of patients to treatment ......................... 216 
7.1.16 HPV status was associated with patient survival and response to treatment .. 218 
7.1.17 Conclusions .................................................................................................... 220 
7.1.18 Future work ................................................................................................... 222 














List of figures 
Figure 1.1  Apoptosis pathways in mammalian cells ........................................................... 25 
Figure 1.2  Domain structure of the mammalian IAPs ......................................................... 30 
Figure 1.3  Mammalian caspases; activation, structure and classification ........................... 31 
Figure 1.4  Bcl-2 family members ........................................................................................ 34 
Figure 1.6  Model of TRAIL mediated apoptotic signalling ................................................ 41 
Figure 2.1  Design and equipment used for tissue microarray construction ......................... 89 
Figure 3.1  Effect of Smac59 and TRAIL on HSC3, HSC3M3 and HN5 cell lines at various 
concentrations ..................................................................................................... 95 
Figure 3.2  Effect of Smac59 and TRAIL on HN30, UMSCC74A and UMSCC74B cell 
lines at various concentrations ............................................................................ 96 
Figure 3.3  Effect of Smac59 and TRAIL titration on H357, UMSCC11B and UMSCC22B 
cell lines at various concentrations ..................................................................... 97 
Figure 3.4  Effect of combined TRAIL and Smac59 treatment on HNSCC cell lines ......... 98 
Figure 3.5  TRAIL sensitisation using Smac59 in HNSCC cell lines .................................. 99 
Figure 3.6  Sensitivity of Normal Human Keratinocytes (NHK) to TRAIL and Smac59.. 101 
Figure 3.7  Sensitivity of HaCat cells to TRAIL and Smac59 ........................................... 102 
Figure 4.1  XIAP protein expression in HNSCC cell lines ................................................ 107 
Figure 4.2  cIAP-1 protein expression in HNSCC cell lines .............................................. 108 
Figure 4.3  cIAP-2 protein expression in HNSCC cell lines .............................................. 109 
Figure 4.4  Smac/DIABLO  protein expression in HNSCC cell lines ................................ 112 
Figure 4.5  Bcl-2 protein expression in HNSCC cell lines ................................................. 113 
Figure 4.6  Mcl-1 protein expression in HNSCC cell lines ................................................ 114 
Figure 4.7  Caspase-8 protein expression in HNSCC cell lines ......................................... 117 
Figure 4.8  Caspase-3 protein expression in HNSCC cell lines ......................................... 118 
Figure 4.9  c-FLIP protein expression in HNSCC cell lines .............................................. 119 
Figure 4.10  EGFR protein expression in HNSCC cell lines ............................................. 120 
Figure 4.11  level of secreted TNF-α in HNSCC cell lines ................................................ 124 
Figure 4.12  TRAIL receptors expression in HNSCC cell lines ......................................... 125 
Figure 4.13  Unsupervised hierarchical clustering of all samples and all probes for gene and 
miRNA profiling results................................................................................. 129 
Figure 4.14  Unsupervised hierarchical clustering ............................................................. 132 




Figure 4.15  Selected miRNA significantly up or down regulated in HNSCC cell lines ... 134 
Figure 5.1  Effect of TRAIL/Smac59 treatment on TNF-α secretion in HNSCC cell lines
 ....................................................................................................................... 143 
Figure 5.2  Effect of TNF-α addition on the viability of HNSCC cell lines....................... 144 
Figure 5.3  Effect of TNF-α inhibition in the HNSCC cell lines ........................................ 145 
Figure 5.4  Effect of Bcl-2 overexpression in Smac59 sensitive cells ............................... 148 
Figure 5.5  Effect of Bcl-2 overexpression in TRAIL sensitive cell lines .......................... 149 
Figure 5.6  TRAIL and Smac59 induce Caspase dependant apoptosis. ............................. 152 
Figure 5.7  Effect of TRAIL and Smac59 on XIAP and cIAP-1 expression in HNSCC cells
 ....................................................................................................................... 153 
Figure 5.8  Effect of caspase inhibitor on IAPs expression with TRAIL/Smac59 treatment
 ....................................................................................................................... 155 
Figure 5.9  Effect of XIAP knockdown using siRNA on TRAIL/Smac59 sensitivity ....... 158 
Figure 5.10  XIAP knockdown stable clones ..................................................................... 159 
Figure 6.1  Clinical and histopathological characteristics of study cases and carcinomas . 165 
Figure 6.2  Clinical and histopathological characteristics of study cases and carcinomas . 166 
Figure 6.3  ERCC1 and HIF-1α expression in HNSCC tissues .......................................... 170 
Figure  6.4  Ku80 and PTEN expression in HNSCC tissues .............................................. 171 
Figure 6.5  Rad51 and XRCC1 expression in HNSCC tissues ........................................... 172 
Figure 6.6  Cox Regression survival analysis graphs of the study cases. ........................... 176 
Figure 6.7  Cox Regression survival analysis graphs of the study cases. ........................... 177 
Figure 6.8  Cox Regression survival analysis graphs of the study cases. ........................... 178 
Figure 6.9  Survival analysis in relation to ERCC1 expression in HNSCC. ...................... 181 
Figure 6.10  Survival analysis in relation to HIF-1α expression in HNSCC ...................... 182 
Figure 6.11  Survival analysis in relation to PTEN expression in HNSCC ....................... 183 
Figure 6.12  Survival analysis in relation to Rad51 expression in HNSCC ....................... 184 
Figure 6.13  Survival analysis in relation to XRCC1 expression in HNSCC ..................... 185 
Figure 6.14  Survival analysis in relation to Ku80 expression in HNSCC ......................... 186 
Figure 6.15  Scatter plot of disease free survival of study cases ........................................ 187 
Figure 6.16  P16 immunostaining and HPV ISH in tonsil carcinomas .............................. 193 
Figure 6.17  Survival analysis in relation to HPV status .................................................... 193 
 




List of tables 
 
Table 3.1 Characteristic features of HNSCC cell lines ........................................................ 94 
Table 4.1  Data summary of the samples used for the gene expression profiling .............. 128 
Table 4.2  Selected miRNA significantly up or down regulated in HNSCC cell lines ...... 133 
Table 4.3 List of miRNA target genes differentially expressed in TRAIL sensitive/Smac 
resistant cells  ................................................................................................... 136 
Table 6.1  Sub-site distribution of the study cases ............................................................. 162 
Table 6.2  Clinical and histopathological characteristics of the study cases and     
carcinomas ........................................................................................................ 164 
Table 6.3  P values, Odds Ratios (OR) and 95% confidence interval (CI) for the survival 
analysis of the study cases ................................................................................ 175 
Table 6.4  P values, Odds Ratios (OR) and 95% confidence interval (CI) for the survival 
analysis of the study cases ................................................................................ 180 
Table 6.5  Left: Chi-square/Exact test p values. Right: logistic regression results of response 









I would like to thank my great supervisors; Prof. Mahvash Tavassoli and Prof. 
Edward Odell for their unlimited continuous guidance and support all the way from 
starting my PhD to the writing of this thesis. 
I would like to thank Prof. Delia Dominico and Prof. Henning Walczak for their 
generosity in providing Smac59 and TRAIL I have used in my research. As well I 
would like to thank Dr Daniele Lecis for his endless help and Dr Kerstin Papenfuss 
for all her technical support. 
I would like to express my gratitude to Dr Katherine Lawler for doing the 
bioinformatics and Prof. Nora Donaldson for her guidance and help in performing 
the statistical analysis. 
I would like to thank people in Oral Pathology lab and in particular Claire Lock for 
their technical help with cutting and staining formalin fixed paraffin embedded 
sections. 
Special thanks go to my colleagues in the lab, Angela, Marcella, Pat, Adeel, Daryl, 
Jessica, Yae-Eun, Zuraiza and Bushra for being such great friends   
I would like to thank the Egyptian government for sponsoring me and giving me the 
opportunity to study in such great university like King’s College London. And 
special thanks go to my colleagues and professors at Oral Pathology Department, 
Tanta University.  
Finally, I would like to express my love, gratitude and appreciation to my beloved 
family; my mother and sisters, their support and prayers kept me going during my 
study. So much love and appreciation goes to my dear husband for his endless 
understanding, support and love. 
Radien Hassan El-Attar, London, 2012 

































ECL    
Ammonium Persulfate  
Ala-Val-Pro-Ile 
B-cell Activating Factor 
Base Excision Repair 
Bcl-2 Homology domains 1-4 
BH3-Interacting Domain death agonist 
Baculovirus IAP Repeat 
Bovine Pituitary Extract  
BIR-containing Ubiquitin Conjugating Enzyme   
Bovine Serum Albumin  
Caspase Recruitment Domain 
 Coiled-Coil  
Cellular FLICE Inhibitory Protein  
Cellular Inhibitory of Apoptosis-1  




Death Effector Domain  
DNA Fragmentation Factor 
Disease Free Survival 
Death-Inducing Signaling Complex 
Dulbecco’s Modified Eagle Media  
Dulbecco’s Modified Eagle Media-Ham’s F12  
Dimethyl Sulfoxide  
Distyrene Plasticizer Xylene 
Death Receptor  
Enhanced Chemiluminescence 




































Epidermal Growth Factor Receptor  
Enzyme Linked Immunosorbent Assay 
Excision Repair Cross Complementation group 1 
Oesophageal Squamous Cell Carcinoma 
Fluorescence-Activated Cell Sorting 
Fas-Associated Death Domain 
Fetal Calf Serum  
Gentamicin Amphotericin  
Haematoxylin and Eosin  
Hypoxia Inducible Factor -1alpha 
Head and Neck Squamous Cell Carcinoma 
Human Papilloma Virus 
Homologous Recombinational Repair  
Inhibitor of Apoptosis Proteins 
Immunohistochemistry  
Inhibitor of κB Kinase  
Isoleucine Zipper–TRAIL  
Inhibitor of κB 
Luria-Bertani  
Leucine Zipper-TRAIL 
Myeloid cell leukaemia-1 
Mismatch Repair  
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
Neuronal Apoptosis Inhibitor Protein  
Nucleotide Excision Repair  
Nuclear factor kappa-light-chain enhancer of activated B cells 
Non Homologous End Joining  
Normal  Human Keratinocytes 
NF-κB-Inducing Kinase  
Nucleotide-binding and Oligomerization Domain 
Non Small Cell Lung Carcinoma  
Optical Density 




































Outer Mitochondrial Membrane Permeabilization 
Osteoprotegerin  
Poly (ADP-ribose) Polymerase 
Phosphate Buffered Saline  
Paraffin Embedded Formalin Fixed 
Phenyl Methyl-Sulfonyl Fluoride  
Retinoblastoma 
Phosphate and tensin homolog deleted on chromosome 10 
Rel Homology Domain  
Recombinant human Epidermal Growth Factor 
Recombinant human TRAIL 
Really Interesting New Gene 
Receptor Interacting Protein 
Radiotherapy 
Severe Combined Immunodeficiency 
Sodium Dodecyl Sulphate  
Small inhibitory RNA 
Second mitochondria-derived activator of caspases, direct 
IAP-binding protein with low PI  





TNF Receptor  
Tumour Necrosis Factors-alpha  
Tumour-Node-Metastases  
TNF Receptor-Associated Factor 1 
TNF Receptor-Associated Factor 2 
Testis-specific Inhibitor of Apoptosis 
Upper Aerodigestive Tract  
Ubiquitin Conjugating Domain 










Vascular Endothelial Growth Factor 
World Health Organization 
X-linked Inhibitor of Apoptosis Protein  









1.1 Head and neck squamous cell carcinoma (HNSCC) 
1.1.1 Definition and incidence 
Head and neck cancer is the term used to describe a wide range of malignant 
tumours originating in the upper aerodigestive tract (UADT), (including oral cavity, 
nasopharynx, oropharynx, hypopharynx and larynx), the paranasal sinuses and the 
salivary glands. Cancers at different sites have different histopathological types and 
head and neck squamous cell carcinoma (HNSCC) is the most common. Cancer of 
the mouth and oropharynx is the 10
th
 most common cancer worldwide, but it is the 
seventh most common cause of cancer induced mortality (Mehanna et al., 2011). 
In 2002, the World Health Organization (WHO) estimated that there were 
600,000 new cases of head and neck cancer and 300,000 deaths each year 
worldwide, with the most common sites being the oral cavity (389,000 cases a 
year), the larynx (160,000) and the pharynx (65,000) (Boyle and Levin, 2008). In 
United Kingdom, about 7,800 patients are diagnosed with head and neck cancer 
every year. The prevalence has risen by more than 20% in the last 30 years 
(National Health Service website; www.nhs.uk, 2012). WHO projections estimate 
worldwide mortality figures from mouth and oropharyngeal cancer in 2008 to be 
371,000. This is projected to rise to 595,000 in 2030 (Mehanna et al., 2011).  
Recently, a marked increase in the prevalence of tonsil and oropharyngeal 
carcinomas associated with human papilloma virus (HPV) has been observed. In a 
population-based study, the incidence of HPV positive oropharyngeal carcinomas 
has increased by 225% between 1988 and 2004, whereas the incidence of HPV 






In general, cancer arises through the accumulation of genetic and epigenetic 
changes in genes acting in cancer associated pathways, causing acquisition of 
cancer-related phenotypes, including limitless replicative potential, self-sufficiency 
in growth signals, insensitivity to anti-growth signals, ability to evade apoptosis and 
ability to invade adjacent tissues and  to metastasise to distant organs (Hanahan and 
Weinberg, 2000).  A key issue in HNSCC pathogenesis is that carcinomas develop 
within large preneoplastic fields of mucosal epithelium consisting  of genetically 
altered cells that are clonally related to the carcinoma and often extend to  the 
surgical margins when tumours are excised and can cause local recurrences and 
secondary primary tumours (Leemans et al., 2011).  
HPV-induced carcinogenesis is primarily associated with the oropharynx. 
This subsite of the head and neck region includes the soft palate, base of tongue, 
and tonsils. More specifically, HPV infection is most commonly associated with the 
palatine and lingual tonsils (Pai and Westra, 2009). The patient characteristics 
associated with HPV positive carcinomas differ significantly than HPV negative 
carcinomas. Patients with HPV positive carcinomas are slightly younger, frequently 
white males, non smokers or infrequent smokers, and moderate or non alcohol 
drinkers. Conversely, HPV negative carcinomas develop in slightly older, often 
heavy smokers, and experience an enhanced risk with alcohol consumption 
(Gillison et al., 2008). 
HPV associated carcinomas in tonsil and oropharynx may be genetically 
distinct though their pathogenesis is not yet clear. They are presumed to arise in a 
similar way to cervical carcinomas through E6/7 effect on P53 and retinoblastoma 
(pRb) (Howard and Chung, 2012). Therefore these carcinomas probably show 





1.1.3 Risk factors 
Smoking and tobacco products, alcohol use, and infection with human 
papilloma virus (HPV) are among the major risk factors for head and neck cancer; 
globally, smoking and alcohol have historically been aetiologies for approximately 
42% of head and neck cancer. However, a shift in HNSCC epidemiology in recent 
decades has been noted, unrelated to tobacco and alcohol  and linked to HPV driven 
malignancies particularly for oropharynx tumours (Cmelak, 2012). Besides the 
above mentioned exogenous risk factors, certain inherited disorders and also a more 
general genetic susceptibility predispose to HNSCC (Hopkins et al., 2008). 
1.1.4 Histopathological features 
HNSCC is divided histologically into three types according to their 
differentiation status (resemblance to normal surface epithelium); well, moderately 
and poorly differentiated. This differentiation is assessed in terms of keratinisation, 
cellular pleomorphism, mitotic activity and nuclear aberrations (Woolgar and 
Triantafyllou, 2009). 
1.1.5 Prognosis 
Several factors affect the prognosis of head and neck cancer; the most 
important prognostic factors are site and TNM (tumour, node, and metastasis) stage. 
Recently HPV status has been shown to be of significant prognostic importance; 
HPV positive cases tend to have better prognosis (Gillison et al., 2008).  
Molecular markers of prognosis have been studied but none has yet entered 
routine clinical reporting. Several candidates have been suggested such as p53 but 
because of inconsistencies across studies, p53 status has not had a conclusive 
prognostic value. Other studies showed that patients who were positive for vascular 
endothelial growth factor (VEGF) had double the risk of death. Many other studies 
associated tumour hypoxia with adverse prognosis, in particular increased 
expression of hypoxia inducible factor-1α and carbonic anhydrase 9. High 





prognosis and also correlated with better response to radiotherapy treatment (Silva 
et al., 2007). Although many biomarkers correlate with recurrence, metastasis and 
death, none is sufficiently predictive or independent to be used routinely. 
1.1.6 Treatment 
1.1.6.1  Conventional treatment 
Early stage tumours are usually treated with surgical excision or 
radiotherapy. Both modalities have shown to have similar cure rates but have 
different adverse effects. Radiotherapy offers better organ preservation but the 
morbidity associated with radiation therapy for example, xerostomia, loss of taste, 
life-long risk to dentition and post irradiation sarcoma can be considerable. For 
advanced squamous cell carcinoma of the head and neck, single modality treatment 
(surgery or radiotherapy) is associated with poorer outcomes and randomized 
studies have shown that combined use of surgery and postoperative radiotherapy or 
combined chemotherapy and radiotherapy offer the highest chance of cure 
(Bhalavat et al., 2003). Postoperative radiotherapy is recommended when the risk 
for loco-regional recurrence in the head and neck cancer exceeds 20%. Chemo-
radiotherapy is used when surgical margins are positive for tumour or when lymph 
nodes show extra-capsular extension (Schoder et al., 2009). All treatments for 
HNSCC are frequently compromised by late stage presentation and co-morbidity, 
particularly cardiovascular diseases associated with chemotherapy. 
Radiotherapy induces DNA damage leading tumour cells to undergo 
apoptosis (Lima et al., 2012). Tumour radio-resistance, including intrinsic radio-
resistance before treatment and acquired radio-resistance during radiotherapy is a 
main obstacle to the efficacy of radiotherapy; this radio-resistance is associated with 
disruptions in DNA damage repair mechanisms, apoptosis and cell cycle 
checkpoints (Xu et al., 2008). 
These treatment modalities are usually accompanied by several 
complications. Following the surgical treatment, patients present with functional 





neck dissection, weak shoulders (Mehanna et al., 2010). Radiotherapy has acute 
complications including radiation dermatitis, xerostomia, excessive mucous 
production and painful mucositis and late radiation toxicity including xerostomia, 
fibrosis of soft tissues, dysphagia, osteo-radionecrosis and post irradiation sarcoma 
(Denis et al., 2003). This highlights the need for target specific drugs and 
biomarkers to target treatment in order to improve cure rate and reduce adverse 
effect. 
1.1.6.2  Targeted therapy  
 Improved understanding of the molecular biology of cancer development 
and progression has led to the emergence of new therapeutic agents that target 
specific molecules involved in cell proliferation and apoptosis. Some of these agents 
have been approved and are currently in use for treatment of patients with different 
types of cancer. Many other novel targeted agents are still under laboratory and 
clinical investigation.  
EGFR signalling is important in tumourigenesis and disease progression 
particularly in cancer with epithelial origin. Cetuximab, a monoclonal antibody 
against EGFR has been shown to reduce patient mortality and increase loco-
regional control of HNSCC tumours when combined with radiotherapy. It became 
the first molecular targeting strategy approved by U.S. food and drug administration 
for HNSCC in 2006 (Bonner et al., 2006). 
Angiogenesis is essential for tumour growth and metastasis, antiangiogenic 
therapies for example Bevacizumab, a recombinant human monoclonal antibody 
against vascular endothelial growth factor (VEGF) has been used in combination 
with radiotherapy and or chemotherapy for treatment of head and neck cancers in 
phase III clinical trials with 14.6% response rate (Seiwert and Cohen, 2008). 
Tumour necrosis factor-related apoptosis inducing ligand (TRAIL, see 
section 1.2.8) has been shown to induce selective cytotoxicity in several different 
types of malignant cell lines. In this study the potential of TRAIL as an anti-





TRAIL is currently used in phase I/II clinical trials for treatment of patients with 
advanced solid tumours and has a favourable safety records (Herbst et al., 2010).  
Smac mimetics (see section 1.2.9) have been investigated since 2004 as 
potential anticancer targeted therapeutic candidate. They have been tested on 
several cancer cell lines either as a single agent or in combination with other 
therapeutic modalities (Chen and Huerta, 2009). 
Resistance to apoptosis is believed to be the main cause of treatment failure 
and cancer recurrence following chemo- and radio- therapy. This resistance can be 
partially correlated with inherent or acquired genetic and epigenetic changes of the 
components of the death pathways in the tumour cells (Goh et al., 1995). It is hoped 
that further understanding of the molecular pathology of HNSCC will lead to novel 
therapies and improved tailoring of existing treatment modalities for individualised 
treatment of  HNSCC patients (Leemans et al., 2011). 
1.2 Cell death 
Cell death generally is classified into two forms based on morphological and 
biochemical criteria: necrosis and apoptosis (Wyllie et al., 1980). 
1.2.1 Necrosis 
Necrosis is a pathological cell death resulting from extreme cellular trauma. 
It affects groups of cells rather than individual cells, and evokes inflammation 
(Darnell et al., 1994). Cells undergoing necrosis fail to maintain proper plasma 
membrane function; therefore they can no longer regulate osmotic pressure. 
Consequently, the cells swell and rupture, spilling their cellular contents into the 
surrounding tissue, resulting in nonspecific cellular destruction that leads to an 
inflammatory response necessary to remove debris and begin tissue repair (Griffith 






Apoptosis or programmed cell death was first described in 1972 by Currie 
and colleagues (Jin and El-Deiry, 2005) and it is both physiological and 
pathological process. It is characterized histologically by the formation of small, 
spherical cytoplasmic fragments, some of which contain pyknotic nuclei (Vaux and 
Strasser, 1996). The nuclear changes are accompanied by fragmentation of the 
cellular DNA into a ladder of regular bands, the result of random double stranded 
breaks in the linker regions between nucleosomes (Cao et al., 2001). While these 
intracellular changes are taking place, the cell membrane becomes ruffled and 
blebbed in a process called zeiosis. The fate of the apoptotic cell is to be 
phagocytised by surrounding cells before it ruptures and release its potentially 
inflammatory contents. Thus, apoptotic cell death is important in tissue 
homeostasis, by which cell number within tissues and organs is maintained, as it 
results in the deletion of cells with little tissue disruption (Griffith et al., 2009). 
There are two major apoptotic pathways namely the extrinsic or death 
receptor pathway and the intrinsic or mitochondrial pathway (Figure 1.1). 
1.2.2.1  Extrinsic pathway  
The extrinsic pathway is triggered by the activation of tumour necrosis 
factor (TNF) death receptor superfamily (Fas, TNF-α, TRAIL). These cell surface 
receptors are activated when cross linked to their ligands. Death ligand stimulation 
results in oligomerization of the receptors and recruitment of the adaptor protein 
Fas-associated death domain (FADD) and caspase-8, forming a death-inducing 
signaling complex (DISC). Inside the DISC, autoactivation of caspase-8 occurs. The 
activated caspase-8 consequently leads to activation of effector caspase-3, -6 and -7. 
These caspases stimulate the cleavage of many cellular proteins causing the 





1.2.2.2  Intrinsic pathway  
The intrinsic pathway is triggered by DNA damage induced by irradiation or 
chemicals, growth factor deprivation or oxidative stress. These signals cause outer 
mitochondrial membrane permeabilization (OMMP) leading to the release of 
cytochrome c, Smac/DIABLO and other proapoptotic proteins into the cytoplasm. 
Released cytochrome c assembles with procaspase-9 to form the apoptosome. 
Within the apoptosome, caspase-9 is activated and leads to activation of caspase-3, 
which initiates apoptosis execution.  The intrinsic pathway could also be activated 
in response to death receptor activation. This occurs via activated caspase-8 which 
leads to the activation of BID (BH3-interacting domain death agonist) transforming 
it to truncated BID (tBID). tBID consequently leads to OMMP (Newsom-Davis et 
al., 2009).  These pathways are summarised in Figure 1.1. 
Cells may be divided into two distinct types in response to different pro-
apoptogenic agents.  In type I cells, activation of death receptors is sufficient to 
induce apoptosis whilst in type II cells co-activation of the mitochondrial pathway is 
necessary to induce effector caspase activation. The distinction between type I and 
type II cells depends on the expression profile of anti-apoptotic molecules as well as 




















Figure 1.1  Apoptosis pathways in mammalian cells 
Apoptosis activation by the extrinsic pathway involves the binding of extracellular death ligands 
(such as TNF /TRAIL) to death receptors, provoking the recruitment of adaptor proteins, such as the 
Fas-associated death domain protein (FADD) and recruiting caspase-8. Active caspase-8 then 
activates effector caspase-3, -6 or -7. In the intrinsic pathway, stresses such as radiation or 
chemotherapeutic agents target mitochondria and induce efflux pro-apoptotic proteins, such as 
cytochrome c and Smac/DIABLO , into the cytosol. On release from mitochondria, cytochrome c 
can interact with the apoptosome assembly. Active caspase-9 then activates effector caspase-3, -6 or 
-7. Effector caspases stimulate the cleavage of many cellular proteins causing the characteristic 





1.2.3 Inhibitor of apoptosis protein (IAPs) family 
Inhibitor of apoptosis proteins (IAPs) is a group of cellular proteins that 
function as potent endogenous inhibitors of apoptosis. They suppress apoptosis 
induced by a variety of stimuli, including death receptor activation, growth factor 
withdrawal, ionizing radiation, viral infection and genotoxic damage. The IAPs 
family contains eight members; Neuronal apoptosis inhibitor protein (NAIP), X-
linked inhibitor of apoptosis protein (XIAP/MIHA/hILP/ BIRC4/ILP-1), cellular 
IAP1 /human IAP2 (c-IAP1/HIAP2/MIHB/ BIRC2), cellular IAP2/human IAP1 (c-
IAP2/HIAP1/MIHC/ API2/BIRC3), Testis-specific IAP (Ts-IAP/hILP2 /BIRC8 
/ILP2), BIR-containing ubiquitin conjugating enzyme (BRUCE/ Apollon/BIRC6), 
Survivin (TIAP/BIRC5) and Livin (KIAP/ ML-IAP/BIRC7) (Dai et al., 2009a). 
The defining characteristic of the IAP family is the presence of at least one 
Baculovirus IAP Repeat (BIR) domain. The human IAPs contain either one 
(Survivin, Livin, TsIAP, BRUCE) or three (XIAP, cIAP1, cIAP2, NAIP) tandem 
BIR domains. Along with BIR domains, several IAPs contain a RING (really 
interesting new gene)-zinc finger domain at carboxy terminus. Both c-IAP1 and c-
IAP2 contain a caspase recruitment domain (CARD) in the linker region between 
the BIR domains and the RING domain. NAIP contains a nucleotide binding site 
domain as well as a leucine-rich repeat domain. BRUCE contains a ubiquitin-
conjugation domain (Figure 1.2). In XIAP, c-IAP1 and c-IAP2, the RING domain 
has been shown to possess E3 ubiquitin ligase activity directly regulating self-
ubiquitination and protein degradation (Hunter et al., 2007). 
IAP proteins are divided into two groups based on their binding properties to 
caspases and inhibition of caspase activity. The first group includes XIAP, cIAP-1, 
cIAP-2, Livin, NAIP and TsIAP; these IAPs bind to and inhibit caspase-3, -7 and -9 
and function as potent apoptosis inhibitors. The second group includes Survivin and 
BRUCE; these IAPs do not bind to caspases and in addition to their anti-apoptotic 
activity, rather they regulate cytokinesis and mitototic spindle formation (Yang et 





of both initiator and effector caspases (LaCasse et al., 2008). IAPs inhibit apoptosis 
by preventing the activation of procaspases and inhibiting the enzymatic activity of 
mature caspases (Chai et al., 2000).  
1.2.3.1  X-linked inhibitor of apoptosis protein (XIAP) 
XIAP is a 57 kDa protein that is expressed ubiquitously in adult and fetal 
tissues. XIAP is the first well characterized IAP family member due to its potent 
anti-apoptotic activity. XIAP is the only cellular protein that potently inhibits the 
enzymatic activity of mammalian caspases at both the initiation phase (caspase-9) 
and the execution phase (caspase-3 and -7) of apoptosis (Kashkar, 2010). Two 
regions in XIAP confer different specificity in the inhibition of caspase-3, -7 and -9. 
BIR3 domain of XIAP selectively targets caspase-9 whereas the linker region 
between BIR1 and BIR2 of XIAP inhibits caspase-3 and caspase-7, the effector 
caspases that triggers downstream apoptosis. While XIAP prevents the activation of 
all three caspases, it has been shown that the interaction of XIAP with caspase-9 is 
the most critical for its inhibition (Dai et al., 2009a). Because effector caspase 
activity is essential for irreversible programmed cell death, XIAP functions as a 
gatekeeper to this final stage of apoptosis (Li et al., 2004). 
XIAP is overexpressed in many cancer cell lines and tumours compared to 
normal cells, and high levels of XIAP result in apoptosis-resistance of cancer cells 
to a wide variety of therapeutic agents (Huang et al., 2001). XIAP expression was 
associated with adverse tumour histology and decreased patient survival and it has 
been proposed as an important adverse biomarker of chemoresistance in cancer 
(Kashkar, 2010). However, other studies showed that elevated XIAP expression 
alone cannot serve as a predictive marker of chemoresistance and that in order to 
predict impact of XIAP on chemoresistance, both level of XIAP and the functional 
status of all XIAP modulators (Smac and Bcl-2) need to be taken into account 





1.2.3.2  Cellular inhibitor of apoptosis proteins (cIAP-1 and cIAP-2) 
cIAP-1 and cIAP-2 are weak caspase inhibitors in vitro. Although the role of 
cIAP-1 and cIAP-2 in apoptosis is less well defined than XIAP, their function on 
the cellular responses other than apoptosis is widely reported. cIAP-1 and cIAP-2 
are associated with the TNF receptor 1 signalling complex as well as regulating NF-
ҡB signalling (Dai et al., 2009a).  cIAP-1 and cIAP-2 are identified for the ability to 
interact with TRAF1 and TRAF2, localizing the cIAPs to the TNF receptors. The 
recruitment of cIAP-1 and cIAP-2 to TNFR1 inhibits TNF-α dependent, RIPK1- 
dependent activation of caspase-8 (Greer et al., 2011). 
1.2.4 Caspases (cysteine-aspartate proteases) 
Caspases are a class of cysteine-aspartyl proteases that are synthesized as 
inactive precursor enzymes or proenzymes. These proteases lie dormant in the 
healthy cell and in response to cell death stimuli are converted, either by proteolytic 
cleavage or by recruitment into large complexes, into active enzymes. Once 
activated, caspases cleave their substrates, this is responsible for most of the 
biochemical and morphological features of apoptotic cell death (Hunter et al., 
2007).  
Caspases in their proenzyme form contain three domains, amino-terminal 
prodomain followed by a large (P20) subunit containing the active site cysteine and 
carboxy-terminal small (P10) subunits. Aspartate cleavage sites are present between 
prodomains and large subunit and between large and small subunits. Two cleavage 
events are required to activate caspases into functional proteases. The first 
proteolytic cleavage divides the proenzyme into large and small subunits. A second 
cleavage event removes the amino terminal prodomain. The resultant functional 
caspase is a tetramer of two large and two small subunits (Figure 1.3A). 
14 mammalian caspases are known. Based on their function, the caspases 





1) Inflammatory caspases, this group includes caspase-1, -4, -5, -11, -13 
and -14 which are involved in inflammation.  
2) Apoptotic initiator caspases, initiator caspases have a long 
prodomain containing either a death effector domain (DED) 
(caspase-8 and -10) or a caspase activation and recruitment 
domain (CARD) (caspase-2 and -9).  
3) Apoptotic effector caspases, which include caspase -3, -6 and -7 and 
they are characterised by the presence of a short prodomain. 






















Figure 1.2  Domain structure of the mammalian IAPs 
The domain organization is shown for the eight mammalian IAPs. The presence of at least one 
baculovirus IAP repeat (BIR) domain is the defining characteristic of the IAP family. The human 
IAPs possess either one (survivin, BRUCE, livin and ILP2) or three tandem amino-terminal BIR 
domains (XIAP, cIAP1, cIAP2 and NAIP). Several IAPs contain an E3 ubiquitin ligase zinc-finger 
(RING) domain at the carboxy terminus. Both cIAP1 and cIAP2 possess a caspase-recruitment 
(CARD) domain in the linker region between the BIR and the RING domains. Uniquely, NAIP 
possesses a nucleotide-binding and oligomerization (NOD) domain. BRUCE contains an ubiquitin 
conjugating (UBC) domain but no RING domain. Survivin contains a coiled-coil (CC) domain that 
























Figure 1.3  Mammalian caspases; activation, structure and classification  
A:   Structure of caspases as pro-enzymes and after activation, from Hunter et al., 2007; Caspases are 
synthesized as inactive zymogens. Cleavage at aspartate (Asp) sites results in an active tetramer 
consisting of two large (p20) and two small (p10) subunits.  B: Classification of mammalian 
caspases, from Jin and El-Deiry, 2005; Caspases can be classified into three groups: 1) Inflammatory 
caspases, include caspase-1, -4, -5, -11, -13 and -14. 2) Apoptotic initiator caspases, initiator 
caspases posses long prodomain containing either a death effector domain (DED) (caspase-8 and -
10) or a caspase activation and recruitment domain (CARD) (caspase-2 and -9). 3) Apoptotic 
effector caspases, which include caspase -3, -6 and -7 and they are characterized by the presence of a 







1.2.5 Cellular FLICE inhibitory protein (cFLIP) 
cFLIP is a cellular protein that shares high sequence homology with the 
initiator caspases. It inhibits caspase activation at the death-inducing signalling 
complex (DISC) by competing for binding to the death effector domain (DED) of 
Fas associated death domain protein (FADD). cFLIP exists as many splice variants, 
of which only a longer (cFLIPL) and a shorter version (cFLIPS) could initially be 
detected at the protein level. Both variants contain DED domains that are 
structurally similar to the N-terminal part of pro-caspase-8. The C-terminus of 
cFLIPL consists of two catalytically inactive caspase-like domain (P20 and P10), 
whereas the short C-terminus of cFLIPS does not (Newsom-Davis et al., 2009). 
1.2.6 Bcl-2 family proteins 
Bcl-2 family proteins are group of proteins involved in cell death/survival 
balance. At least 20 Bcl-2 family members have been identified in mammals. The 
key determinant of a Bcl-2 related protein is the presence of at least one of four 
conserved Bcl-2 homology (BH1-BH4) domains. The Bcl-2 family proteins are 
divided into three groups according to their structure and function (Figure 1.4):  
1) Anti-apoptotic, usually contain all four BH domains and includes 
Bcl-2, Bcl-XL, Bcl-W, Mcl-1 and A1/Bfl-1. 
2) Multi-domain pro-apoptotic, containing BH1, BH2 and BH3 and 
include Bax, Bak and Bok/Mtd. 
3) BH3-only proteins, which contain only BH3 domain and include 
Bid, Bim/Bod, Bad, Bmf, Bik/Nbk, Bik, Noxa, Puma/Bbc3 and 
Hrk/DP5. BH3-only members stimulate apoptosis either by 
interaction with anti-apoptotic proteins to inhibit their function 
and/or by interaction with pro-apoptotic proteins to stimulate their 
activity (Martinou and Youle, 2011).  
Many Bcl-2 members have a conserved C-terminal transmembrane (TM) 





envelope, the endoplasmic reticulum and the outer mitochondrial membrane. Bcl-2 
family proteins act at the mitochondrial level, regulating the exit of apoptogenic 
factors such as cytochrome c that are sequestered in mitochondria (Fleischer et al., 
2006). 
1.2.6.1  Bcl-2 protein 
Bcl-2 protein is an anti-apoptotic member of the Bcl-2 family. It is a 26 kDa 
protein that is localized in the mitochondria, endoplasmic reticulum and perinuclear 
membrane (Korsmeyer, 1995). Bcl-2 belongs to the proto-oncogene family but the 
ability of Bcl-2 to promote tumour growth is different from other oncogenes; it can 
rescue cells that otherwise destined to die without affecting their proliferation rate 
(Kinloch et al., 1999). Bcl-2 is involved in maintaining cellular homeostasis, 
including the mitochondrial membrane status and balance of the interaction between 
the members of the Bcl-2 protein family. In addition, Bcl-2 has a role in the 
regulation of calcium homeostasis in the cell (Veis et al., 1993). 
Bcl-2 protein overexpression was found to mediate resistance to TRAIL 
induced apoptosis in neuroblastoma, glioblastoma and breast carcinoma cell lines in 
which Bcl-2 overexpression reduced TRAIL-induced cleavage of caspase-8 and Bid 
and blocked cleavage of caspases-9, -7 and -3 into active subunits (Fulda et al., 
2002). However, Ndozangue-Touriguine et al. showed that there was no difference 
in expression level of Bcl-2 between primary colon carcinoma cell line (SW480, 
TRAIL sensitive) and the metastatic cell line (SW20, TRAIL resistance) 
(Ndozangue-Touriguine et al., 2008). 
1.2.6.2  Mcl-1 protein 
Mcl-1 (myeloid cell leukaemia-1) is another anti-apoptotic member of the 
Bcl-2 family protein originally identified in differentiating myeloid cells in 1993 
(Kozopas et al., 1993). Mcl-1 is expressed in a wide variety of cell types (Krajewski 
et al., 1995) and Mcl-1 expression is highly induced by survival and differentiation 
signals such as cytokines and growth factors (Craig, 2002). Mcl-1 contains BH 





proteins, Mcl-1 also contains a C-terminal transmembrane (TM) domain that serves 
to localise Mcl-1 to various intracellular membranes, particularly outer 
mitochondrial membrane (Yang et al., 1995). Mcl-1 also plays a critical role in the 
survival of malignant cells because depletion of Mcl-1 via antisense 
oligodeoxynucleotides triggers apoptosis in cancer cells (Derenne et al., 2002). It is 
believed that Mcl-1 induces its anti-apoptotic effect via suppression of cytochrome 
c release from the mitochondria, possibly via heterodimerization with, and 













Figure 1.4  Bcl-2 family members  
The Bcl-2 family members are divided into three groups of proteins according to their structure and 
function. The anti-apoptotic family members usually contain all four BH domains and include Bcl-2, 
Bcl-XL, and Bcl-w. The multi-domain pro-apoptotic members are lacking the BH4 domain and 
include Bax, Bak, and Bok. Finally, the BH3-only pro-apoptotic family members contain only the 






1.2.7 Nuclear factor kappa-light-chain enhancer of activated B cells (NF-
κB) 
NF-κB is a protein complex that control transcription of DNA. It was first 
discovered in David Baltimore’s laboratory via its interaction with an 11 base pair 
sequence in the immunoglobulin light chain gene in B cells (Sen and Baltimore, 
1986). The NF-κB family consists of several members categorised into two classes; 
class I which includes NF-κB1 and NF-κB2 and class II which includes Rel1A, 
Rel1B and c-Rel.  
The activity of NF-κB is tightly regulated by interaction with inhibitory IκB 
proteins. As with the NF-κB transcription factors, there are several IκB proteins, 
IκBα, IκBβ, IκBγ and IκBε   that have different affinities for individual NF-κB 
dimers. Individual IκBs are regulated by phosphorylation and proteolysis, and show 
differences in their tissue-specific expression patterns (reviewed by (Chen and 
Ghosh, 1999).  In most cells, NF-κB is present as a latent, inactive, IκB-bound 
complex in the cytoplasm. Activation of NF-κB is mediated via activation of 
canonical (classical) and non-canonical (alternative) pathways (Hoffmann et al., 
2006).   
In the canonical pathway, the binding of a ligand to a cell surface receptor 
recruits adaptors (e.g., TRAFs and RIP) to the cytoplasmic domain of the receptor. 
In turn, these adaptors often recruit an IKK (inhibitor of κB kinase complex) 
complex leading to activation of the IKK complex. IKK then phosphorylates IκB 
which leads to its ubiquitination and degradation by the proteasome. NF-κB then 
enters the nucleus to activate target genes. The non-canonical pathway is for 
activation of p100/RelB complexes during B- and T-cell organ development. n the 
non-canonical pathway, receptor binding leads to activation of the NF-κB-inducing 
kinase NIK, which phosphorylates and activates an IKKα complex, which in turn 
phosphorylates p100, leading to its partial proteolysis and liberation of the p52/RelB 





1.2.8 Tumour necrosis factor-related apoptosis inducing ligand (TRAIL)  
Tumour necrosis factor belongs to a family of cytokines that interact with a 
corresponding set of receptors of the TNF receptor family. Signals induced by these 
interactions serve diverse functions including differentiation, proliferation, 
activation or induction of cell death. Two of these ligands CD95L and TNF are able 
to induce apoptosis in transformed cells but they have acute toxic effects on normal 
tissues which limit their use as anticancer agents (Cosman, 1994). TRAIL was first 
identified by Wiley and co-workers in 1995 as a 281 amino acid type II 
transmembrane protein, whose C-terminal extracellular domain showed clear 
homology to other TNF family members and its transcripts are detected in a variety 
of human tissues, mostly in spleen, lung and prostate (Wiley et al., 1995). 
 Early studies identified two unique characteristics of TRAIL upon other 
members of TNF family (FasL and TNF). First, TRAIL induced apoptosis occurs 
only in tumourigenic or transformed cells and not normal cells (Wiley et al., 1995). 
Second, mRNA for TRAIL is detected in a wide range of tissues (Kayagaki et al., 
1999). It has been suggested that TRAIL’s selectivity is in part due to the presence 
of decoy receptors on normal cells that prevent TRAIL from binding to death 
receptors and inhibits TRAIL-induced apoptosis (Kimberley and Screaton, 2004). 
1.2.8.1  TRAIL receptors 
Five different TRAIL receptors have been identified. Two are death 
receptors, TRAIL-R1 (death receptor DR4) and TRAIL-R2 (death receptor DR5) 
which are able to transmit an apoptotic signal. They contain a death domain (DD) in 
their intracellular portion, a six to seven α-helices motif which can bind to other 
DDs via homotypic interaction. There are two decoy receptors, TRAIL-R3 (decoy 
receptor DcR1) which lacks DD and TRAIL-R4 (decoy receptor DcR2) with a 
truncated death domain (DD) that could induce activation of NF-ҡB. TRAIL also 
binds a soluble receptor called osteoprotegerin (OPG) which is involved in the 





1.2.8.2  Recombinant human TRAIL 
Early studies showed that full length cell surface expressed TRAIL and 
soluble TRAIL induced apoptosis in a wide variety of transformed cell lines (Wiley 
et al., 1995). This discovery has been followed by production of several forms of 
recombinant TRAIL. In 1999, Ashkenazi and co-workers generated a soluble 
version of the native Apo2-L (TRAIL) protein and showed that the recombinant 
protein induced cytostatic or cytotoxic effect on 32 of 39 cell lines from colon, lung, 
breast, kidney, brain and skin cancer in vitro. It also reduced tumour incidence and 
tumour progression in a mouse model without affecting normal cells or tissues 
(Ashkenazi et al., 1999). Walczak and co-workers also created leucine Zipper forms 
of human TRAIL which was able to induce apoptosis in target cells in vitro and was 
able to reduce tumour growth in SCID (Severe Combined Immunodeficiency) mice 
with no toxicity to normal tissues (Walczak et al., 1999). Consequently TRAIL has 
emerged as a promising targeted cancer therapy. 
A variety of different forms of human recombinant soluble TRAIL have 
been designed, each encoding the extracellular domain of human TRAIL. Some 
preparations are amino-terminally fused to either polypeptide tags (Pitti et al., 
1996), FLAG epitope (Schneider, 2000), leucine Zipper (LZ) (Ganten et al., 2006; 
Walczak et al., 1999) or isoleucine Zipper (IZ) trimerization domains (Ganten et al., 
2006). 
To overcome the short half life and toxicity of high doses of soluble TRAIL, 
another method of introducing TRAIL to tumour tissues was developed in mouse 
model.  Adenovirus infected CD34
+
 cells expressing membrane bound TRAIL have 
been generated and tested using a subcutaneous myeloma model in 
immunodeficient mice via intravenous injection. The transduced cells were found to 
home in the tumour peaking at 48 hours. Both CD34-TRAIL expressing cells and 
soluble TRAIL significantly reduced tumour volume by 40% and 29%, respectively. 
CD34-TRAIL expressing cells but not soluble TRAIL significantly damaged 





cells induces early vascular disruption, resulting in hemorrhagic necrosis and 
tumour destruction (Lavazza et al., 2010).  
Some recombinant TRAIL variants may induce systemic toxicity; 
polyhistidine tagged TRAIL has been shown to induce apoptosis in normal human 
hepatocytes (Jo et al., 2000) and recombinant human leucine zipper (LZ) and 
polyhistidine tagged have been shown to induce apoptosis in normal keratinocytes 
(Leverkus et al., 2000). Recombinant LZ-TRAIL was cytotoxic to astrocytes in 
vitro (Walczak et al., 1999).  
Conversely,  recombinant TRAIL that lacked exogenous sequences did not 
induce apoptosis in normal cynomolgus monkey hepatocytes (Lawrence et al., 
2001), human mammary, renal or prostatic epithelial cells, umbilical vein 
endothelial cells, lung fibroblasts, colon smooth muscle cells, astrocytes or 
keratinocytes (Ashkenazi et al., 1999; Qin et al., 2001) and thus has been selected as 
the most promising candidate for clinical trials in cancer patients.  Based on these 
results, a phase I study with rhTRAIL (Genentech, San Fransisco, CA, USA) has 
been initiated (Duiker et al., 2006). The results from phase I clinical trials showed 
that 50% of 32 evaluable patients with solid and haematological malignancies 
achieved stable disease and one patient demonstrated a partial response in doses up 
to 15 mg/kg indicating that Apo2L/TRAIL was safe and well tolerated when used in 
escalating doses for patients with advanced cancer in phase I trials (Herbst et al., 
2010). 
1.2.8.3  TRAIL-mediated apoptosis 
TRAIL induces cell death by activation of apoptosis pathways following 
binding to its corresponding receptors. After binding of TRAIL to TRAIL-R1 or R2, 
the trimerized receptors recruit several cytosolic proteins that form the death-
inducing signaling complex (DISC). FADD binds directly to the intracellular death 
domain of the receptors where it binds the inactive pro-form of caspase-8 or 
caspase-10 leading to their activation. Then two different pathways can be 





3,-6,-7) leading to cell death, and the other involving caspase-8 dependent cleavage 
of Bid thus engaging the intrinsic death pathway. Cleaved Bid translocates to the 
mitochondria where it interacts with Bax and Bak to form pores in the 
mitochondrial membrane, leading to the release of cytochrome c and 
Smac/DIABLO from the mitochondria. Cytochrome c together with Apaf-1 and 
procaspase-9 form the apoptosome which leads to caspase-9 activation and 
subsequent activation of effector caspases (Kruyt, 2008). 
Recent studies demonstrated that TRAIL can sometimes promote survival, 
proliferation, migration and invasion in TRAIL-resistant tumour cells. Binding of 
TRAIL to death receptors (DR4 and DR5) and even to decoy receptor (DecR2) 
induces NF-κB activation (Degli-Esposti et al., 1997). TRAIL-induced NF-κB 
activation was initially suggested to be a mechanism for negative regulation of 
TRAIL-induced apoptosis. However, in TRAIL-resistant cells, it has been shown to 
mediate RIP-dependent TRAIL-induced survival and proliferation in Jurkat cells 
(Ehrhardt et al., 2003). In apoptosis-resistant cholangiocarcinoma cells, TRAIL has 
been shown to promote NF-κB-dependent tumour cell migration and invasion, but 
not proliferation (Ishimura et al., 2006).  
1.2.8.4  TRAIL resistance in primary tumours 
The majority of human primary tumour cells are resistant to TRAIL-
mediated apoptosis. However, treatment with chemotherapeutic or other biological 
agents can sensitise many primary tumour cells to killing by TRAIL while leaving 
normal cells largely unaffected. The mechanisms of TRAIL resistance has been 
extensively studied and several mechanisms have been proposed; overexpression of 
DcR1 and DcR2 by acting as decoys and competing against DR4 and DR5 
(LeBlanc and Ashkenazi, 2003), elevated cFLIP expression (Clarke and Tyler, 
2007), high expression of IAPs (Makhov et al., 2008) and overexpression of Bcl-2 
(Fulda et al., 2002) and Bcl-xl (Hinz et al., 2000). In colon carcinoma cells, TRAIL 
resistance has been proposed to be due to overexpression of XIAP and 
mitochondrial block but it was not related to Bcl-2, Bcl-xL and Mcl-1 levels 





A novel mechanism of TRAIL resistance in glioblastoma cells was found to 
be due to overexpression of ubiquitin-modifying enzyme A20. After TRAIL 
receptor stimulation, A20 mediates the polyubiquitination of RIP1 at the TRAIL 
receptor tail, resulting in the interaction of polyubiquitin chain to procaspase-8 that 
is recruited to the TRAIL-bound receptors. The inability of ubiquitin-bound 
procaspase-8 to be dimerized and activated prevents the execution of the apoptosis 
(Bellail et al., 2012; Verbrugge and Johnstone, 2012). 
1.2.8.5  TRAIL sensitisation  
Although some tumour cells develop resistance to TRAIL, there are various 
sensitising agents that could mediate the reversal of TRAIL resistance. Nitrous 
oxide was used to sensitise TRAIL resistant cells by its inhibitory effect on NF-ҡB 
and upregulation of TRAIL death receptor 2 (DR5) (Lee et al., 2007). Proteasome 
inhibitor MG132 sensitised hepatocellular carcinoma to TRAIL via inhibition of the 
NF-ҡB pathway (Ganten et al., 2005). Similarly, proteasome inhibitor Bortezomib 
has been used to sensitise malignant human glioma cells (Jane et al., 2011). 
Ultraviolet radiation has been used to sensitise melanoma cells to TRAIL-
mediated apoptosis. The sensitisation was due to XIAP degradation, which allowed 
full processing of caspase-3. It was also accompanied by degradation of IҡBα 
(Inhibitor of κB), resulting in NF-ҡB-dependant transcriptional repression of XIAP 
(Thayaparasingham et al., 2009). Neuroblastoma cells were sensitised to TRAIL-
mediated apoptosis by inducing NF-ҡB inhibition using IҡBα-superrepressor or 
small molecule NF-ҡB inhibitor BMS-345541. The sensitisation was because NF-
ҡB inhibition prevented TRAIL-triggered up-regulation of Mcl-1 promoting 
TRAIL-induced cytochrome c release and caspase activation (Ammann et al., 
2009).  Smac mimetics were used to sensitise breast cancer cells to TRAIL through 
their binding to IAPs and consequent caspase-3 activation (Fandy et al., 2008; Li et 
al., 2004) and use of XIAP inhibiting compound was able to sensitise chronic 


















Figure 1.5  Model of TRAIL mediated apoptotic signalling 
Upon binding of trimeric TRAIL to TRAIL-R1/-R2, FADD associates with the receptors’ death 
domains (DD) enabling the recruitment of caspase-8/10 and cFLIP to the DISC. In the direct 
apoptotic pathway, activated caspase-8/10 cleaves downstream effector caspases. Type II cells 
require pro-apoptotic changes at the mitochondria (the intrinsic pathway) resulting in apoptosome 





1.2.9 Second mitochondria-derived activator of caspases, direct IAP-
binding protein with low PI (Smac/DIABLO) 
Smac/DIABLO (second mitochondria-derived activator of caspases, direct 
IAP-binding protein with low PI) is a 25-kDa mitochondrial protein. The discovery 
of Smac was first published in 2000 by Du et al. and at the same time by Verhagen 
et al. who named the protein DIABLO, hence the name Smac/DIABLO (Du et al., 
2000; Verhagen et al., 2000). Smac resides within the mitochondrial intermembrane 
space and released into cytosol upon the induction of apoptosis (Chen and Huerta, 
2009).  
Smac/DIABLO promotes apoptosis through its ability to antagonize IAP-
mediated caspase inhibition once released into the cytoplasm. Initial mitochondrial 
targeting of Smac depends on 53-55 amino acid sequence found at its amino 
terminus. This sequence is proteolytically cleaved within the mitochondria to 
generate AVPI (Ala-Val-Pro-Ile) containing amino terminus polypeptide, which is 
sequestered until an apoptotic stimulus is sensed. On receiving an apoptotic signal 
through the intrinsic mitochondrial pathway, both Smac and cytochrome c are 
released through mitochondrial membrane pores (LaCasse et al., 2008). 
1.2.9.1  Function of Smac/DIABLO  
Smac/DIABLO is considered a general IAP inhibitor due to its ability to 
bind to XIAP, c-IAP1, c-IAP2, Survivin, Livin and BRUCE but not NAIP. Smac is 
able to interact with IAPs by binding to BIR2 and BIR3 domains but not BIR1 
domain. The first four amino-terminal residues of mature Smac/DIABLO, AVPI are 
required for Smac/DIABLO function. Activation of Smac/DIABLO is mediated by 
homodimerization to form a stable protein dimer in which the amino terminus AVPI 
makes contact with XIAP BIR3. This prevents XIAP from binding to caspases, thus 
freeing caspases from inhibition (LaCasse et al., 2008).   
In HNSCC cell lines, Smac mediates apoptosis induced by several 
chemotherapeutic agents through the mitochondrial pathway and Smac knockdown 





release. Furthermore, Smac levels modulated the therapeutic response of HNSCC 
cells to gemicitabine in xenograft models (Sun et al., 2011). Smac/DIABLO 
expression was lower in oesophageal squamous cell carcinoma tissue than normal 
counterpart. Furthermore, the level of Smac expression tested by 
immunohistochemistry using tissue microarray correlated with the response to 
chemotherapy (high Smac, better response) and Smac downregulation induced 
chemoresistance to cisplatin and inhibited caspase3 activation. Furthermore, Smac 
mimetics restored the sensitivity of oesophageal squamous cell carcinoma to 
cisplatin. (Xu et al., 2011). 
1.2.9.2  Smac isoforms 
There are two additional Smac isoforms Smacβ and Smac3. Smacβ is an 
alternatively spliced cytoplasmic isoform of Smac that lacks the mitochondrial 
targeting sequence. Smacβ is still considered to be proapoptotic due to its ability to 
potentiate apoptosis following death receptor activation and chemical stimuli. 
Smac3 isoform contains both mitochondrial targeting and IAP binding motif 
sequence. Similar to Smac, upon apoptotic stress, Smac3 is released from the 
mitochondria into the cytoplasm where it interacts with XIAP. Smac3 is able to 
induce the acceleration of XIAP auto-ubiquitination and degradation whereas 
Smacβ only has this effect on cIAP1 and cIAP2 (LaCasse et al., 2008).  
1.2.9.3  Smac mimetics 
Smac/DIABLO is the natural inhibitor of XIAP activity that is released from 
the mitochondria to the cytoplasm following activation of the intrinsic pathway. 
Smac/DIABLO removes the inhibitory effect of XIAP on effector caspases allowing 
for apoptosis execution. Smac mimetics are molecules that echo the action of 
Smac/DIABLO and different types of Smac mimetics have been introduced as 
potential anticancer agents in multiple cancers; these include Smac based peptides, 





1.2.9.3.1 Peptides mimetics 
  A Fusion peptide of the last four to eight N-terminal residues of Smac 
combined with a carrier protein (Drosophila antennapaedia penetratin sequence) 
was able to enhance apoptosis induced by chemotherapeutic drugs (paclitaxel, 
etoposide, 7-ethyl-10-hydroxycamptothecin (SN-38), and doxorubicin) in MCF-7 
and other breast cancer cell lines. It has been shown that the Smac-penetratin fusion 
peptide crossed the cell membrane, bound XIAP and cIAP1, displaced caspase-3 
from cytoplasmic aggregates, and enhanced drug-induced caspase activation (Arnt 
et al., 2002). 
1.2.9.3.2 Polynucleotides mimetics 
Plasmid DNA containing full length and mature Smac increased sensitivity 
of leukaemia cell lines to UV (ultraviolet radiation) and TRAIL induced apoptosis 
(Jia et al., 2003). 
1.2.9.3.3 Small molecules mimetics 
Compound 3 was the first reported small molecule mimetic in 2004 by Li et 
al. (Li et al., 2004). Since then, many other Smac mimetic molecules have been 
introduced including SM-164 also known as Smac59 which is a bivalent Smac 
mimetic that has cell-permeable capabilities (Sun et al., 2007),  Low molecular 
weight LBW242 Smac mimetics (Weisberg et al., 2007), Compound A (Vince et 
al., 2007) and Smac37 (Cossu et al., 2009). 
1.2.9.4  Smac mimetics- induced apoptosis 
Several mechanisms by which Smac mimetics could induce apoptosis have 
been proposed; induction of TNF-α dependent apoptosis (Petersen et al., 2007), 
blocking of IAPs (Bockbrader et al., 2005), or antagonizing caspase-IAP 
interactions and repressing IAP ubiquitin ligase activities  (Creagh et al., 2004). 
Recently, it has been proposed that Smac mimetics induce apoptosis via formation 





1 (RIP1), FADD and caspase-8 and it assembles in response to Smac-mimetic 
induced depletion of XIAP, cIAP1 and cIAP2 (Tenev et al., 2011). 
Smac mimetics have been used successfully as a sensitiser for other 
therapeutics; compound 3 potentiated TRAIL and TNF-α-mediated cell death in 
human glioblastoma cells (Li et al., 2004), SH122 Smac mimetics sensitized 
prostate cancer cells to TRAIL-induced apoptosis (Dai et al., 2009b) and  Smac 
mimetic JP1201 sensitised non-small cell lung carcinoma cells to different standard 
chemotherapeutic drugs (Greer et al., 2011). Probst et al. showed that the 
combination effect of Smac mimetics and conventional chemotherapy in variable 
cancer cell lines was because of multiple mechanisms involving both inhibition of 
cell proliferation by the chemotherapy agents and enhanced autocrine TNF-α 
feedback loop by the Smac mimetic/chemotherapy combination (Probst et al., 
2010).  
1.2.10   TNF-alpha 
TNF-α is a cytokine that is involved in many biological responses, including 
inflammation, cell proliferation, differentiation and apoptosis. Although the 
molecular mechanisms of TNF signaling have been largely elucidated, the principle 
that regulates the balance between life and death is still unknown (Dai et al., 2009a).  
Several potential mechanisms for the involvement of TNFα signalling in 
Smac mimetic-induced apoptosis in cancer cells have been proposed. Smac-
mimetics stimulate autoubiquitination of cIAPs, resulting in their proteasomal 
degradation. This is in turn leads to NIK stabilization and facilitates RIP1 
recruitment and results in the activation of non-canonical and canonical NF-ҡB 
pathways, causing autocrine TNF-α production in many cell lines (Lu et al., 2007). 
Blocking NF-ҡB activation reduced TNF-α production and protected cells from 
Smac mimetic induced cell death (Ahn et al., 2007).  
Autocrine TNF-α secretion was a strong predictor of sensitivity to JP1201 
Smac mimetics in non small cell lung carcinoma cells as the sensitive cells showed 





by JP1201 in resistant cells to Vinorelbine was independent of TNF-α because 
knockdown of RIPK1, caspase8 or TNFR1 did not protect cells from combined 
treatment with JP and Vinorelbine (Greer et al., 2011). Autocrine TNF-α contributes 
to Smac mimetic-induced tumour regression as a single agent or in combination 
with chemotherapeutics in HCC461 lung cancer cell xenograft mouse models 
(Probst et al., 2010).  
1.3 DNA damage repair 
The initial reaction of a cell to DNA damage is to repair the damage. 
However, with increasing DNA damage the cell triggers cell cycle arrest or 
apoptosis. The maintenance of this switching mechanism is important for avoiding 
progression to cancer (Bernstein et al., 2002). DNA damage repair capacity varies 
between individuals as a result of inheritance, environmental factors and 
physiological factors. Cytogenetic and molecular analysis in oral cancer have shown 
changes in several chromosomes and genes, including those involved in the repair 
of DNA damage (Scully et al., 2000).  
Five major DNA repair pathways exist. In each of these DNA repair 
pathways, different proteins function to detect DNA damage and repair (Bernstein 
et al., 2002): 
1. Homologous recombinational repair (HRR) 
In homologous recombinational repair sequence information that is lost due 
to damage in one double stranded DNA molecule is accurately replaced by physical 
exchange of a segment from the homologous intact DNA molecule. 
2. Non homologous end joining (NHEJ) 
Non homologous end joining repairs double strand breaks and involves re-
joining of the broken ends. 
3. Nucleotide excision repair (NER) 
Nucleotide excision repair repairs DNA with double helix-distorting damage 





DNA defects, incision and removal of damaged strands and filling the gap by repair 
synthesis. 
4. Base excision repair (BER) 
 Base excision repair is a major DNA repair pathway protecting against 
single-base DNA damage caused by methylating and oxidizing agents. 
5. Mismatch repair (MMR) 
Mismatch repair is responsible for the post-replication correction of 
nucleotide mispairs and extrahelical loops as well as repairing DNA damage caused 
by variety of DNA damaging agents. 
 Studying the DNA damage responses is important for understanding cancer 
biology as DNA damage causes cancer, affects response to treatment and 
contributes to the side effects of treating cancer (Kastan, 2008). Impaired DNA 
repair was correlated with sensitivity of HNSCC cells to γ radiation suggesting that 
DNA repair might be critical for HNSCC treatment (Rusin et al., 2009). 
1.3.1 Excision repair cross complementation group 1 (ERCC1) 
Excision repair cross complementation group 1 (ERCC1) is a protein 
component of the nucleotide excision repair complex. It is  involved in both 
recognition of the damage and excision of the damaged part of DNA (Hoeijmakers, 
2001). Expression of ERCC1 was correlated with resistance of HNSCC patients to 
cisplatin-based chemotherapy (Handra-Luca et al., 2007). Genetic polymorphism in 
ERCC1 was found to be correlated to the response to radiotherapy in early head and 
neck cancers (Carles et al., 2006). In non small lung carcinoma, patients with 
cancers that were immunopositive to ERCC1 expression survived longer 
than patients with ERCC1 negative cancers and multivariate analysis suggested that 
ERCC1  expression  was an independent prognostic marker for long survival (Lee et 
al., 2008). ERCC1 may be an important prognostic marker and the correlation 
between ERCC1 expression and the clinical features or the survival of the patients 





1.3.2 Hypoxia inducible factor -1alpha (HIF-1α) 
Human cancers frequently contain areas of necrosis in which cancer cells 
have died due to inadequate oxygenation (hypoxia). A major mechanism mediating 
adaptive responses to hypoxia is the regulation of transcription by HIF-1. HIF-1 is a 
heterodimeric transcription factor composed of constitutively expressed HIF-1β 
subunit and O2-dependaent HIF-1α subunit. Under normoxic conditions HIF-1α 
degrades rapidly but under hypoxic conditions, HIF-1α accumulates in the nucleus, 
dimerizes with HIF-1β subunit and activates transcription of more than 100 target 
genes that are responsible for inducing cell proliferation, angiogenesis, local 
invasion and metastasis. Increased levels of HIF-1α in tumours have been 
associated with poor clinical outcome in different tumour types for example breast, 
cervical and endometrial cancers (Semenza, 2010). Hypoxia influences the response 
of HNSCC to radiotherapy. Radiation acts by generating highly reactive oxygen 
free radicals that damage DNA and this process is enhanced in the presence of 
oxygen. Hypoxia inducible factor-1 α (HIF-1α) is a key factor in hypoxia and 
increased HIF-1α expression in HNSCC has been correlated with poor loco-regional 
control when radiotherapy is the primary treatment (Silva et al., 2007). 
HIF-1α expression was a more significant adverse prognostic factor in the 
tonsil than the tongue base tumours and was significantly correlated with loco-
regional control and cancer specific survival (Silva et al., 2008). Low HIF-1α 
expression was significantly related to disease free survival in T2 stage oral tongue 
cancer patients (Roh et al., 2009). HIF-1α inhibitors sensitised tumours to radiation 
therapy (Semenza, 2010). However, HIF-1α expression was not predictive for radio-
sensitivity in human lung cancer cell lines (Schilling et al., 2012). Whether HIF-1α 
level could be used as a prognostic predictor for HNSCC patient treated with 
radiotherapy remains unclear.  
1.3.3 Ku80 
Ku is a nuclear protein originally identified as an autoantigen that was 





syndrome. The name Ku was derived from the first two letters of the family name of 
the patient. Ku protein is a complex of two subunits, Ku70 and Ku80. Ku protein 
plays a key role in multiple nuclear processes, for example, DNA repair, 
chromosome maintenance and transcription regulation. Ku protein is important for 
initiation of non homologous DNA end joining repair, for which heterodimerization 
between Ku70 and Ku80 is essential. Cells genetically deficient in either Ku70 or 
Ku80 are particularly sensitive to ionizing radiation (Koike, 2002). 
Ku80 overexpression is a common feature of HNSCC and highly predictive 
of loco-regional failure and death (Moeller et al., 2011). In vitro studies have shown 
that Ku80 overexpression correlated with radiation resistance in HNSCC cell lines 
(Chang et al., 2006) and that silencing Ku80 using small interfering RNA enhanced 
radiation sensitivity in lung, pancreas, oesophageal, prostate and breast carcinoma 
cell lines (Nimura et al., 2007). These findings suggest that Ku80 expression may 
provide a predictive test of radiosensitivity in head and neck cancers. 
1.3.4 Phosphate and tensin homolog deleted on chromosome 10 (PTEN) 
PTEN was first identified as a candidate tumour suppressor gene mutated in 
brain, breast and prostate tumours that mapped to chromosome 10q23. It is a central 
negative regulator of the PI3K/AKT signalling cascades that influences multiple 
cellular functions including cell growth, survival, proliferation and migration. PTEN 
was considered to be a strictly cytoplasmic protein however, recent studies have 
shown that the protein localizes to the nucleus of a wide variety of tissue types and 
model organisms (Chow and Baker, 2006). Cytoplasmic PTEN expression was 
correlated with histological grade and biological behaviour of oral squamous cell 
carcinoma; PTEN immuno-expression was higher in well differentiated carcinomas, 
reduced in less differentiated tumours and was completely absent at the invasive 
front (Squarize et al., 2002).  
In various human cancers, PTEN is frequently found to be mutated, deleted 
or epigenetically silenced. Recently PTEN was also found to play a critical role in 





defective double strand break repair (Ming and He, 2012). PTEN expression  seems 
to plays a role in the response of cancers to radiotherapy as reduced levels of PTEN 
were associated with radio resistance (Ming and He, 2012) and patients with high 
PTEN expression had a favourable outcome after accelerated postoperative 
radiotherapy, compared to patients with low PTEN expression. Furthermore, 
adenoviral-mediated expression of PTEN sensitised lung cancer cells to 
radiotherapy by suppressing DNA repair capacity (Pappas et al., 2007). PTEN may 
serve as a valuable prognostic and predictive marker in postoperative radiotherapy 
for high risk HNSCC (Snietura et al., 2012). 
1.3.5 Rad51 
Rad51 has a central role in homologous recombinational repair. It binds to 
DNA and promotes homologous pairing and strand exchange, which is a central 
reaction in the repair process. Overexpression of Rad51 protein increased resistance 
of mammalian cells to ionizing radiation (Vispe et al., 1998). Similarly, antisense 
inhibition of Rad51 in mouse models enhanced their radio-sensitivity and Rad51 
homozygous mutant mouse embryos were hypersensitive to ionizing radiation. This 
sensitivity was due to the loss of ability to repair double strands breaks (Bernstein et 
al., 2002). High levels of Rad51 protein expression have been reported in a number 
human cancer cell lines (Raderschall et al., 2002). Head and neck cancer patients 
with high Rad51 protein levels in their pre-treatment tumour biopsies demonstrated 
poor cancer-specific survival rates than patients with lower Rad51 levels (Connell et 
al., 2006). Similarly, elevated expression of Rad51 was associated with poor 
prognosis in oesophageal squamous cell carcinoma (Li et al., 2011). 
1.3.6 X-ray repair cross complementing 1 (XRCC1) 
XRCC1 protein plays an important role in repair of three common forms of 
DNA damage induced by ionizing radiation; single strand break repair, double 
strand break repair and base excision repair. After excision of damaged base, 





subsequent restoration of the site. XRCC1 deficient cells show reduced rate of 
repair of radiation induced single strand breaks (Thacker and Zdzienicka, 2003). 
High levels of ERCC1 and XRCC1 mRNA were detected in the peripheral 
blood of non-small cell lung carcinoma and HNSCC patients proportional to tumour 
expression which could allow the introduction of a simple clinical test to determine 
prognosis (Schena et al., 2012). High XRCC1 protein expression in HNSCC was 
associated with poor survival, especially in patients receiving chemoradiation (Ang 
et al., 2011).  
1.3.7 Human papilloma virus (HPV)  
HPV is a circular double-stranded DNA virus consisting of an 8-kb genome 
encoding viral and capsid proteins (de Villiers et al., 2004).  Over 120 types have 
been identified and are referred to by number, classified as either high risk or low 
risk types on the basis of their associations with genital and other carcinomas. The 
common  high risk types such as HPV-16 and 18 are associated with dysplasia that 
can progress to higher grade and to carcinoma while low risk types such as HPV-6 
and 11 are associated with benign genital lesions that rarely progress to cancer 
(Schlecht et al., 2001).  
High risk types code for at least three proteins with growth stimulating and 
transforming properties (E5, E6 and E7). E5 protein contributes to cellular 
transformation by increasing the mitogenic stimulus from growth factor receptors to 
the nucleus (Straight et al., 1993). The E6 and E7 proteins stimulate cellular 
progression through G1/S transition despite the presence of various G1 arrest 
signals in their host cells. E6 targets P53 protein through binding and inducing 
degradation. E7 targets retinoblastoma (pRb) gene causing its silencing. E2 encodes 
a regulatory protein which is involved in the negative regulation of E6 and E7 
expression. In high risk HPV types, the integration of the viral genome into host 
chromosomes results in the loss of the viral E2 which leads to constitutively high 
E6/E7 expression levels (Lagunas-Martinez et al., 2010) and is thought to 





HPV infection is recognized to play a role in the pathogenesis of a subgroup 
of HNSCC affecting tonsil and pharyngeal tissues. This subgroup is clinically 
characterized by the presence of high-risk HPV genomic DNA sequences in the 
tumours (approximately 95% contain HPV-16 DNA). Patients with HPV-positive 
HNSCC have a better prognosis than patients with HPV-negative HNSCC, in part 
because of their better therapeutic response to chemoradiotherapy (Gillison et al., 
2008). HPV positive cancers probably have a different molecular and phenotypic 
profile from HPV negative cancers, including poor differentiation (though how to 
assess differentiation is contentious as the normal epithelia are non-keratinising), 
scant keratinization and basaloid phenotype, compared with the typically 
keratinizing morphology of HPV negative tumours (Miller et al., 2012). 
Methods of determining HPV status in patient specimens involve detecting 
high risk HPV DNA or RNA either by in situ hybridization (ISH) or polymerase 
chain reaction (PCR). Additionally, mRNA expression of high risk HPV 
oncoproteins, such as E6 and E7 can be detected by qRT-PCR and indicates active 
infection. The p16 protein expression determined by immunohistochemistry is only 
an indirect marker for HPV infection  (Howard and Chung, 2012) but it does 
indicate biologically significant high risk infection because p16 levels are only 
raised when E6/7 is present.  
1.3.8 Cancer stem cells 
Recent data indicate that the initiation, growth, recurrence and metastasis of 
cancers are related to the behaviour of a small population of malignant cells with 
properties of stem cells (Mannelli and Gallo, 2012). A cancer stem cell is defined as 
a cell within a tumour that possesses the capacity to self renew and to generate the 
heterogeneous lineages of cancer cells that comprise the tumour (Clarke et al., 
2006).  
Radiobiological research over the past decades has provided evidence that 
cancer stem cell content and the intrinsic radiosensitivity of cancer stem cells varies 





Anticancer therapy can cure a tumour only if all cancer cells are killed (Dingli and 
Michor, 2006) and following radiotherapy any cancer stem cells left in its natural 
environment will cause tumour recurrence. The high proportion of cancer stem cells 
in tumour correlates with tumour radioresistance (Hill and Milas, 1989).  
Cancer stem cells have been identified in human head and neck squamous 
cell carcinoma (HNSCC) using markers such as CD133 and CD44 expression, and 
aldehyde dehydrogenase (ALDH) activity. The head and neck cancer stem cells 
reside primarily in perivascular niches in the invasive front (Zhang et al., 2012). 
Although the existence of cancer stem cells in most solid tumours has not been 
formally proven, application of the cancer stem cell concept has enhanced 
understanding of HNSCC heterogeneity and progression (Bhaijee et al., 2012). 
Further researches studying differences in radioresistance between cancer stem cells 
and non stem cells, determination of stem cell density and distribution of stem cells 
within tumours is essential for future optimization of treatment strategies and for 
individualization of radiotherapy(Baumann et al., 2008).  Therefore studying cancer 














1.4 Aims of the current study 
Most approaches used in cancer treatment, such as chemotherapy and 
radiation therapy, kill cancer cells by inducing apoptosis indirectly through the 
chemical or physical damage of DNA. However, cancer cells often develop 
resistance. Treatments that directly target and specifically activate apoptosis would 
be predicted to be both safer and more effective than existing therapies (Hunter et 
al., 2007).  
This study sought to investigate prognostic and predictive markers for 
outcomes of HNSCC to conventional and targeted therapy as well as identifying 
molecular markers useful for determining preoperative prognosis through routine 
tumour biopsy. The overall aim of this study was to identify a genetic signature of 
HNSCC patients to predict response to novel targeted therapeutics as well as 
radiotherapy.  
Specific objectives were to: 
 Test the sensitivity of HNSCC cell lines to two novel targeted 
therapeutic agents (IZ-TRAIL and Smac mimetic, (Smac59) 
 Identify biomarkers which could predict response of HNSCC cell 
lines to TRAIL and Smac59. 
 Investigate the underlying mechanisms of TRAIL and Smac59- 
mediated apoptosis in HNSCC cell lines. 
 Examine the expression level of different proteins involved in DNA 
damage repair and tumour hypoxia (ERCC1, HIF-1α, Ku80, PTEN, 
Rad51 and XRCC1) in HNSCC tissues using immunohistochemistry. 
 Correlate expression levels of the above proteins to overall and 
disease free survival of the patients. 
 Correlate expression levels of these proteins with the treatment 






 In the present studies, in which the aim was to assess carcinoma 
radiosensitivity and outcome and related biomarkers, it was 
important to identify HPV carcinomas because they are 
radiosensitive, have better survival and could act as a confounding 
factor in analysis.  These studies were not primarily targeted at HPV-
associated carcinomas, which have become of increasing interest 
since this work started.  At the outset, large numbers of HPV 
carcinomas were not available for analysis and only small numbers 
were likely to have been included in the study.  The object of these 
experiments was to identify any HPV-associated carcinomas in the 
study, analyse them separately and check that they did not confound 
analysis of the main non-HPV carcinomas.  It was not expected that 
there would be sufficient HPV-associated carcinomas for meaningful 
analysis of this subtype.  
 




2 Materials and Methods 
2.1 Materials  
Plastics used in tissue culture were purchased from Greiner Bio-one, UK (6, 
12, 24 and 96 well plates, 5, 10 and 25 ml pipettes, cell scrapers and cryovials) and 
PAA (15 and 50 ml Falcon tubes, 10 cm dishes, T25 and T75 flasks). 0.2 µm and 
0.45 µm filters were purchased from Fisher Scientific, UK. Solutions and buffers 
were stored at room temperature unless specified.  Cell culture media were stored at 
4ºC. 
2.1.1 Chemicals and solutions 
All chemicals were purchased from Sigma-Aldrich, UK unless stated 
otherwise. 
Ammonium persulfate (APS) 
10%APS solution was made in dH2O and stored at 4ºC for a maximum of 
two weeks. 
Blasticidin S 
Blasticidin 10mg/ml purchased from InvivoGen (cat# ant-bl-1) 
Blocking buffer for western blotting 
5 or 10% (w/v) Marvel milk powder (purchased from Sainsbury 
supermarket) in Tris-Buffered Saline-Tween20 (TBST) 
Caspase inhibitor 
20 mM caspase inhibitor Z-VAD-FMK, purchased from Promega (cat# 
G7231) 
Coomassie Brilliant Blue staining solution for Western blotting 
 0.25% Coomassie Brilliant Blue G-250 (cat# 6104-58-1) 




 45% methanol  
 44.75% dH2O 
 10% acetic acid 
Coomassie Brilliant Blue destain 
 45% methanol 
 45% dH2O 
 10% acetic acid 
Coumaric acid 
 90 mM p-coumaric acid in Dimethyl Sulfoxide (DMSO) 
 Stored at -20 ºC 
Dulbecco’s Modified Eagle Media (DMEM) 
Purchased from PAA (Cat # E15-810) and supplemented before use with 
 10% fetal calf serum (FCS), PAA (cat# A15-151) 
 50 µg/ml streptomycin 
 100 µg/ml penicillin 
 1 mM sodium pyruvate 
Dulbecco’s Modified Eagle Media-Ham’s F12 (DMEM-F12)  
Purchased from Gibco BRL (cat# 21331-020) and supplemented before use 
with 
 4 mM L-Glutamine 
 25 µg/ml hydrocortisone 
 5% Fetal calf serum (FCS) 
 50 µg/ml streptomycin 
 100 µg/ml penicillin 
 1 mM sodium pyruvate 
 




EDTA buffer (10x), pH 8.0 
1 mM EDTA, made in dH2O, pH was adjusted to 8.0 and the solution was 
stored at 4ºC 
Enhanced Chemiluminescece (ECL) buffer 
 100 mM Tris-HCL (tris [hydroxymethyl] aminomethane hydrochloride) pH 
8.5 
 Stored at 4ºC  
ELISA assay buffer   
 1x  phosphate buffered saline (PBS)  
 0.5% Bovine Serum Albumin (BSA) 
 0.1% Tween 20 
 Stored at 4ºC 
ELISA kit for TNF-α  
 Human TNF-α CytoSetTM, 10 plates format purchased from Invitrogen (cat# 
CHC1753) and consisted of 
 Coating antibody: anti-human TNF-α 
 Detection antibody: anti-human TNF-α Biotin 
 Standard: recombinant human TNF-α 
 Streptavidin-HRP 
ELISA wash buffer 
 1x phosphate buffered saline (PBS) 
 0.05% Tween 20 
FACS buffer for flow cytometry 
 1x phosphate buffered saline (PBS) 
 4% fetal calf serum (FCS) 
 




Freezing medium for cell culture 
 10% Dimethyl Sulfoxide (DMSO)  
 20% fetal calf serum (FCS) 
 70% Dulbecco’s Modified Eagle Media (DMEM)  
 Stored at 4ºC 
G418 sulphate  
Purchased from InvivoGen (Cat# ant-gn-1) 
IZ-TRAIL 
 Recombinant human isoleucine zipper trimerization TRAIL (Ganten et al., 
2006) 
 From Prof. Henning Walczak, Imperial College London 
Keratinocyte Growth Medium-2 (KGM-2) BulletKit  
 Purchased from Lonza (Cat# CC3107) and consisted of 
 Keratinocyte basal medium, supplemented before use with; 
 0.5 ml Hydrocortisone 
 0.5 ml Transferrin  
 0.25 ml Epinephrine  
 0.5 ml Gentamicin, amphotericin (GA-1000)  
 0.5 ml Bovine pituitary extract (BPE) 
 0.5 ml Recombinant human epidermal growth factor (rhEGF)  
 0.5 ml Bovine insulin 
Laemmli Sample Buffer 
 62 mM Tris base pH 6.8 
 10% glycerol 
 2% SDS 
 5% β-mercaptoethanol 




 Luria-Bertani (LB)-agar plates 
 1.5% (w/v) agar in Luria-Bertani medium 
 Sterilised by autoclaving  
 Cooled to 50ºC 
 Appropriate antibiotic was added 
 Poured in 10 cm plates  
Luminol 
 250 mM luminol in DMSO 
 Stored at -20ºC in the dark. 
Luria-Bertani medium 
 1% NaCl 
 0.5% Bacto-yeast extract 
 1% Bacto-tryptone 
 Made up in dH2O  
  pH was adjusted to 7.0 with 5M NaOH. 
 Sterilised by autoclaving. 
Midiprep solutions  
Plasmid Midi Kit was purchased from QIAGEN (cat#12143) 
Miniprep solution  
Wizard
® 
Plus SV Minipreps DNA Purification System was purchased from 
Promega (Cat# A1330) 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) stock 
 5 mg/ml MTT (Merck chemicals, cat# 475989)  
 Prepared in phosphate buffered saline (PBS) 
 Sterilised by filtering through a 0.2 µm filter 




 Stored in -20ºC in dark 
Opti-MEM reduced serum medium 
Purchased from Invitrogen (cat# 31985047) 
Phosphate –Buffered Saline (PBS) 
 140 mM NaCl 
 2.7 mM KCl 
 8.0 mM Na2HPO4 
 1.5 mM KH2PO4 
 Made in dH2O and sterilised by autoclaving. 
Penicillin/Streptomycin (500x) stock solution 
 1.25 g Streptomycin sulphate 
 2.5 g Penicillin 
 Made in 50 ml dH2O  and sterilised by filtering through a 0.2 µm filter 
Phenylmethyl-sulfonyl fluoride (PMSF) 
10 mM PMSF was made in isopropanol and stored at -20ºC. 
Running/Transfer buffer (10x) for western blotting 
 250 mM Tris base 
 2.5 M Glycine 
 1% sodium dodecyl sulphate (SDS) 
 Made in dH2O 
Running buffer (1x) for western blotting 
 10% 10x Running/Transfer buffer  
 90% dH2O 
SDS-Polyacrylamide Resolving gel 10% (10 ml) 
 The reagents were added in order as follow 




 4 ml dH2O 
 3.3 ml acrylamide mix (purchased from Fisher Scientific, cat# EC-890-1) 
 2.5 ml 1.5M Tris pH 8.8 
 1 ml 10%  sodium dodecyl sulphate (SDS) 
 1 ml 10% ammonium persulphate (APS) 
 0.004 ml TEMED  
SDS-Polyacrylamide Resolving gel 12% (10 ml) 
 3.3 ml dH2O 
 4 ml acrylamide mix 
 2.5 ml 1.5M Tris pH 8.8 
 1 ml 10%  sodium dodecyl sulphate (SDS) 
 1 ml 10% ammonium persulphate (APS) 
 0.004 ml TEMED  
 
 SDS-Polyacrylamide Stacking gel 5% (4 ml) 
 2.7 ml dH2O 
 0.67 ml acrylamide mix 
 0.5 ml 1 M Tris pH 6.8 
 0.04 ml 10%  sodium dodecyl sulphate (SDS) 
 0.04 ml 10% ammonium persulphate (APS) 
 0.004 ml TEMED 
siRNA (small inhibitory RNA) 
XIAP siRNA oligonucleotide was purchased from MWG Biotechnology 
 5’ AUCCAUCCAUGGCAGAUUA 3’ 
Smac mimetic (Smac59, SM-164) 
 Bivalent Smac mimetic (Sun et al., 2007) 
 From Prof Dominico Delia, Fondazione IRCCS Istituto Nazionale Tumori, 
Milan, Italy 




Sodium citrate buffer pH 6.0 
 10 mM anhydrous citric acid 
 1M  NaOH 
 Made in dH2O, pH was adjusted to 6.0 and the solution was stored at 4ºC 
Sodium dodecyl sulphate (SDS) 10%  
 10% (w/v) solution of SDS was made in dH2O 
  pH was adjusted to 7.2 with concentrated HCl 
Solubilisation solution for MTT assay 
 50% dimethylformamide 
 0.2% glacial acetic acid 
 20 mM HCl 
 10% SDS 
 Made in dH2O 
Stripping buffer for western blotting 
Re-Blot Plus (strong/mild) solutions were purchased from Millipore (cat# 
2504/2502)  
Tris-Buffered Saline TBS (10x)  
 250 mM Tris base 
 1.5 M NaCl 
 Made in dH2O 
 pH adjusted to 7.4 with concentrated HCl 
 sterilized by autoclaving 
Tris-Buffered Saline-Tween 20 (TBST) 
0.05% Tween 20 in 1x TBS 
 




Tris/EDTA buffer pH 9.0 
 10 mM Tris Base 
 1 mM EDTA  
 Made in dH2O 
 pH was adjusted to 9.0  
 Stored at 4ºC 
Tris-EDTA (TE) 
 10 mM Tris-HCl pH 8.0 
 1 mM EDTA pH 8.0 
 Made in dH2O 
TMB Substrate Kit 
Purchased from Thermo Scientific (cat# 34021) 
TNF-α (recombinant human) 
 Recombinant human TNF-α  
 Gift from Prof. Henning Walczak, Imperial College London. 
Transfection Reagents 
 X-tremeGENE HP DNA Transfection Reagent, purchased from Roche (cat# 
06 366 244 001) 
 X-tremeGENE siRNA Transfection Reagent, purchased from Roche (cat# 
04 476 093 001) 
Transfer buffer (1x) for western blotting 
 10% 10x running/transfer buffer 
 20% methanol 
 70% dH2O 
Trypsin (1x) 
 10% 10xTrypsin purchased from Sigma (cat# T4549) 




 90% versene  
Versene 
 0.270 mM EDTA pH 8.0 
 Made in PBS and sterilised by autoclaving 





Primary antibodies listed by antigen 
β-Actin 
 Mouse monoclonal anti-β-Actin (AC-15) 
 Provider: Sigma Aldrich (cat# A5441) 
 Dilution: 1:5000 (Western Blotting) 
Bcl-2 
 Mouse monoclonal anti- Bcl-2 (100)  
 Provider: Santa Cruz Biotechnology (cat# sc-509) 
 Dilution:1:1000 (Western Blotting) 
Caspase-3  
 Rabbit polyclonal anti-caspase-3 
 Provider: Cell Signaling (cat# 9662) 
 Dilution: 1:1000 (Western Blotting) 
Caspase-8 
 Mouse monoclonal anti-caspase-8 (1C12) 
 Provider: Cell Signaling (cat# 9746) 
 Dilution: 1:1000 (Western Blotting) 
CD 120a (TNF-R1) 
 Mouse monoclonal anti-human CD120a (TNF-R1), clone H398 
 Provider: ABD Serotec (cat# MCA2789Z) 
 Dilution: 10 µg/ml, functional assays 
cIAP-1 
 Affinity-purified goat anti-human cIAP-1 (HIAP) Antibody 
 Provider : RandD system (cat# AF8181) 




 Dilution: 0.5 µg/ml (Western Blotting) 
cIAP-2 
 Purified mouse anti-human c-IAP-2 
 Provider : BD Pharmingen (cat# 552782) 
 Dilution: 4 µg/ml (Western Blotting)  
EGFR 
 Monoclonal mouse anti-EGFR (F4) 
 Provider: Gift from Prof. William Gullick, Department of Bioscience, 
University of Kent at Canterbury, UK 
 Dilution: 1:1000 (Western Blotting) 
ERCC1 
 Mouse monoclonal anti-ERCC1 
 Provider: ABR-Affinity (cat# MA1-21734) 
 Dilution: 1:50 (Immunohistochemistry) 
c-FlIP  
 Mouse monoclonal anti-human FLIP (NF6) 
 Provider: Enzo Life Science (cat# ALX-804-428) 
 Dilution: 1:500 (Western Blotting) 
HIF-1α 
 Mouse monoclonal anti-human HIF-1α 
 Provider: Becton Dickinson (cat# 610958) 
 Dilution: 1:50 (Immunohistochemistry) 
HS101 and HS201  
 Mouse monoclonal anti-TRAIL receptor 1  and 2 antibodies 
 Provider: gift from Prof. Henning Walczak, Imperial college London 
 Dilution: 5 µg/ml ( flow cytometric analysis)  





 Neutralizing IgA monoclonal antibody to human tumour necrosis factor 
alpha 
 Provider: InvivoGen (ca# maba-htnfa) 
Ik-Bα 
 Mouse monoclonal anti-Ik-Bα (L35A5) 
 Provider: Cell Signaling (cat# 4814) 
 Dilution: 1:1000 (Western Blotting) 
KU80 
 Rabbit polyclonal anti-KU80 
 Provider: Cell Signaling (cat# 2753) 
 Dilution: 1:200 (Immunohistochemistry) 
Mcl-1 
 Rabbit polyclonal anti-Mcl-1 
 Provider: Cell Signaling (cat# 4572) 
 Dilution: 1:1000 (Western Blotting) 
PARP 
 Mouse monoclonal anti-cleaved PARP  
 Provider: Cell Signaling (cat# 9548) 
 Dilution: 1:1000 (Western Blotting) 
PTEN 
 Mouse monoclonal anti-human PTEN 
 Provider: Dako (cat# M3627) 
 Dilution: 1:50 (Immunohistochemistry) 
P16  
 Mouse ant-human p16 INK4a antibody 




 CINTec Histology V-kit, cat# 9512 
Rad51 
 Mouse monoclonal anti-Rad51 
 Provider: Abcam (cat# ab54188) 
 Dilution: undiluted (Immunohistochemistry)  
Smac/DIABLO  
 Rabbit polyclonal anti-human-SMAC/DIABLO  
 Provider: Epitomics (Cat# 1012-1) 
 Dilution: 1:1000 (Western Blotting) 
XIAP 
 Purified mouse monoclonal anti-XIAP 
 Provider: BD Transduction Laboratories (cat# 610762) 
 Dilution: 1:4000 (Western Blotting) 
XRCC1 
 Mouse monoclonal anti-XRCC1 
 Provider: Abcam (cat# ab1838) 
 Dilution: 1:50 (Immunohistochemistry) 




Secondary antibodies listed by source species 
Anti-mouse peroxidase based Dako EnVision system- HRP-DAB 
 Provider: Dako (cat# K4007) 
  Used for Immunohistochemistry with mouse  monoclonal primary 
antibodies 
Anti-Rabbit peroxidase based Dako EnVision system- HRP-DAB 
 Provider: Dako (cat# K4011) 
  Used for Immunohistochemistry with rabbit polyclonal primary antibodies 
Donkey-anti-goat IgG secondary antibody conjugated to horseradish 
peroxidase 
 Provider: RandD System (cat# HAF109) 
 Dilution: 1:1000 (Western Blotting) 
Donkey-anti-rabbit IgG secondary antibody conjugated to horseradish 
peroxidase 
 Provider: Fisher scientific (cat# NA934) 
 Dilution: 1:2000 (Western Blotting) 
Goat-anti-mouse IgG secondary antibody conjugated to horseradish 
peroxidase 
 Provider: Sigma Aldrich (cat# A0168) 
 Dilution: 1:4000 (Western Blotting) 




2.1.3 Cell lines 
HSC3 
 Human head and neck squamous cell carcinoma (HNSCC) cell line  
 Gift from Dr Kazuya Tominaga, Department of Oral Pathology, Osaka 
Dental University. Japan 
HSC3M3 
 HNSCC cell line 
  Gift from Dr Kazuya Tominaga, Department of Oral Pathology, Osaka 
Dental University. Japan 
HN5 
 HNSCC cell line  
 Gift from Dr Barry Gusterson, Department of Pathology, University of 
Glasgow, UK 
HN30 
 HNSCC cell line 
 Gift from Dr Andrew Yeudall, Virginia Commonwealth University, school 
of Dentistry Philips Institute of Oral and Craniofacial Molecular Biology. 
USA  
H357 
 HNSCC cell line 
 Gift from Dr Stephen Prime, Department od Oral and Dental Science, 
University of Bristol. UK 
UMSCC74A 
 HNSCC cell line 
 Gift from Dr Thomas E. Carey, University of Michigan, Ann Arbor. USA 
UMSCC74B 
 HNSCC cell line 
 Gift from Dr Thomas E. Carey, University of Michigan, Ann Arbor. USA 
UMSCC11B 
 HNSCC cell line 




 Gift from Dr Thomas E. Carey, University of Michigan, Ann Arbor. USA 
UMSCC22B 
 HNSCC cell line 
 Gift from Dr Thomas E. Carey, University of Michigan, Ann Arbor. USA 
Normal Human Keratinocyte (NHK) 
 Primary Oral keratinocyte 
 Gift from Prof. Paul M. Speight, Department of Oral Pathology, School of 
Clinical Dentistry, University of Sheffield 
HaCat 
 Spontaneously immortalized Keratinocyte cell line 
 Gift from Prof P Morgan, Department of Oral Pathology, Dental Institute, 
King’s College London. UK 
H357-bcl2  
 H357 cells stably expressing Bcl-2 
 Gift from Dr Marcella Flinterman. Head and Neck Oncology group, Dental 
Institute, King’s College London. UK 
HSC3M3- bcl2 
 HSC3M3 cell line stably transfected with Bcl-2 expression vector 
 Constructed for this research project 
UMSCC11B-sh-XIAP and UMSCC-sh-LacZ 
 UMSCC11B cell line stably transfected with Plenti6/V5 DEST-sh-XIAP or 
Plenti6/V5 DEST-sh-lacZ plasmid 
 Constructed for this research project 






 pcDNA3 plasmid expressing human bcl-2 
 From Prof. Christoph Borner, Institute of Molecular Medicine and Cell 
Research, Albert-Ludwigs-University of Freiburg, Germany 
PLenti6-sh-XIAP 
 Plenti6/V5-DEST plasmid containing inhibitory sequence against h-XIAP 
 From Prof. Hamid Kashkar, Institute for Medical Microbiology, 
Immunology and Hygiene, University of Cologne, Germany 
PLenti6-sh-lacZ 
 Plenti6/V5-DEST plasmid containing inhibitory sequence against Lac-Z 
 From Prof Dominico Delia, Fondazione IRCCS Istituto Nazionale Tumori, 
Milan, Italy 




2.2 Methods  
2.2.1  Cell culture 
Unless otherwise specified, all cells were maintained at standard culture 
conditions (37ºC and 5% CO2) 
2.2.1.1  Cell line maintenance 
HaCat, HSC3, HSC3M3, HN5, HN30, UMSCC11B, UMSCC22B, 
UMSCC74A and UMCSCC74B were cultured in DMEM supplemented with 10% 
fetal calf serum (FCS), 50µg/ml streptomycin, 100µg/ml penicillin and 1mM 
sodium pyruvate and incubated at 37ºC and 5% CO2. H357 was cultured in DMEM-
F12 supplemented with 5% FCS, 4mM L-Glutamine, 25µg/ml hydrocortisone, 
50µg/ml streptomycin, 100µg/ml penicillin, and 1mM sodium pyruvate. NHK were 
cultured using keratinocyte growth medium-2 bulletKit which consists of 
Keratinocyte Basal Medium (KBM) supplemented before use with Bovine Pitutary 
Extract (BPE), human Epidermal Growth Factor (hEGF), bovine insulin, 
Hydrocortizone, GA-1000 (Gentamicin, Amphtericin), Epinephrine and Transferrin 
(all these reagents were supplied with the kit). For Bcl-2 expressing cells, G418 was 
added at 400µg/ml for selection. For Plenti-sh-XIAP and Plenti-sh-LacZ cells, 
Blasticidin was added at 5µg/ml for HSC3M3 cells and at 10µg/ml for UMSCC11B 
cells. 
2.2.1.2  Passaging of cell lines  
Cells were sub-cultured every 3-5 days or when confluent. The old medium 
was removed and the cells were washed with 5ml versene and then incubated with 
1x trypsin at 37ºC and 5% CO2 for 1-5 min depending on cell line. Once cells 
became rounded and detached from the plates, they were re-suspended in fresh 
medium and seeded at the desired density. 




2.2.1.3  Freezing and thawing of cell lines 
Cells were trypsinized as mentioned in 2.2.1.1 and centrifuged for 5 min at 
900g in IEC Centra-4x centrifuge, international equipment company, UK. The cell 
pellet was resuspended in 1ml freezing medium, transferred to a cryovial and stored 
in container filled with isopropanol to control the freezing speed and kept at -70ºC 
for 24 hours before being moved to liquid nitrogen. To thaw the cells, they were 
taken from liquid nitrogen, thawed in the vial in a 37ºC water bath and plated in 10 
cm dishes with 9ml of fresh medium pre-warmed to 37ºC and incubated at 37ºC and 
5% CO2. Fresh medium was added 24 hours later. 
2.2.1.4  Cell counting 
The cells were trypsinized and resuspended in fresh medium. 10µl of cell 
suspension was pipetted into the counting chambers of a haemocytometer (SLS, 
cat# HAE2118) and the number of cells in the outer 4 large squares was counted. 




2.2.2 MTT cell viability assay 
To assess the viability of cell population in response to different treatments, 
cells were seeded in 96 well plates at a density of 2-4 x10
3
 cells in 100µl 
medium/well. After 24 hours, the medium was removed and the drug was dissolved 
in fresh medium and 100µl was added to cells. The cells were incubated for 24-72 
hours at 37ºC and 5% CO2. Then 20µl of MTT solution was added to each well, 
incubated with cells for 2-4 hours at 37ºC and 5% CO2 before adding 150µl of 
solubilisation solution to each well. The plates were incubated for a further 16-24 
hours and the optical density (OD)595 was measured using LT-400 micro-plate 
reader, Labtech, using Manta software. The results were calculated after 
background subtraction by comparing the readings for treated cells in relation to 
control untreated cells. 




2.2.3   Western blotting 
2.2.3.1  Protein extraction 
In order to lyse the cells for protein extraction, growth medium was 
removed, and the cells were washed twice with 5ml cold PBS. Cells were lysed by 
adding Laemmli sample buffer and scraping the cells with sterile disposable cell 
scraper (Greiner Bio-one). Lysates were kept on ice until use or at -20ºC for long 
term storage. Lysates were homogenized using Kontes Pellet Pestle Micro Grinders 
(Cat #SF24837V) and boiled for 5 min before loading onto SDS-PAGE gel. 
2.2.3.2  SDS-polyacrylamide gel preparation and electrophoresis 
The vertical gel-casting apparatus was set up according to the 
manufacturer’s instructions (Bio-Rad, Mini PROTEIN II, cat# 165-2940). The 
resolving polyacrylamide gel solution was prepared and poured. 200µl of 100% 
ethanol was added on top of the gel to flatten its surface. After the gel had set the 
ethanol was removed with filter paper, then the gel was washed with dH2O and 
dried with filter paper. The stacking gel was prepared and poured on top of the 
resolving gel and the comb was inserted. After the gel had set, the comb was 
removed and the gel was placed into the electrophoresis apparatus. The gel tank was 
filled with 1x running buffer and equal amounts of protein were loaded in each 
well.The first lane was loaded with 4µl of protein molecular weight marker 
(Fermentas, cat# SM0671). Electrophoresis was performed for 1.5-2 hours at 80V. 
2.2.3.3  Coommassie Brilliant Blue staining 
5µl of lysate of each sample was run in SDS-PAGE gel. Then the gel was 
incubated with Coommassie Brilliant Blue stain for at least 4 hours and destained 
with Coommassie Brilliant Blue destain for 24 hours on a rocking table. By 
comparing the intensity of the protein staining, equal amounts of protein could be 
loaded for protein expression testing. 




2.2.3.4  Transfer of proteins onto a nitrocellulose membrane 
Proteins were transferred onto 0.45µm pore nitrocellulose membrane 
(Schleicher and Schuell, cat# BA85-401191). In a tray filled with 1x transfer buffer, 
a soft scouring pad was put onto the black side of a transfer cassette, followed by 2 
pieces of 3mm filter paper (Whatman, cat# 3030917), the gel, the nitrocellulose 
membrane and another 2 pieces of filter paper, all cut to the same size as the gel. A 
soft scouring pad was put on top, the transfer cassettes were closed and placed in the 
transfer tank (Bio-Rad Mini PROTEIN II) filled with 1x transfer buffer. Transfer 
was performed at 50V for 2-3 hours at 4ºC or 40mA overnight at room temperature. 
2.2.3.5  Probing of western blot and detection 
The antibodies used for western blot analysis were directed against β-Actin, 
Bcl-2, Caspase-3, Caspase-8, cIAP-1, c-IAP-2, EGFR, Ik-Bα, Mcl-1, FLIP, PARP, 
Smac/DIABLO and XIAP. The blots were blocked for 30min in 5% blocking buffer 
followed by incubation with primary antibody diluted in 5% blocking buffer at 
concentrations mentioned at 2.1.2 for 1.5 hour at room temperature or overnight at 
4ºC on a rocking table . The blots were then rinsed 3times in TBST and washed 
once for 15min and 2times for 5min in TBST. Then the blots were incubated with 
secondary anti-mouse, anti-rabbit or anti-goat antibodies diluted in 5% blocking 
buffer. Finally the blots were rinsed three times in TBST, washed for 1 hour 
followed by further 2washes of 5min each in TBST. 
2.2.3.6  Enhanced Chemiluminescence detection method (ECL)  
10ml of the ECL buffer was first mixed with 3µl H2O2, then with 25µl 
coumaric acid and 50µl luminol. The blots were incubated with ECL solution for 
1min, drained and wrapped in cling film and exposed to RX autoradiograph film 
(Fuji) from 5sec to 20min. Before re-probing with another primary antibody, the 
blot was stripped with stripping buffer for 15min and incubated with blocking 
buffer 2times for 5min each. 




2.2.4 Enzyme Linked ImmunoSorbent Essay (ELISA) 
ELISA test was used for detecting the secreted TNF-α in cells growth 
medium, to prepare samples for ELISA, an equal number of cells under 
investigation were seeded in 1ml medium in 12well plates, incubated at 37ºC and 
5% CO2.  After 24 hours, medium was replaced with fresh medium to which TRAIL 
50ng/ml or Smac59 50nM were added, and incubated for further 24 hours. The 
medium was removed and stored at -70ºC until it was used to measure the level of 
secreted TNF-α using ELISA. 
ELISA was performed according to manufacture instructions, briefly, the 
capture/coating antibody (anti-human TNF-α) was diluted 1:1000 to a final 
concentration of 2µg/ml in PBS and 100µl was added to each well in a 96well 
polysterene plate (Nunc Immunosorp, cat# 475094). The plate was incubated 
overnight at 4ºC in a humid chamber, supernatant aspirated and the wells were 
washed once with ELISA wash buffer. 250µl of ELISA assay buffer was added to 
each well. The plate was then incubated at room temperature for 1-2hours. Assay 
buffer was aspirated and the wells were washed once with ELISA wash buffer. Test 
samples of cell medium and standards of recombinant human TNF-α, was added in 
100µl to designated wells and were then incubated at room temperature for 2hours. 
Then samples and standard were aspirated, wells were washed 3times with ELISA 
wash buffer. 100µl of detection antibody (1:1250 in ELISA assay buffer) was added 
to each well and the plate was incubated at room temperature for further 2 hours. 
Wells were then washed 3times, and 100µl of streptavidin-HRP solution (diluted 
1:1000 in ELISA assay buffer) was added to each well and incubated at room 
temperature for 30min. Wells were washed 3times, and 50µl TMB substrate was 
added and the plate was incubated in the dark for 10-20 min or until the colour 
developed. Finally 50µl of 2N H2SO4 stop solution was added and the colour 
intensity was measured at OD450 using an LT-4000 micro plate reader and Manta 
software. 




2.2.5 Transformation of plasmid DNA into competent bacterial cells 
2µl of plasmid DNA in Tris-EDTA buffer was added to 100µl of competent 
cells (One-Shot mach1 T1, Invitrogen, cat# C8620-03). The mixture was mixed by 
flicking the tube gently 2-3times. The cells were incubated on ice for 30min, 
transferred to a heat block at 42ºC for 30sec and back on ice for 2 min. 400µl of LB 
medium was added and the cells were then incubated in water bath at 37ºC for 
1hour. The cells were spun at 13000g for 1min and 300µl of supernatant was 
discarded. Cells were resuspended in the remaining medium and 50µl of this 
suspension was plated on an agar plate containing the appropriate selection 
antibiotic (carbencillin or kanamycin) and were incubated overnight at 37ºC. A 
single colony was used to inoculate LB medium for mini- or midi-prep plasmid 
isolation. 
2.2.6  Plasmid mini-prep 
10ml of LB medium containing either 50µg/ml carbencillin or 25µg/ml 
kanamycin as appropriate was inoculated with a single bacterial colony, grown 
overnight at 37ºC with shaking at 220 rpm. The mini-prep was performed using the 
Wizard
® 
Plus SV Minipreps DNA Purification System (Promega) following 
centrifugation protocol recommended by the manufacturer. Briefly, the overnight 
culture was centrifuged at 6000g for 5min to harvest the bacterial cells, and then the 
cleared lysate was produced by adding 250µl cell suspension solution, 250µl cell 
lysis solution, 10µl alkaline protease and 350µl neutralization solution to the 
bacterial cell pellet and centrifuged at 13000g for 10min at room temperature. 
Binding of plasmid DNA to column was performed by centrifugation of the cleared 
lysate within the column at 13000g for 1min at room temperature. Then the column 
was washed by adding 750µl wash solution and centrifuged at 13000g for 2min at 
room temperature. Finally the plasmid DNA was eluted by 100µl of nuclease free 
water to the spin column and centrifuged at 13000g for 1 min at room temperature 
then stored at -20ºC until the DNA concentration was measured using NanoDrop 
spectrophotometer (Thermo Scientific). 




2.2.7  Plasmid midi-prep 
5ml of LB medium containing either 25µg/ml carbencillin or 12.5µg/ml 
kanamycin as appropriate was inoculated with a single bacterial colony, grown for 
6-8 hours at 37ºC with shaking at 220rpm. Then 100µl of this culture was added to 
inoculate 50ml LB medium containing appropriate antibiotic and grown overnight 
at 37ºC with shaking at 220rpm. Large quantities of plasmid DNA were purified 
using DNA purification columns from a midi-prep kit (QIAGEN) as recommended 
by the manufacturer. Briefly, the bacterial cells were harvested by centrifuging 
50ml of overnight culture at 6000g for 15min at 4ºC, then the bacterial pellet was 
resuspended in 4ml resuspension buffer, then 4ml lysis buffer was added and the 
cells were incubated for 5min at room temperature. 4ml of neutralization buffer was 
added to the previous mixture and incubated for 15min on ice before it was 
centrifuged for 1hour at 2000g and 4ºC. 4ml equilibration buffer was passed 
through the purification column before applying the supernatant to pass through the 
column. The plasmid DNA was then eluted using 5ml elution buffer, then DNA was 
precipitated by adding 3.5ml isopropanol and centrifuged at 5000g for 1hour at 4ºC. 
Supernatant was then removed and pellet was washed with 70% ethanol and 
centrifuged at 5000g for 1hour at 4ºC. Supernatant was removed and pellet was air 
dried and then dissolved in 150µl TE buffer and stored at 4ºC until measuring DNA 
concentration using NanoDrop. 
2.2.8 Transfection using X-tremeGENE HP DNA Transfection Reagent 
The transfection was performed using X-tremeGENE HP DNA Transfection 
Reagent blend of lipids that complexes with and transports DNA into cells as 
recommended by the manufacturer (Roche). Cells were plated 24hours before 
transfection in 12well plates in growth medium and incubated at 37ºC and 5% CO2. 
1.0µg of plasmid DNA was added to 100µl Opti-MEM reduced serum medium and 
mixed gently, and then 2µl of X-tremeGENE HP DNA Transfection Reagent was 
added to the diluted DNA mixture and mixed gently. The mixture was incubated at 
room temperature for 15-30min to allow X-tremeGENE HP Reagent:DNA complex 




formation. The mixture was added drop-wise to different areas of the well. The 
plate was gently rocked back-and-forth and side-to-side to evenly distribute the X-
tremeGENE HP Reagent:DNA complex. The cells were then incubated at 37ºC and 
5% CO2 for 24-72hours until tested. 
2.2.9  Transfection using X-tremeGENE siRNA Transfection Reagent 
siRNA transfection was performed using X-tremeGENE siRNA 
Transfection Reagent (Roche). Cells were plated 24 hours before transfection in 24 
well plate in growth medium and incubated at 37ºC and 5% CO2. The transfection 
reagent: siRNA complex was prepared in separate eppendorf test tubes; the first was 
to dilute 10µl of the X-tremeGENE siRNA transfection reagent in 40µl of Opti-
MEM serum reduced medium. The second was to dilute 2µg of siRNA in Opti-
MEM serum reduced medium to a total volume of 50 µl. The content of both tubes 
was mixed within 5min, and incubated for 15-20min at 15-25ºC to allow X-
tremeGENE HP Reagent:siRNA complex formation. The mixture was then added 
drop-wise to the cells and the plate was swirled to ensure complete and even 
distribution. The cells were incubated with the mixture for 24 to 48 hours and the 
gene knockdown was tested using western blotting. 
2.2.10   Cloning of cells 
2.2.10.1  Titration of antibiotic stocks (kill Curves) 
Prior to using G418 and Blasticidin to establish stable cell lines, the optimal 
concentration of the selectable marker for each cell line was determined. Cells were 
plated in 12well plates containing 1ml of complete growth medium with either 0, 
50, 100, 200, 400 and 800µg/ml of G418 or 0, 5, 7 and 10µg/ml of Blasticidin. The 
cells were incubated at 37ºC and 5% CO2 for 10-14 days, the selective medium was 
replaced every 4days and the cells were checked for cell death every 2days. The 
concentration used for selection was the lowest concentration that gave detectable 
cell death in up to 5days and killed all the cells within two weeks. 




2.2.10.2  Establishment of stably transfected cell lines 
Cells were plated and transfected with the construct of interest as mentioned 
in 2.2.5. After 24 hours, the medium was replaced with fresh medium supplemented 
with the selection antibiotic G418 or Blasticidin at a concentration previously 
determined to be optimal (section 2.2.10.1). The cells were incubated at 37ºC and 
5% CO2 for 1-2weeks during which medium was changed every 2days. Most of the 
cells were killed and washed off the bottom of the plate during medium changing, 
leaving colonies of stably transfected cells. The stable colonies were collected by 
trypsinization and transferred to T25 flasks for expansion. The cells were tested for 
successful transfection using western blotting. 
2.2.11   Flow cytometric analysis (FACS) for TRAIL receptor expression 
In order to test TRAIL receptor expression on HNSCC cell membrane using 
flow cytometry, cells to be tested were washed twice with PBS, trypsinized and 
resuspended in fresh medium to be counted as mentioned in section 2.2.1.4. 400,000 
cells in 400µl fresh medium were added to each well in 96well tissue culture plate. 
The cells were pelleted by centrifugation at 3000rpm for 3 min. The supernatant 
was discarded and the pellet was resuspended in the primary antibody (HS101 anti-
TR1 or HS201 anti-TR2) diluted to 5µg/ml in FACS buffer and incubated on ice for 
30 min. The cells were then spun at 3000rpm for 3 min, and washed 3 times with 
ice cold FACS buffer by adding 100µl of buffer and centrifuged at 3000rpm for 
3min each time. The secondary antibody diluted to 1:200 in FACS buffer was added 
to the cells and incubated for 20min on ice. As above, cells were spun for 3min and 
washed 3times with ice cold FACS buffer. The Streptavidin-PE coupled antibody 
diluted 1:200 in FACS buffer was added to the cells and incubated on ice for 20min 
in the dark. As above, cells were spun for 3min and washed 3 times with ice cold 
FACS buffer. The cells were then resuspended in 100µl of PI solution (1µg/ml, 
diluted in FACS buffer). Number of cell surface binding to the tested antibodies was 
analyzed by FACS. This experiment was performed in Prof. Henning Walczak 
laboratory, Imperial College London as a part of the collaboration. 




2.2.12   Gene and mi-RNA expression profiling 
HNSCC cells were seeded in 10cm dishes and 24 and 48 hours later, the 
cells were trypsinized and resuspened in fresh medium and were centrifuged at 900g 
for 5 min.  The cell pellets then were mixed with 1ml Trizol (Invitrogen, cat# 
15596026) and were stored at -80ºC. Samples were then shipped to Fondazione 
IRCCS Istituto Nazionale Tumori, Milan, Italy for performing RNA extraction and 
expression profiling analysis. Gene expression profiling was performed using the 
Illumina Human HT-12 v3 Expression BeadChip, which targets more than 25,000 
annotated genes with more than 48,000 probes. miRNA expression profiling was 
performed using the Illumina Human v2 miRNA Beadchip  which detects 1,146 of 
known human miRNAs.  
Data obtained were imported into BeadStudio and were processed and 
analyzed by Katherine Lawler, bioinformatics analyst at KCL/UCL Comprehensive 
Cancer Imaging Centre, King's College London. Raw probe-level intensity values, 
detection p-values and bead counts were exported from GenomeStudio V2010:1 
(miRNA) / BeadStudio V3 (mRNA) and annotated using Illumina manifests 
HumanMI_V2_R0_XS0000124-MAP.bgx / HumanHT-12_V3_0_R1_11283641. 
bgx. Arrays were quantile normalized using the R/Bioconductor package beadarray 
(v2.0.2). The hierarchical clustering (dendrograms) indicated on expression 
heatmaps were obtained using complete linkage agglomerative clustering based on 
Euclidean distance Where multiple probes on the array mapped to the same gene 
symbol, only the most variable probe is displayed (highest standard deviation). 
Differential expression between sample groups was called using limma (Smyth, 
2004) empirial Bayes moderated t-tests (because of small numbers of samples in the 
sample groups used for comparison, especially HN5 vs. HN30), at a false discovery 
rate (FDR)-corrected p-value threshold of 0.05.  
2.2.13   Patient selection 
Tissue biopsies from 150 head and neck squamous cell carcinoma (HNSCC) 
cases were selected from the pathology archives of the Oral Pathology Department, 




Dental Institute, King’s College London from patients treated in the period 1997 to 
2004. The ethics approval is covered by existing project approval (REC reference, 
04/02/10). The cases were selected to be representative of a range of primary sites. 
Original diagnostic slides were reviewed and blocks selected if they had enough 
tumour tissue to be used for construction of tissue microarray (TMA) blocks. The 
cases were categorized according to the site of the primary tumour. 27 cases were 
from the lateral border of the tongue, 17 from the floor of the mouth, 18 from the 
alveolus, 17 from the buccal mucosa, 17 from the lip vermillion border, 19 from the 
tonsils, 16 from the pharynx and 19 were from palate, tuberosity and retromolar 
area. Clinical and histological data for these cases were obtained from pathology 
reports and laboratory records of processing, follow up data bases maintained by the 
Department of Oral and Maxillofacial surgery and Radiotherapy departments and 
the central patient index of Guy’s and St Thomas NHS foundation trust. Age at 
diagnosis, sex, site of occurrence, stage of the tumour, histological grade, presence 
of metastasis, time and type of treatment (surgery alone, surgery and radiotherapy or 
radiotherapy alone), time of recurrence and time of death were recorded on Excel 
spreadsheets, anonymised and stored in encrypted format according to NHS 
information governance requirements. 
2.2.14   Tissue Microarray construction (TMA)  
Haematoxylin and eosin (H&E) slides used for diagnosis of each case were 
reviewed to select representative carcinoma and dysplasia tissue areas to be used to 
construct the tissue microarray blocks. From each case a minimum of four and a 
maximum of eight area cores were selected according to tissue availability. The 
selected areas included four samples of carcinoma, and if available up to four 
additional cores of normal epithelium, epithelial dysplasia and up to two of 
metastatic carcinoma from two different lymph nodes. The selected areas were 
marked on the H&E slides and overlaid the respective paraffin blocks to identify the 
area to be sampled. The TMA recipient block was designed to include eight cases; 
the cores from each case were aligned vertically in one column. In addition, four 
cores of irrelevant animal tissues were placed on top left side of the array for 




orientation (Figure 2-1A). Donor blocks were re-embedded to standard mould depth 
if the original blocks were of different thicknesses. 
TMA blocks were constructed on the semi-automated Alphelys MTA 
Booster machine at the Breast Cancer Unit, Guy’s Hospital using 1.0mm manual 
tissue arrayer punches (Beecher Instrument, Inc. cat# MP10) (Figure 2-1B). Tissue 
cores four mm long were punched from the donor blocks and inserted in four mm 
deep holes created by the recipient punch in the recipient block. After all cores were 
inserted, the blocks were incubated at 56ºC in an oven for 15min in order to 
enhance the adhesion between the tissue cores and the paraffin of the recipient 
blocks.  
18 TMA blocks were constructed, three for carcinoma of the lateral border 
of tongue, one for the lips, two for the floor of the mouth, two for alveolus, two for 
the buccal mucosa, two for the tonsils, two for the pharynx and two for palate, 
tuberosity and retromolar area. Additional two blocks were required for extra cases 
that could not be included into the original blocks due to cases number limitation.  
2.2.15   Immunohistochemistry (IHC) 
The TMA blocks were sectioned at 4µm sections using routine histological 
procedures on a LEICA-RM2235 microtome. Sections were cut by BMS staff at the 
KCL Department of Oral Pathology within three days of the staining and stored 
until use.  For each TMA, two sections were used for immunohistochemical staining 
using five primary antibodies directed against; ERCC1, HIF-1α, KU80, PTEN, 
Rad51 and XRCC1 using methods recommended by manufactures when available. 
All were optimized for tissues under investigation.  
Paraffin sections were deparaffinised by immersion in xylene with agitation 
for five min (twice) followed by immersion in absolute alcohol for five min (twice). 
Then the sections were washed with dH2O for two min. To block the endogenous 
peroxidase the sections were immersed in 3% H2O2 for 15min, and then washed 
with dH2O for five min. The antigen retrieval was performed by immersing the 
sections in the appropriate buffer in the microwave at 800W for 20min. The buffer 




differs according to the antibody used; sodium citrate buffer pH 6.0 was used for 
ERCC1, KU80, PTEN and Rad51 antibodies. Tris/EDTA buffer pH 9.0 was used 
for XRCC1 antibody. 1mM EDTA buffer pH 8.0 was used for HIF-1α antibody. 
The sections were left to cool down, transferred to humified chamber and the 
primary antibodies were diluted in phosphate buffered saline and added on top of 
the tissue sections, and incubated either at room temperature or 4ºC for the required 
incubation period for each antibody as mentioned in section 2.1.2. The sections then 
washed in PBS for 15 min. Then Dako EnVision kit (anti-mouse or anti-rabbit as 
appropriate) were used to visualize the antibody staining. Finally, the sections were 
counterstained with haematoxylin and mounted in Distyrene Plasticizer Xylene 
(DPX). For each antibody a positive and a negative control section were used as 
follows; ERCC1 antibody was used at 1:50 dilution and incubated for overnight at 
4ºC and thyroid carcinoma tissue was used as a positive control. HIF1-α antibody 
was used at 1:50 dilution and incubated for overnight at 4ºC and thyroid carcinoma 
tissue was used as a positive control. KU80 antibody was used at 1:200 dilution and 
incubated for overnight at 4ºC and oral squamous cell carcinoma tissue was used as 
a positive control. PTEN antibody was used at 1:50 dilution and incubated for 
overnight at 4ºC and breast cancer tissue was used as a positive control. Rad51 
antibody was used undiluted and incubated for 3hours at room temperature and oral 
squamous cell carcinoma tissue was used as a positive control. XRCC1 antibody 
was used at 1:50 dilution and incubated for one hour at room temperature and oral 
squamous cell carcinoma tissue was used as a positive control.   
2.2.16   Scoring of the immunohistochemistry staining  
 The expression of each antibody was scored by consensus between two 
pathologists blind to clinical and pathological data. Two parameters were scored for 
each antibody, the intensity of the staining (1=no stain, 2=equivocal, 3=weak, 
4=moderate or 5=strong) and the percentage of the stained cells (1=0-25%, 2=25-
50%, 3=50-75% or 4=75-100%). Four carcinoma cores were scored for each case 
and a final combined score was calculated as the average of the eight scores. The 
scores were recorded in the spreadsheet with the clinical and the histological data 




for each case and imported into the IBM SPSS statistics 20 programme for 
statistical analysis.  
Because of low number of cases for each category in the scoring system, the 
multiple scoring system of antigen expression has been transformed into binary 
scoring system before the analysis. Staining intensity scores were transformed into 
either negative (which included 1=no stain, 2=equivocal) or positive (which 
included 3=weak, 4=moderate or 5=strong). Percentage of the stained cells was 
transformed to either low (which included 1=0-25%) or high (which included 2=25-
50%, 3=50-75% or 4=75-100%) expression. 
Descriptive analyses were used to summarize clinical and histopathological 
characteristics of the study group. Cox regression was used to identify the 
significant predictors of overall survival and disease free survival. The association 
between antigen expression and response to treatment was tested using Chi-
square/exact test. Logestic regression analysis was carried out to identify the 
significant predictors of response. The analysis was performed under the 
supervision of Dr Ana Nora Donaldson BSc MSc PhD CStat, statistical analyst for 
Kings’ College London Dental Institute. 
2.2.17   P16 immunostaining and HPV in situ hybridization (ISH) 
TMA sections of tonsil and pharyngeal carcinomas were immunostained for 
detection of p16 protein. P16 IHC was carried out using a proprietary kit (CINtec 
Histology, mtm Laboratories) on a Ventana Benchmark Autostainer (Ventana 
Medical Systems). A tonsil SCC with high P16 expression was used as a positive 
control and same section without adding the p16 primary antibody as a negative 
control.  
Eight cases of tonsil carcinomas were P16 positive, and whole FFPE 
sections of these cases were used for performing HPV DNA ISH. High-risk HPV 
DNA ISH was carried out using proprietary reagents (Inform HPV III Family 16 
Probe (B), Ventana Medical Systems) on a Benchmark Autostainer (Ventana 




Medical Systems). The Inform HPV III Family 16 Probe (B) detects high-risk 
genotypes HPV-16, -18, -31, -33, -35, -39, -51, -52, -56, -58 and -66. 
 





















Figure 2.1  Design and equipment used for tissue microarray construction 
A-left; the template design for each TMA included eight cases, each in a single column. In each 
column, the eight cores from each case were four cores of carcinoma, one core of normal epithelial 
tissue, one core of dysplastic epithelial tissue and two cores of metastatic tissue from regional lymph 
nodes. Four orientation cores made from animal tissue were included in the top left of the TMA 
block. A-right; A TMA block. B-left. Alphelys MTA Booster equipment. B- right 1.0 mm manual 
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3 Results I 
3.1 Effect of TRAIL and Smac mimetics on the viability of 
HNSCC cell lines 
TRAIL and Smac mimetics are important candidates as anticancer agents 
because of their specific activity against cancer cells. TRAIL has been shown to 
effectively induce apoptosis in a range of tumour cell lines including leukaemia, 
multiple myeloma, neuroblastoma, lung, liver, colon, breast, prostate, pancreas, 
kidney and thyroid cancer in vitro (Newsom-Davis et al., 2009) as well as mouse 
models in vivo (Walczak et al., 1999). Recombinant TRAIL (AMG951, 
Apo2L/TRAIL) has proved to be effective when used in Phase I trials on patients 
with advanced solid and haematological malignancies (Herbst et al., 2010). Several 
reports have demonstrated that Smac mimetics are effective at inducing cell death in 
vitro and in vivo, both as a single agent and/or synergistically with other pro-
apoptotic stimuli (Petersen et al., 2010). The effect of these two promising drugs on 
the HNSCC remains unknown. In this study, the response of HNSCC cell lines to 
TRAIL and Smac mimetics was investigated to determine whether these drugs 
could be potential candidates for treating HNSCC.   
3.1.1 TRAIL and Smac59 titration in HNSCC cell lines 
To test the cytotoxic effect of recombinant IZ-TRAIL and Smac59 on the 
viability of HNSCC lines, a panel of 9 cell lines (HSC3, HSC3M3, HN5, HN30, 
UMSCC74A, UMSCC74B, UMSCC11B, UMSCC22B and H357) were used. 
These cells represented HNSCC from different sites and different molecular 
features. The details of the molecular characteristics of these cell lines are shown in 
Table 3.1. The cells were seeded in 96 well plates at a density of 500-2000 
cells/well. After 24 hours incubation at 37ºC and 5% CO2 the cells were treated with 
different concentrations of TRAIL (100, 50, 25, 12.5, 6.25, 3.125 and 1.65 ng/ml) 
and Smac59 (200, 100, 50, 25, 12.5, 6.25 and 3.125 nM) for 72 hours. The cell 
viability was measured using MTT assay. IC50 (the concentration of the tested drug 




that induced 50% cell death) was calculated for each cell line using GraphPad 
Prism5.  
HSC3, HSC3M3 and HN5 cell lines were highly sensitive to Smac59 
showing similar levels of cell death at both the lowest concentration (3.125 nM) and 
the highest concentration (200 nM) tested which made the IC50 calculation for these 
cell lines not possible at this dose range (data not shown). This suggested that a 
lower concentration range for Smac59 needed to be used for these cell lines (2, 1, 
0.5, 0.25, 0.125, 0.0625, 0.03125 nM).  
The results showed that HSC3, HSC3M3 and HN5 cells were sensitive to 
Smac59 and resistant to TRAIL. HN5 showed only 20% loss of viability when 
treated with 100 ng/ml TRAIL (Figure 3.1). The degree of sensitivity to Smac59 
was different among the three cell lines with HSC3 being the most sensitive. The 
relative degree of sensitivity was reflected by the IC50 values which were 0.03639, 
0.4712 and 0.2531 for HSC3, HSC3M3 and HN5 respectively. With the partial 
exception mentioned above, the three cell lines were resistant to TRAIL even at the 
highest concentration tested. 
The results in Figure 3.2 showed the dose response of HN30, UMSCC74A 
and UMSCC74B for Smac59 and TRAIL. The results indicate that these three cell 
lines were resistant to Smac59 at all the concentrations tested with the exception of 
HN30 cells which showed only 20% loss of cell viability when treated with 
Smac59. HN30 was not considered to be Smac59 sensitive cells because its noted 
sensitivity to Smac59 was very low in comparison with the sensitivity of HSC3, 
HSC3M3 and HN5 cells. Conversely, these three cell lines showed marked 
sensitivity to TRAIL. HN30 cell line was very sensitive with an IC50 value of 6.759 
ng/ml. UMSCC74B was more sensitive than UMSCC74A with IC50 of 28.31 and 
82.1ng/ml respectively. 
The sensitivity or resistance of H357, UMSCC11B and UMSCC22B to 
TRAIL and Smac59 was similar to HN30, UMSCC74A and UMSCC74B (Figure 
3.3), data showing resistant to Smac59 and sensitivity to TRAIL. The degree of 
sensitivity to TRAIL varied between the three cell lines, UMSCC11B was the most 




sensitive. IC50 values were 0.7764, 2.821 and 110.3 ng/ml for UMSCC11B, H357 
and UMSCC22B respectively.  
In summary, the data showed that three out of the nine cell lines tested were 
Smac59 sensitive and TRAIL resistant, while six out of the nine cell lines were 
TRAIL sensitive and Smac59 resistant. Most of the sensitive cells were shown to be 
highly sensitive to the respective drug as well as to have a dose dependent pattern of 
sensitivity. For individual cell lines, it was interesting to see that the Smac59 
sensitive cell lines were TRAIL resistant and vice versa. None of the cells tested 
was found to be sensitive or resistant to both drugs. Therefore, the mechanism of 
resistant/sensitivity of each cell line to these drugs was further investigated. 
3.1.2 Sensitivity of HNSCC cell lines to combined TRAIL and Smac59 
treatment  
The effect of the combined treatment with both drugs was investigated to 
determine whether they could synergize to induce cytotoxicity.  The HNSCC cell 
line panel was seeded in 96 well plates and after 24 hours of incubation at 37ºC and 
5% CO2 they were treated with TRAIL (50 ng/ml), Smac59 (28.33 nM) or both. The 
cells were incubated with the drugs for 72 hours and the cell viability was tested 
with MTT assay. 
 The results shown in Figure 3.4 confirmed the previous observations and 
indicated that the tested cells showed similar pattern of sensitivity to Smac59 and 
TRAIL. Smac59 and TRAIL in combination effectively inhibited cell viability of all 
the tested HNSCC cell lines. When Smac59 and TRAIL were combined, the 
reduction in the cell viability observed in the Smac59 sensitive cells was similar to 
the levels obtained with single Smac59 treatment, indicating that TRAIL did not 
increase the cytotoxicity of Smac59; the difference between the effect of Smac59 
alone and the combination treatment was not statistically significance (P > 0.05). 
Conversely, the reduction in cell viability observed in the TRAIL sensitive cells was 
higher with the combination treatment than single TRAIL treatment; the difference 
in the response between single TRAIL treatment and combination treatment with 




Smac59 was statistically significant (P < 0.05). This indicated that adding Smac59 
to TRAIL enhanced TRAIL cytotoxic effect in TRAIL sensitive cells. 
3.1.3 Sensitisation of TRAIL resistant cell lines to TRAIL using Smac59 
The previous experiments suggested that adding Smac59 to TRAIL 
enhanced the cytotoxic effect of TRAIL in the TRAIL sensitive cell lines. Whether 
Smac59 enhanced TRAIL cytotoxic effect in TRAIL resistant cell lines was 
difficult to measure because of high susceptibility to Smac59 in TRAIL resistant 
cells. In order to test whether Smac59 could sensitise the TRAIL resistant cells to 
TRAIL, it was necessary to use a non toxic concentration of Smac59.  
 Smac59 sensitive cell lines, HSC3, HSC3M3 and HN5 were treated with 
either TRAIL (50 ng/ml), Smac59 (0.025 nM) or both in combination and cell 
viability was measured with MTT assay. As shown in Figure 3.5 (A and B), in 
HSC3 and HSC3M3 cell lines, adding  non toxic concentrations of Smac59 to 
TRAIL resulted in 20-25% reduced cell viability than TRAIL alone, which was a 
statistically significant change (p value <0.01). This was not the case for HN5 cell 
line (Figure 3.5 C); the combined effect of both TRAIL and Smac59 was not 
significantly different than the effect of TRAIL alone for this cell line.  




Table 3.1 Characteristic features of HNSCC cell lines 
 
HSC3 HSC3M3 HN5 HN30 H357 UMSCC74A UMSCC74B UMSCC11B UMSCC22B 
Age 
63 63 73 Unknown 74 N/A N/A 65 59 
Sex 








Tongue Pharynx Tongue Base of 
tongue 




differentiation Poorly diff. Poorly diff. Mod. diff. N/A Well diff N/A N/A N/A N/A 
TNM 
N/A N/A T2 N0M0 N/A T1N0M0 N/A N/A T2N2aM0 T2N1M0 
Stage 













Mutant Mutant Mutant Wild type Mutant Wild type Wild type Mutant Mutant 
Ras status 
Mutant Mutant N/A N/A Mutant N/A N/A N/A N/A 
HPV status 
Negative  Negative N/A Negative Negative N/A N/A N/A N/A 
Abbreviations: M, male; F, female and N/A, not available. 















Figure 3.1  Effect of Smac59 and TRAIL on HSC3, HSC3M3 and HN5 cell lines at various concentrations 
HSC3, HSC3M3 and HN5 cell lines were seeded in 96 well plates and treated with Smac59 (2, 1, 0.5, 0.25, 0.125, 0.0625, 0.03125nM) and TRAIL (100, 50, 25, 
12.5, 6.25, 3.125 and 1.65ng/ml). Cells were incubated at 37ºC and 5%CO2 for 72 hours then the cell viability was measured using MTT assay. The results are 































































































































































































Figure 3.2  Effect of Smac59 and TRAIL on HN30, UMSCC74A and UMSCC74B cell lines at various concentrations 
HN30, UMSCC74A and UMSCC74B cell lines were seeded in 96 well plates and treated with Smac59 (200, 100, 50, 25, 12.5, 6.25, 3.12nM) and TRAIL (100, 50, 25, 
12.5, 6.25, 3.125 and 1.6 ng/ml). Cells were incubated at 37ºC and 5%CO2 for 72 hours then the cell viability was measured using MTT assay. The results are shown as 


















































































































































































Figure 3.3  Effect of Smac59 and TRAIL titration on H357, UMSCC11B and UMSCC22B cell lines at various concentrations 
H357, UMSCC11B and UMSCC22B cell lines were seeded in 96 well plates and treated with Smac59 (200, 100, 50, 25, 12.5, 6.25, 3.12nM) and TRAIL (100, 50, 25, 
12.5, 6.25, 3.125 and 1.65ng/ml).). Cells were incubated at 37ºC and 5%CO2 for 72 hours then the cell viability was measured using MTT assay. The results are shown 



















































































































































































Figure 3.4  Effect of combined TRAIL and Smac59 treatment on HNSCC cell lines 
Nine HNSCC cell lines were seeded in 96 well plates and treated with TRAIL (50ng/ml), Smac59 (28.33nM), or combination. Cells were incubated at 37ºC and 5%CO2 
for 72hours and the cell viability was measured using the MTT assay. The results are shown as the percentage of the viable cells after treatment with respect to viable 
untreated treated cells. All experiments were performed in triplicate, error bars indicate SD. Red rectangle encloses Smac59 sensitive cells and green rectangle encloses 
































































Figure 3.5  TRAIL sensitisation using Smac59 in HNSCC cell lines  
HSC3, HSC3M3 and HN5 cell lines were seeded in 96 well plates and treated with TRAIL 
(50ng/ml) and Smac59 (0.025nM) or both combined for 72 hours. Cell viability was measured using 
MTT assay. The results are shown as the percentage of the viable cells after treatment with respect to 
untreated viable cells. All experiments were performed in triplicate, error bars indicate SD.  















































































































































3.1.4 Sensitivity of normal human keratinocytes to TRAIL and Smac59 
As TRAIL and Smac59 have a clear cytotoxic effect on HNSCC cell lines, 
they might be future anticancer agents in head and neck carcinoma. However, one 
of the main limitations for most anticancer drugs is the non-specific cytotoxic effect 
on normal cells. To test the cytotoxic effect of TRAIL and Smac59 on normal 
epithelium, human oral keratinocytes (NHK) were seeded in 6 well plates, along 
with HSC3M3 and SCC11B cell lines. Cells were treated in duplicates with either 
TRAIL (50ng/ml), Smac59 (50nM) or left untreated. HSC3M3 and SCC11B were 
used as controls for sensitivity to drugs. The cell viability was tested using phase 
contrast microscope (to investigate changes in cell morphology) as well as using 
MTT assay. 
The results shown in Figure 3.6A indicated that NHK treated with TRAIL 
showed signs of apoptosis as indicated by, membrane blebbing, cytosolic 
condensation and breakdown of nuclear DNA. The Smac59 treated NHK showed no 
difference from untreated control cells. These observations indicated that TRAIL 
was cytotoxic to normal head and neck cells while Smac59 was not. Drug activity 
was confirmed by positive control treatment of HSC3M3 and UMSCC11B cells. 
This killing of normal cells was further confirmed by measuring cell viability with 
MTT assay and the results are shown in Figure 3.6 B. 
For further investigation of TRAIL and Smac59 effect on a non-
tumourigenic cell line, this experiment was repeated using HaCat spontaneously 
immortalised non-tumourigenic keratinocyte. HaCat cells were sensitive to TRAIL 
and resistant to Smac59 as shown in Figure 3.7.  Collectively, we show that TRAIL 
was effective in killing most of our cancer cell lines as well as normal and non-
transformed immortalised cell lines. 

























Figure 3.6  Sensitivity of Normal Human Keratinocytes (NHK) to TRAIL and Smac59 
A: Normal human keratinocytes, HSC3M3 and UMSCC11B were seeded in 6 well plate and treated 
with TRAIL (50ng/ml) or Smac59 (50nM). Cytotoxic effect was determined by apoptotic 
morphological features using phase contrast microscopy. B: Normal human keratinocytes, HSC3M3 
and UMSCC11B were seeded in 96 well plates and treated with TRAIL (50ng/ml) or Smac59 
(50nM). Cell viability was determined by MTT assay, the results are shown as percentage of viable 



























































Figure 3.7  Sensitivity of HaCat cells to TRAIL and Smac59 
HaCat cells were seeded in 96 well plates and treated with TRAIL (50ng/ml) and Smac59 (50nM) 
for 72 hours. Cell viability was measured using MTT assay. The results are shown as the percentage 
of the viable cells after treatment with respect to viable untreated cells. All experiments were 



















































In summary, the cytotoxic effect of recombinant IZ-TRAIL and Smac59 was 
investigated using a panel of HNSCC cell lines, normal oral keratinocytes and 
spontaneously transformed keratinocyte cell lines. The data obtained suggested: 
 Both drugs were effective in killing cancer cells even at very low 
concentrations when the cells are inherently sensitive.  Six cell lines 
were TRAIL sensitive and three cell lines were Smac59 sensitive. 
Combined treatment was effective in killing all the cell lines tested.  
 Smac59 was able to sensitise the TRAIL resistant cells to TRAIL. 
However, single drug treatment was efficient in killing the sensitive 
HNSCC cell lines. 
 Normal primary or immortalised cells were sensitive to TRAIL but 
not to Smac59 treatment. 
Predicting response of HNSCC cell lines to TRAIL and Smac mimetics will 
enable to achieve maximum efficiency of each drug. The next chapter will focus on 
the identification of molecular mechanisms underlying the response of HNSCC cell 
lines to TRAIL and Smac59. 
 




4 Results II  
Identification of biomarkers to predict response of HNSCC cell lines to 
TRAIL and Smac59 
TRAIL induces cell death by activation of apoptosis pathways following the 
binding to its corresponding receptors, TRAIL-R1 (DR4) or TRAIL-R2 (DR5). 
Smac mimetics induce cell death by inducing the activation of procaspase-3 and 
promote the enzymatic activity of mature caspase-3 through the binding to inhibitor 
of apoptosis proteins (IAPs) (Chai et al., 2000). In this chapter, different proteins 
involved in the apoptotic pathways activated by TRAIL and Smac59 will be 
investigated to identify the possible predictors for the sensitivity/resistant pattern 
which were observed in HNSCC cell lines. 
4.1 Expression analysis of target proteins 
Expression of XIAP, cIAP-1, cIAP-2, Bcl-2, Mcl-1, Smac/DIABLO, 
Caspase-8, Caspase-3, FLIP and EGFR proteins were analysed. Nine HNSCC cell 
lines; three Smac59 sensitive (HSC3, HSC3M3 and HN5) and  six TRAIL sensitive  
(HN30, H357, UMSCC74A, UMSCC74B, UMSCC11B and UMSCC22B), normal 
human oral keratinocyte (NHK) and immortalised keratinocyte HaCat cells were 
seeded in 10cm dishes and incubated at 37ºC and 5% CO2 for 48-72 hours 
depending on the cell line. When the cells reached 80-90% confluence, they were 
washed with cold PBS and then 500µl of lysis buffer was added and the cell lysates 
were collected using sterile cell scrapers. Protein analysis was performed using 
western blotting.   
In order to obtain approximate values for expression level of different 
proteins, the bands obtained from western blot analysis were quantified using ImagJ 
program. The quantification was performed for the bands of the protein of interest 
normalized to β-actin used as internal loading control. The data were plotted on 
excel worksheets to produce graphs representing protein expression levels in 
different cell lines. 




4.1.1 Inhibitors of apoptosis proteins (IAPs) 
Cancer cells acquire resistance to apoptosis by upregulating multiple pro-
survival factors. The inhibitors of apoptosis proteins are a family of eight members 
that potently suppresses apoptosis triggered by a large variety of apoptotic stimuli. 
All members can block the caspase cascade but only some of them directly interact 
with caspases (Hunter et al., 2007). 
4.1.1.1  X-linked inhibitor of apoptosis protein (XIAP) 
XIAP is the most potent inhibitor of apoptosis of all the inhibitor of 
apoptosis proteins family (IAPs). XIAP effectively inhibits both intrinsic and 
extrinsic apoptosis pathways by binding and inhibiting the initiator caspase-9 and 
the effector caspase-3 and -7, whose activity is crucial for apoptosis execution 
(Deveraux et al., 1997). XIAP is over-expressed in many cancer cell lines and 
tumours but not in normal cells, and a high level of XIAP results in apoptosis-
resistance of cancer cells to a wide variety of therapeutic agents (Dai et al., 2009a). 
XIAP expression levels could affect TRAIL/Smac59 sensitivity in HNSCC cell 
lines. In this study we investigated the expression levels of XIAP protein in both 
cancer and normal cell lines and correlated this with the sensitivity/resistant to 
TRAIL and Smac59. 
The results shown in Figure 4.1 indicated that all HNSCC cell lines tested as 
well as NHK cells expressed XIAP. HaCat cells showed undetectable XIAP 
expression. With the exception of H357 cell line, HNSCC cell lines expressed more 
XIAP than normal NHK. This data indicated that XIAP is overexpressed in HNSCC 
cell lines. No correlation between the XIAP expression levels and TRAIL or 
Smac59 sensitivity of the tested cell lines was observed. 
4.1.1.2  Cellular inhibitor of apoptosis proteins (cIAP-1 and cIAP-2) 
cIAP-1 and cIAP-2 are members of IAPs family. They inhibit death 
receptor-mediated apoptosis by regulating receptor mediated signaling pathways 
upstream of mitochondria through the interaction with TNF receptor associated 




factor 1 and 2, TRAF1 and TRAF2, (Guicciardi et al., 2011). cIAP-1 is known to be 
highly expressed in cancer cells however cIAP-2 is present in low abundance in the 
cells (LaCasse et al., 2008). 
The results shown in Figure 4.2 indicated that cIAP-1 was expressed by all 
HNSCC cell lines and normal cell lines tested. No major differences in cIAP-1 
expression between normal and cancer cell lines were observed. No correlation 
between level of cIAP-1 in HNSCC cell lines and their sensitivity/resistant to 
TRAIL or Smac59 was detected.  
 With regard to cIAP-2 expression, the results shown in Figure 4.3 indicated 
that five (HSC3, HN30, H357, UMSCC11B and UMSCC22B) of the nine HNSCC 
cell lines tested expressed cIAP-2 at different levels;  HN30 and H357 cell lines 
expressed the highest level. cIAP-2 expression in HSC3M3, HN5, UMSCC74A and 
UMSCC74B was undetectable. cIAP-2 expression in HaCat cells was high, but 
NHK cells showed low cIAP-2 expression level. With the exception of UMSCC74A 
and UMSCC74B, cIAP-2 expression levels showed correlation with TRAIL 
sensitivity in HNSCC cell lines; TRAIL sensitive cell lines showed higher 
expression levels of cIAP-2 than TRAIL resistant cell lines. 
 






















Figure 4.1  XIAP protein expression in HNSCC cell lines 
Nine HNSCC cell lines, NHK and HaCat cells (untreated) were lysed and subjected to western blot 
analysis for endogenous XIAP protein expression (top). The intensity of the bands from the western 
blotting was quantified in relation to β-actin level using the ImagJ program. Red rectangle encloses 
the Smac59 sensitive (TRAIL resistant) cell lines and the green rectangle encloses the Smac59 





















































































 Figure 4.2  cIAP-1 protein expression in HNSCC cell lines 
Nine HNSCC cell lines, NHK and HaCat cells (untreated) were lysed and subjected to western blot 
analysis for endogenous cIAP-1 protein expression (top). The intensity of the bands from the western 
blotting was quantified in relation to β-actin level using the ImagJ program. Red rectangle encloses 
the Smac59 sensitive (TRAIL resistant) cell lines and the green rectangle encloses the Smac59 




















































































Figure 4.3  cIAP-2 protein expression in HNSCC cell lines 
Nine HNSCC cell lines, NHK and HaCat cells (untreated) were lysed and subjected to western blot 
analysis for endogenous cIAP-2 protein expression (top). The intensity of the bands from the western 
blotting was quantified in relation to β-actin level using the ImagJ program. Red rectangle encloses 
the Smac59 sensitive (TRAIL resistant) cell lines and the green rectangle encloses the Smac59 




































































4.1.2 Smac/DIABLO  
Smac/DIABLO (second mitochondria-derived activator of caspases, direct 
IAP-binding protein with low PI) is a 25 kDa mitochondrial protein that promotes 
apoptosis through its ability to antagonize IAP-mediated caspase inhibition once 
released into the cytoplasm following intrinsic apoptosis pathway activation. It 
functions by binding to IAPs which results in releasing their inhibitory effects on 
caspases (Du et al., 2000). Therefore sensitivity of cancer cells to different 
therapeutics could be influenced by the amount of Smac/DIABLO available to 
antagonise the inhibitory effect of IAPs. 
The results shown in Figure 4.4 indicated that all HNSCC cell lines as well 
as NHK and HaCat cell lines expressed endogenous Smac/DIABLO  at different 
levels with NHK showing the lowest level of expression. Smac59 sensitive (TRAIL 
resistant) cell lines (HSC3 and HN5) expressed more Smac/DIABLO than Smac59 
resistant (TRAIL sensitive) cell lines which indicated that a correlation between the 
level of expression of Smac/DIABLO and Smac59 sensitivity TRAIL resistant in 
the tested cells was identified. 
4.1.3 Bcl-2 family 
Bcl-2 family members are divided into three categories of protein according 
to their structure and function and are defined as: anti-apoptotic, multi-domain pro-
apoptotic and BH3-only pro-apoptotic members.  As mentioned in the introduction, 
Bcl-2 family members are responsible for determining whether or not the 
apoptosome complex can assemble and consequently execute apoptosis.  
4.1.3.1  Bcl-2 protein 
Bcl-2 is an anti-apoptotic member that potently inhibits apoptosis, mediated 
by inhibition of apoptosome formation. Endogenous bcl-2 protein level was 
investigated in HNSCC cell lines and in NHK and HaCat cells. 
As shown in Figure 4.5, bcl-2 protein expression was undetectable in 
Smac59 sensitive (TRAIL resistant) cell lines HSC3 and HSC3M3. Conversely 




Smac59 resistant (TRAIL sensitive) cell lines UMSCC74A, UMSCC74B, 
UMSCC11B and UMSCC22B, showed considerably high levels of bcl-2 protein 
expression. Neither NHK nor HaCat cell lines showed detectable bcl-2 expression. 
With the exception of HN5, HN30 and H357, bcl-2 expression pattern in HNSCC 
cell lines correlated with TRAIL and Smac59 sensitivity. Smac59 sensitive (TRAIL 
resistant) cell lines had lower bcl-2 levels than Smac59 resistant (TRAIL sensitive) 
cell lines. 
4.1.3.2  MCL-1 
Mcl-1 is an anti-apoptotic member of the bcl-2 family that promotes cell 
survival by inhibiting release of cytochrome c from the mitochondria. Mcl-1 has a 
short half life and plays a critical role in determining the fate of the cells. The level 
of Mcl-1 may be a useful predictive indicator for the treatment of various cancers 
(Michels et al., 2005)  
In this study, Mcl-1expression was observed in all the nine cell lines tested 
and NHK and HaCat. Level of Mcl-1 expression was varied by cell line. HaCat cell 
line had the highest level of Mcl-1 expression of all tested cells. Mcl-1 expression 
was higher in Smac59 sensitive (TRAIL resistant) cell lines than in Smac59 
resistant (TRAIL sensitive) cell lines (Figure 4.6) indicating that resistance to 
TRAIL could be associated with Mcl-1 level in the cells. 
 


















Figure 4.4  Smac/DIABLO protein expression in HNSCC cell lines 
Nine HNSCC cell lines, NHK and HaCat cells (untreated) were lysed and subjected to western blot 
analysis for endogenous Smac/DIABLO protein expression (top). The intensity of the bands from the 
western blotting was quantified in relation to β-actin level using the ImagJ program. Red rectangle 
encloses the Smac59 sensitive (TRAIL resistant) cell lines and the green rectangle encloses the 








































































































 Figure 4.5  Bcl-2 protein expression in HNSCC cell lines 
Nine HNSCC cell lines, NHK and HaCat cells (untreated) were lysed and subjected to western blot 
analysis for endogenous Bcl-2 protein expression (top). The intensity of the bands from the western 
blotting was quantified in relation to β-actin level using the ImagJ program. Red rectangle encloses 
the Smac59 sensitive (TRAIL resistant) cell lines and the green rectangle encloses the Smac59 





















































































Figure 4.6  Mcl-1 protein expression in HNSCC cell lines 
Nine HNSCC cell lines, NHK and HaCat cells (untreated) were lysed and subjected to western blot 
analysis for endogenous Mcl-1 protein expression (top). The intensity of the bands from the western 
blotting was quantified in relation to β-actin level using the ImagJ program. Red rectangle encloses 
the Smac59 sensitive (TRAIL resistant) cell lines and the green rectangle encloses the Smac59 



































































Initiation and execution of apoptosis relies on a complex network of cysteine 
proteases named caspases that exist in the cytoplasm as inactive pro-enzymes and 
are activated by proteolysis. Caspases involved in apoptosis are divided into two 
main groups: initiator and effector caspases. Caspase-8 and -10 initiate the extrinsic 
pathway. Caspase-9 is involved in the intrinsic pathway. Activation of this upstream 
caspases leads to activation of the effector caspase-3, -6 and -7 which are involved 
in the cleavage of specific proteins causing the characteristic apoptotic appearance 
(Lopez-Hernandez et al., 2003).  
4.1.4.1  Caspase-8  
Caspase-8 initiates the extrinsic pathway and it is activated upon binding of 
cell surface death receptors to their ligand. In type-I cells, activation of death 
receptors is sufficient to induce apoptosis while in type-II cells co-activation of the 
mitochondrial pathway is necessary to induce effector caspase activation. Activation 
of the intrinsic pathway is mediated via activated caspase-8 (Scaffidi et al., 1998). 
The results in Figure 4.7 showed that Smac59 resistant (TRAIL sensitive) 
cell lines (HN30, H357, UMSCC74A, UMSCC74B, UMSCC11B and 
UMSCC22B) had a higher level of caspase-8 expression than Smac59 sensitive 
(TRAIL resistant) cell lines (HSC3, HSC3M3 and HN5). Caspase-8 expression was 
also detected in the NHK and HaCat cell lines. Casapase-8 level directly correlated 
with TRAIL sensitivity in HNSCC cell lines, suggesting that lack of caspase-8 may 
be the cause of HSC3, HSC3M3 and HN5 cell lines being resistant to TRAIL. 
4.1.4.2  Caspase-3 
Caspase-3 is an executioner caspase, its activation leads to cleavage of 
specific cellular proteins marking the irreversible cell death. Caspase-3 expression 
was investigated in HNSCC cell lines. The results shown in Figure 4.8 indicated 
that caspase-3 was expressed in all HNSCC cell lines as well as in NHK and HaCat 




cell lines. No correlation was observed between caspase-3 levels and TRAIL or 
Smac59 sensitivity/resistant in HNSCC cell lines. 
4.1.5 Cellular FLICE-inhibitory Protein (c-FLIP) 
c-FLIP proteins exist as a long (c-FLIPL) and a short (c-FLIPS) splice 
variant. Both forms protect the cells from death receptor-mediated apoptosis by 
blocking pro-caspase-8 activation at the death inducing signalling complex (DISC) 
(Krueger et al., 2001). 
The results shown in Figure 4.9 indicated that only the long (c-FLIPL) variant was 
detected in the tested cell lines. Smac59 sensitive cell lines (HSC3 and HSC3M3) 
had a lower level of c-FLIP in comparison with TRAIL sensitive cell lines (HN30, 
H357, UMSCC22B, UMSCC11B, UMSCC74A and UMSCC74B). Interestingly, 
NHK and HaCat cells had a higher level of c-FLIP than HNSCC cell lines.  
4.1.6 Epidermal growth factor receptor (EGFR) 
EGFR is overexpressed in many solid cancers and has been shown to be 
involved in the development and progression of human malignancies. EGFR 
regulates many cellular function including cell growth, angiogenesis, inhibition of 
apoptosis, cell adhesion, cell motility and invasion (Lui and Grandis, 2002). Over-
expression of EGFR in many cancers has been associated with resistance to 
treatment. In this study we investigated whether EGFR expression was associated 
with TRAIL and Smac59 sensitivity/resistance pattern in HNSCC cell lines. 
The results shown in Figure 4.10 indicated that HSC3, HSC3M3, HN5, 
HN30 and H357 cell lines expressed EGFR at different levels while UMSCC (74A, 
74B, 11B and 22B) showed no detectable EGFR expression. A direct association 
between EGFR expression and sensitivity to TRAIL and Smac59 was observed as 
Smac59 sensitive (TRAIL resistant) cell lines expressed higher levels of EGFR than 
Smac59 resistant (TRAIL sensitive) cell lines. NHK cells expressed EGFR protein 
while HaCat cells showed undetectable EGFR expression.  























Figure 4.7  Caspase-8 protein expression in HNSCC cell lines 
Nine HNSCC cell lines, NHK and HaCat cells (untreated) were lysed and subjected to western blot 
analysis for endogenous caspase-8 protein expression (top). The intensity of the bands from the 
western blotting was quantified in relation to β-actin level using the ImagJ program. Red rectangle 
encloses the Smac59 sensitive (TRAIL resistant) cell lines and the green rectangle encloses the 






































































































Figure 4.8  Caspase-3 protein expression in HNSCC cell lines 
Nine HNSCC cell lines, NHK and HaCat cells (untreated) were lysed and subjected to western blot 
analysis for endogenous caspase-3 protein expression (top). The intensity of the bands from the 
western blotting was quantified in relation to β-actin level using the ImagJ program. Red rectangle 
encloses the Smac59 sensitive (TRAIL resistant) cell lines and the green rectangle encloses the 












































































































Figure 4.9  c-FLIP protein expression in HNSCC cell lines 
Nine HNSCC cell lines, NHK and HaCat cells (untreated) were lysed and subjected to western blot 
analysis for endogenous FLIP protein expression (top). The intensity of the bands from the western 
blotting was quantified in relation to β-actin level using the ImagJ program. Red rectangle encloses 
the Smac59 sensitive (TRAIL resistant) cell lines and the green rectangle encloses the Smac59 







































































































Figure 4.10  EGFR protein expression in HNSCC cell lines 
Nine HNSCC cell lines, NHK and HaCat cells (untreated) were lysed and subjected to western blot 
analysis for endogenous EGFR protein expression (top). The intensity of the bands from the western 
blotting was quantified in relation to β-actin level using the ImagJ program. Red rectangle encloses 
the Smac59 sensitive (TRAIL resistant) cell lines and the green rectangle encloses the Smac59 



































































4.2 Tumour necrosis factor alpha (TNF-α) and TRAIL/Smac59 
sensitivity 
Tumour necrosis factor alpha (TNF–α) is a pleiotropic ligand of tumour 
necrosis factor receptor 1 and 2 (TNFR1 and TNFR2) that can signal both cell 
survival and cell death. The pro-survival and the pro-death signalling aspects of 
TNF-α are mediated through two different protein complexes. Various human 
cancer cell lines undergo apoptosis upon Smac mimetic treatment without the need 
for exogenous pro-apoptotic stimuli. Smac mimetics were able to switch the pro-
survival signal to cell death in certain cancer cells that secrete TNF-α (Petersen et 
al., 2007). The underlying mechanisms by which Smac mimetics induce cell death 
through TNF-α pathway remains unknown. 
 To investigate the role of TNF-α in TRAIL or Smac59 sensitivity in 
HNSCC cell lines, three Smac59 sensitive (TRAIL resistant) cell lines (HSC3, 
HSC3M3 and HN5) and three Smac59 resistant (TRAIL sensitive) (HN30, H357 
and UMSCC11B) cell lines were analyzed for the level of TNF-α  protein secreted 
in their growth media using ELISA. Equal numbers of cells were seeded in 12well 
plates in 1ml of media, incubated at 37ºC and 5% CO2 for 24 hours then the medium 
was replaced with fresh medium (with or without serum). The cells were then 
incubated for 24 hours after which the medium was collected and stored at -70ºC. 
The level of TNF-α in the medium was measured using Human TNF-α CytoSetTM 
ELISA Kit.  
This kit provides a recombinant h-TNF-α and a standard curve for TNF-α 
was generated to ensure linear correlation between colour intensities and TNF-α 
concentration and to obtain the curve equation used to calculate the TNF-α 
concentration in the test samples. Experiments were performed in duplicate and 
ELISA was performed in triplicate for each of duplicate samples. 
The results in Figure 4.11 show the standard curve for TNF-α with the 
equation (A) and the level of secreted TNF-α in the test samples (B). Smac59 
sensitive (TRAIL resistant) cell lines (HSC3 and HSC3M3) secreted a higher level 




of TNF-α than Smac59 resistant (TRAIL sensitive) cell lines (HN30, H357 and 
UMSCC11B). The level of TNF-α in HN5 cell line, Smac59 sensitive, was not as 
high as other Smac sensitive cell lines. TNF-α secretion was tested in the presence 
and absence of serum in growth media.  Presence or absence of serum had minimal 
effect on TNF-α secretion. It was concluded from these data that there is a direct 
correlation between the level of TNF-α secreted by HNSCC cell lines and their 
sensitivity to Smac59.  
4.3 TRAIL receptors and TRAIL/Smac59 sensitivity. 
TRAIL triggers apoptosis via interaction with TRAIL receptors in target 
cells. Five receptors bind TRAIL; TRAIL-R1 (DR4, TNSFRSF10a) and TRAIL-R2 
(DR5, TNSFRSF10b) contain an extracellular ligand-binding domain and a 
cytoplasmic death domain that is required for activation of extrinsic apoptotic 
pathway after TRAIL binding. TRAIL-R3 (DcR1, TNFRSF10c), TRAIL-R4 
(DcR2, TNFRSF10d) and circulating osteoprotegerin (OPG, TNFRSF11b) lack a 
functional death domain and are thought to be involved mainly in negatively 
regulating apoptosis by sequestering TRAIL or stimulating pro-survival signals 
(Kruyt, 2008). The ability of TRAIL to induced apoptosis in different cell lines 
could be affected by the number of its receptors expressed on the cell membrane. In 
order to investigate the level of TRAIL-R1 (DR4, TNSFRSF10a) and TRAIL-R2 
(DR5, TNSFRSF10b) expressed by HNSCC cell lines, three TRAIL sensitive cell 
lines (HN30, UMSCC74A and UMSCC11B) and three TRAIL resistant cell lines 
(HSC3, HSC3M3 and HN5) were stained with TRAIL receptor antibodies (HS101, 
anti-TRAIL-R1 and HS201, anti-TRAIL-R2) and analysed by flow cytometric 
analysis (FACS) to measure the level of expression of the receptor on the cells 
surface. The data was analysed using FlowJo program. These experiments were 
performed in collaboration with Dr Kerestin Papenfuss, Imperial College London.  
  The results shown in Figure 4.12 indicated that both TRAIL-R1 and 
TRAIL-R2 were expressed in all tested cell lines but at different levels. The level of 
expression is measured by the degree that receptor histogram shifts from isotype 




histogram toward the right hand side.  TRAIL-R2 was expressed at a higher level 
than TRAIL-R1 in all cell lines. TRAIL-R1 expression was higher in Smac59 
sensitive (TRAIL resistant) cells, HSC3 and HSC3M3. These data indicated that 
sensitivity to TRAIL was independent of the level of its receptor expression. In 
conclusion, no clear association was observed between TRAIL death receptors 
expression and TRAIL sensitivity.   
 





















Figure 4.11  Level of secreted TNF-α in HNSCC cell lines 
Three Smac59 cell lines (HSC3, HSC3M3 and HN5) and three TRAIL sensitive cell lines (HN30, 
H357 and UMSCC11B) were seeded in 12well plate and incubated at 37ºC and 5% CO2 for 24 hours 
then the medium was replaced with fresh medium with or without serum. After 24 hours, the media 
were collected and were used to measure the level of secreted TNF-alpha using ELISA. A: standard 
curve created for the TNF-α used in ELISA. B: Graph showing the level of secreted TNF-α in the 
tested cell lines in the presence or absence of serum. All experiments were performed in duplicates. 
The results shown are the average of the TNF-α concentration in the tested samples. Red rectangle 
encloses the Smac59 sensitive (TRAIL resistant) cell lines and the green rectangle encloses the 


































Figure 4.12  TRAIL receptors expression in HNSCC cell lines 
Three Smac59 sensitive (TRAIL resistant) cell lines (HSC3, HSC3M3 and HN5) and three Smac59 
resistant (TRAIL sensitive) cell lines (HN30, UMSCC74A and UMSCC11B) were seeded in T75 
flasks until they were 80% confluent. Then the cells were stained with HS101, anti- TRAIL-R1 and 
HS201, anti-TRAIL-R2, and the receptor expression was analysed by FACS. Experiments were 
performed three different times and samples were tested in triplicate. The results shown are 
representative of the results obtained from the three experiments. Red rectangle encloses the Smac59 
sensitive (TRAIL resistant) cell lines and the green rectangle encloses the Smac59 resistant (TRAIL 
sensitive) cell lines. 
 
 




4.4 Gene and miRNA expression profiling 
The results of the previous experiments suggested that a number of proteins 
that are involved in TRAIL and Smac59 apoptosis pathways might determine the 
sensitivity to TRAIL or Smac59 in HNSCC cell lines. Gene expression profiling 
analysis could increase the understanding of the molecular mechanisms involved in 
the sensitivity of HNSCC cell lines to TRAIL or Smac59 by testing the expression 
of large number genes which could provide an overall picture why HNSCC have 
this pattern of sensitivity to TRAIL and Smac59. The mRNA expression level of the 
tested proteins as well as other genes and miRNA targets that may affect response to 
TRAIL and Smac59 was investigated by microarray analysis.  
Three Smac59 sensitive (TRAIL resistant) cell lines (HSC3, HSC3M3 and 
HN5) and five Smac59 resistant (TRAIL sensitive) cell lines (HN30, UMSCC74A, 
UMSCC74B, UMSCC11B and UMSCC22B) were seeded in 10cm dishes and 
incubated at 37ºC and 5%CO2. At 24 and 48 hours after seeding, the cells were 
collected for RNA extraction. Gene expression profiling was performed using 
Illumina Human HT-12 v3 Expression BeadChip, which targets more than 25,000 
annotated genes with more than 48,000 probes. The Chip provides genome-wide 
transcriptional coverage of well characterized genes, gene candidates and splice 
variants. Probes were designed using the RefSeq and UniGene data bases. miRNA 
expression profiling  was performed using Illumina Human v2 miRNA Beadchip 
which could detect up to 97% (1,146) of known human miRNAs. 
 miRNA and mRNA microarray data for the samples listed in Table 4.1 were 
performed in Fondazione IRCCS Istituto Nazionale Tumori, Italy. The data were 
processed and analyzed by Katherine Lawler, PhD KCL/UCL Comprehensive 
Cancer Imaging Centre, King's College London. Six colorectal carcinoma cell lines 
available in the department were also included in the gene expression profiling on 
the same chip. The data for these samples presented in the figures as they were used 
for data normalization. 
 




Figure 4.13 showed the hierarchical clustering of the normalized data using 
all probes and samples. mRNA data indicated that the HNSCC cell lines clustered 
separately from the colorectal carcinoma cell lines. Smac59 sensitive (TRAIL 
resistant) cell lines were clustered together. The Smac59 resistant (TRAIL sensitive) 
cell lines were clustered together except for the HN30 cell lines. This indicated that 
the clustered cell lines have similar mRNA expression profile. This confirmed that 
the expression profile and consequently the protein expression in different cell lines 
could be responsible for regulating their response to TRAIL and Smac59 treatment. 
The miRNA data showed different clustering pattern of tested cell lines in which 
UMSCC74A and UMSCC74B clustered separately from other cell lines. However, 
with the exception of HN30 cells, Smac59 sensitive (TRAIL resistant) cell lines 
were clustered together and Smac59 resistant (TRAIL sensitive) cell lines were 
clustered together. 




Table 4.1  Data summary of the samples used for the gene expression profiling  
Array ID* Sample ID TRAIL/ Smac mimetic status Description 
5050509009 _A  
5050509009_ B 
5050509009_C 
5050509009 _D  
5050509009_ E 
5050509009_ F 
5050509009_ G  
5050509009_ H  
5050509009_ I  
5050509009 _J  
5050509009 _K  
5050509009_ L  
5050509063_ A  
5050509063_ B  
5050509063 _C  
5050509063 _D  
5050509063_ E  
5050509063 _F 
5050509063_ G  
5050509063_ H  
5050509063_I  
 
SCC74B (1)  
HN5 (1)  
HSC3M3 (1)  
SCC22B (1)  
HN5 (2)  
SCC74B (2)  
SCC74A (1)  
HN30 (2)  
HN30 (1)   
HSC3 (2)  
HSC3M3 (2)  
SCC11B (1)  
SCC11B (2)  
SCC22B (2)  
HCT116 24h puma -/-  
HCT116 24h p53 -/-  
HCT116 3d h p53 wt  
HCT116 24h h p53 wt  
HSC3 (1)  
HCT116 3d puma -/-  
HCT116 3d p53 -/-  
 
TRAILsens Smacresist 
Smacsens TRAILresist  
SMACsens TRAILresist  
TRAILsens Smacresist  
Smacsens TRAILresist  
TRAILsens Smacresist 
TRAILsens SMACresist 
TRAILsens SMACresist  
TRAILsens Smacresist  
Smacsens TRAILresist  
Smacsens TRAILresist  
TRAILsens Smacresist  
TRAILsens Smacresist  









HNSCC cell line ,24h 
HNSCC cell line,24h 
HNSCC cell line,24h 
HNSCC cell line,24h 
HNSCC cell line, 48h 
HNSCC cell line, 48h 
HNSCC cell line,24h 
HNSCC cell line, 48h 
HNSCC cell line,24h 
HNSCC cell line, 48h 
HNSCC cell line, 48h 
HNSCC cell line,24h 
HNSCC cell line, 48h 









   *The array IDs have the format ‘[chipNumber]_[chipPosition (A-L)] 
















Figure 4.13  Unsupervised hierarchical clustering of all samples and all probes for gene and miRNA profiling results 
Unsupervised hierarchical clustering for all tested samples on the same chip (HNSCC cell lines and colorectal cell lines). Green: Smac59 sensitive (TRAIL resistant) cell 
lines. Red: Smac59 resistant (TRAIL sensitive) cell lines. Grey: colorectal cell lines.  Number 1 or 2 by cell line name indicates the 24 and 48 hours mRNA extraction after 
seeding samples respectively. 




4.4.1 Gene expression profiling 
Expression level of mRNA for proteins that are involved in TRAIL and 
Smac59 apoptosis pathways was analysed.  
Figure 4.14 showed the unsupervised clustering and the gene expression of 
Smac/DIABLO, Mcl-1, CFLAR, TNFRSF10A (TR-1), XIAP, TNFRSF10C (DR-
4), TNFRSF10D (DR-5), TRAF1, Bcl-2, caspase-8, TNF-α, caspase-3, 
TNFRSF10B (TR-2) and EGFR.  
The data indicated that Smac/DIABLO was highly expressed in Smac59 
sensitive (TRAIL resistant) cells than Smac59 resistant (TRAIL sensitive) cell lines. 
With the exception of HN30 cell line, Mcl-1 was expressed at higher levels in 
Smac59 sensitive (TRAIL resistant) cell lines. With the exception of HN30 cell line, 
CFLAR (cFLIP) was higher in Smac59 resistant (TRAIL sensitive) cell lines. With 
the exception of HN5 cells, TNF and TNFR2 were expressed at higher levels in 
Smac59 sensitive (TRAIL resistant) cells while TRAF1 expression pattern was not 
associated with Smac59 sensitivity. With the exception of HN30 cell line, 
TNFRSF10A (TR-1) and TNFRSF10B (TR-2) showed higher levels of expression 
in Smac59 sensitive (TRAIL resistant) cells. No clear association between 
TNFRSF10C (DR-4) and TNFRSF10D (DR-5) and TRAIL or Smac59 sensitivity 
was observed. 
XIAP was highly expressed in Smac59 sensitive (TRAIL resistant) cells. 
With the exception of HN5 and HN30 cell lines, Bcl-2 was overexpressed in 
Smac59 resistant (TRAIL sensitive) cell lines. With the exception of HN5 and 
HN30 cell lines, caspase-8 was highly expressed in Smac59 resistant (TRAIL 
sensitive) cell lines while caspase-3 expression was not correlated to TRAIL or 
Smac59 sensitivity. With the exception of HN30 cell line, EGFR was highly 
expressed in Smac59 sensitive (TRAIL resistant) cell lines. 
In summary, the results from gene expression profiling indicated that, 
Smac/DIABLO, Mcl-1, TRAF-2, TNF, TR-1, TR-2, XIAP and EGFR 
overexpression were associated with Smac59 sensitivity and Bcl-2, CFLIP and 




caspase-8 overexpression were associated with TRAIL sensitivity.  Results of TNF-
α, Bcl-2, c-FLIP, Bcl-2, caspase-8 and EGFR confirmed the results obtained from 
the protein analysis. On the other hand, the difference in the expression of 
TNFRSF10a (TR-1), TNFRSF10b (TR-2) and XIAP was not clearly identified by 
the protein analysis. Taken together, this data suggested that the expression profile 
of different proteins in HNSCC cell lines could be responsible for regulating their 
response to TRAIL and Smac59. However, the exact role of each of these proteins 
in this process required further investigations.  
 






















Figure 4.14  Unsupervised hierarchical clustering 
Unsupervised hierarchical clustering of selected TRAIL/Smac apoptosis pathway members in 
selected cell lines (HNSCC cell lines). Horizontal colour bar indicates TRAIL/Smac sensitivity; 
yellow=TRAIL sensitive/Smac59 resistant; grey=Smac59 sensitive/TRAIL resistant. The orange and 
green colours represent the scale of expression of the tested genes.  Number 1 or 2 by cell line name 









4.4.2 miRNA expression profiling 
Differential miRNAs expression in Smac59 sensitive (TRAIL resistant) cell 
lines versus Smac59 resistant (TRAIL sensitive) cell lines was analysed to identify 
potential biomarkers for predicting sensitivity to TRAIL or Smac59.  
The data shown in Figure 4.15 illustrating the unsupervised clustering and 
the miRNA expression in TRAIL sensitive versus Smac59 sensitive cell lines, 
showed 15 miRNA that were upregulated (A) and 7 miRNA which were 
downregulated (B) in Smac59 resistant (TRAIL sensitive) cell lines compared with 
Smac59 sensitive (TRAIL resistant) cell lines (Table 4.2). This data confirmed that 
the sensitivity/resistant pattern of HNSCC cell lines to TRAIL and Smac59 appears 
to be explained by the differential expression of a number of miRNA. These 
miRNA could be ideal candidates as biomarkers for this sensitivity and will need 
further validation that is not covered in this thesis. 
Table 4.2  Selected miRNA significantly up or down regulated in HNSCC cell lines 
Upregulated miRNA in Smac59 resistant 
(TRAIL sensitive) cell lines (15) 
Downregulated miRNA in Smac59 resistant 









































Figure 4.15  Selected miRNA significantly up or down regulated in HNSCC cell lines 
A: upregulated miRNAs, B: downregulated miRNAs in Smac59 sensitive (TRAIL resistant) versus Smac59 resistant (TRAIL sensitive) cell lines. Heatmaps are displayed 
after hierarchical clustering of samples for the selected miRNAs. Horizontal colour bar indicates TRAIL/Smac sensitivity; yellow= Smac59 resistant (TRAIL sensitive); 
grey=Smac59 sensitive (TRAIL resistant). The orange and green colours represent the scale of expression of the tested miRNA; green is low and red is high as scale bar 














In order to investigate whether the differential expression of miRNAs 
mentioned above is affecting the gene expression in the tested cell lines, two 
miRNAs from each group, hsa-mir-9* and hsa-mir-9 from upregulated group and 
hsa-mir-21* and hsa-mir-124 from the downregulated group, were selected for 
further statistical analysis using the LIMMA package (R/Bioconductor). The 
validated targets for each miRNA were obtained from a microRNA database on 
validated and predicted miRNA targets website called miRWALK.  These validated 
targets were subjected to statistical analysis to identify genes which are significantly 
differentially expressed between the treatment-response groups. The subset of 
miRNA targets which were detected as significantly differentially expressed 
between the treatment-response groups are shown in Table 4.3.  From the list of 
genes that previously identified as differentially expressed between Smac59 
sensitive/TRAIL resistant and Smac59 resistant/TRAIL sensitive cells (Figure 
4.14), EGFR is the only gene presented as differentially expressed between the two 
treatment groups. Further investigation is needed to validate these identified genes 
and to investigate their role in determining the sensitivity/resistant to Smac59 and 
TRAIL in HNSCC cell lines. 




Table 4.3 List of miRNA target genes differentially expressed in TRAIL 
sensitive/Smac resistant cells  
miRNA Genes upregulated in 
TRAIL sensitive/Smac 
resistant cells 
























































In conclusion, identification of biomarkers for predicting the response of 
HNSCC cell lines to TRAIL and Smac59 was investigated. This was performed by 
associating the expression of several proteins, genes and miRNA in HNSCC cell 
lines using several different experimental techniques. The data obtained suggested: 
 TNF-α, MCl-1, XIAP, Smac/DIABLO, TR-1, TR-2 and EGFR were 
overexpressed in Smac59 sensitive (TRAIL sensitive) cell lines and 
underexpressed in Smac59 resistant (TRAIL sensitive) cell lines.  
  Bcl-2, Caspase-8 and cFLIP were overexpressed in Smac59 resistant 
(TRAIL sensitive) and underexpressed in Smac59 sensitive (TRAIL 
sensitive) cell lines.  
 15 miRNA were significantly upregulated and 7 were significantly 
downregulated in the Smac59 resistant (TRAIL sensitive) versus 
Smac59 sensitive (TRAIL sensitive) cell lines. 
 These proteins and miRNAs could be potential biomarkers for 
TRAIL or Smac59 sensitivity in HNSCC cell lines and possibly 
other cells. 
In the next chapter, validation and functional analysis for number of these 
proteins will be addressed in order to investigate the mechanisms underlying 







5 Results III 
Mechanisms of TRAIL and Smac mimetic-induced apoptosis in 
HNSCC cell lines 
In the previous chapter, a number of proteins were found to be involved in 
determining the TRAIL/Smac59 sensitivity/resistance pattern in the tested HNSCC 
cell lines. TNF-α, Bcl-2 and XIAP were selected for further functional studies. 
HSC3M3 was selected as a candidate Smac59 sensitive cell line and UMSCC11B as 
a candidate TRAIL sensitive cell line to investigate the role of TNF-α, Bcl-2 and 
XIAP proteins in TRAIL and Smac59 induced apoptosis. 
 TRAIL induces apoptosis mainly via activation of the extrinsic pathway, 
which is initiated by binding of TRAIL to TRAIL-R1 and R2 receptors leading to 
activation of caspase-8 and consequently caspase-3 activation. In some cell lines 
extrinsic pathway activation is not sufficient to accomplish apoptosis; in these cells 
the intrinsic pathway will also be activated. Smac mimetics were originally 
designed to mimic the interaction between XIAP and its antagonist Smac/DIABLO. 
However, the exact mechanism by which Smac mimetics induce apoptosis is still 
not fully understood. 
5.1  Role of TNF-α in TRAIL/ Smac59 induced apoptosis  
It has been shown that Smac mimetics kill cancer cells via activation of the 
NF-ҡB pathway which leads to the production of TNF-α, the newly synthesized 
TNF-α is subsequently secreted to activate TNF receptors through autocrine or 
paracrine pathways (LaCasse et al., 2008). 
Our results indicated that the level of secreted TNF-α in HNSCC cell lines 
correlated with their sensitivity to Smac59. In order to understand the role of TNF-α 
in TRAIL and Smac59 induced apoptosis, the effect of TRAIL and Smac59 
treatment on the level of secreted TNF-α was investigated together with the effect of 





5.1.1  Effect of TRAIL and Smac59 treatment on TNF-α secretion in 
HNSCC cell lines 
Three Smac59 sensitive (TRAIL resistant) cell lines (HSC3, HSC3M3 and 
HN5) and three Smac59 resistant (TRAIL sensitive) cell lines (HN30, H357 and 
UMSCC11B) were tested for the level of secreted TNF-α before and after treatment 
with TRAIL and Smac59. Equal numbers of cells were seeded in 12well plates in 
1ml media, incubated at 37ºC and 5% CO2 for 24hours. Then the medium was 
replaced with fresh medium containing TRAIL 50ng/ml or Smac59 50nM. The cells 
were then incubated for 24hours and the medium was collected and stored at -70ºC. 
Level of TNF-α in the medium was measured by ELISA as described in material 
and methods. 
The results shown in Figure 5.1 indicated that in Smac59 sensitive (TRAIL 
resistant) cell lines (HSC3, HSC3M3 and HN5), Smac59 treatment induced 
autocrine TNF-α secretion up to six folds over the endogenous level. In Smac59 
resistant (TRAIL sensitive) cell lines (HN30, H357 and UMSCC11B), Smac59 
induced TNF-α secretion at a much lower level. TRAIL treatment had no significant 
stimulatory effect on the TNF-α secretion in all tested cell lines. These results 
suggested that autocrine secretion of TNF-α may be one of the mechanisms by 
which Smac59 induce apoptosis in HNSCC cell lines. Whether lack of TNF-α in 
Smac59 resistant (TRAIL sensitive) cell lines is responsible for their resistance 
required a separate investigations. 
5.1.2 Effect of adding recombinant TNF-α in HNSCC cell lines 
The results in section 5.1.1 opened two lines of investigation.  The first was 
to investigate whether TNF-α could replace Smac59 in the sensitive cell lines to 
induce cell death. Recombinant human TNF-α was added to HSC3M3 and 
UMSCC11B cell lines. Cells were seeded  in 96well plates, incubated at 37ºC and 
5% CO2 for 24hours, then the medium was removed and was replaced with fresh 





(50nM). Cells were incubated for 24 hours then cell viability was tested using MTT 
assay. 
The results in Figure 5.2A showed that TNF-α inhibited HSC3M3 cell 
viability by about 20% while Sma59 induced approximately 70% loss of cell 
viability. TNF-α had a minimal cytotoxic effect on UMSCC11B (Smac59 
resistant/TRAIL sensitive cell line).  This data suggested that Smac59-induced 
TNF-α autocrine secretion in HNSCC is not the only mechanisms by which Smac59 
induces apoptosis in these cell lines. 
The second line of investigation was to examine whether low Smac59 
induced TNF-α secretion in Smac59 resistant (TRAIL sensitive) cell lines is the 
cause of their resistance to Smac59 treatment. Smac59 resistant (TRAIL sensitive) 
cell line, UMSCC11B, was seeded in 96well plate, incubated at 37ºC and 5% CO2 
for 24hours. Then the medium was removed and replaced with fresh medium 
containing recombinant h-TNF-α at (10, 5, 2.5, 1.25, 0.625, 0.3125, 0.15625 ng/ml) 
concentrations alone or in combination with TRAIL (50ng/ml) or Smac59 (50nM).  
After 24 hours the cell viability was measured using the MTT assay. 
The results shown in Figure 5.2B indicated that adding rh-TNF-α to Smac59 
reduced cell viability of UMSCC11B (Smac59 resistant/TRAIL sensitive) by 70-
80%. This effect was even greater than the effect induced by TRAIL treatment 
alone or combined with rh-TNF-α. As UMSCC11B is resistant to Smac59 and as 
shown in Figure 5.1, it secretes a low level of TNF-α after Smac59 treatment, this 
result suggested that TNF-α sensitises resistant cells to Smac59 and  further 
confirmed that TNF-α is important for Smac59 induced apoptosis in HNSCC cell 
lines. 
5.1.3 Effect of antagonizing TNF-α in HNSCC cell lines 
To further confirm the importance of TNF-α in Smac59 sensitivity in 
HNSCC cell lines, the effect of TNF-α inhibition on Smac59 sensitivity in HNSCC 





neutralizing antibody to inhibit its interaction with its receptors, or by using 
blocking antibodies to TNF-α receptors. 
HSC3M3 cell line (Smac59 sensitive) was seeded in 96 well plate, incubated 
at 37ºC and 5%CO2 for 24hours. Then the medium was replaced with fresh medium 
containing either neutralizing antibody (anti-h-TNF-α, 10ug/ml, InvivoGen) or 
blocking antibody (anti-TNFR1, 20 ug/ml, ABD Serotec). The cells were incubated 
with the antibody for 1hour before adding Smac59 (50nM). After 24 hours cell 
viability was measured using MTT assay. 
The results illustrated in Figure 5.3A indicated that the neutralizing antibody 
was not able to protect the HSC3M3 cells from the cytotoxic effect of Smac59. 
Smac59 inhibited cell growth by 60% in the presence or absence of TNF-α 
neutralizing antibody. Similarly, as shown in Figure 5.3B, the anti-TNFR1 blocking 
antibody was unable to inhibit Smac59 induced apoptosis in the HSC3M3 cell line. 
 In MCF-7 breast cancer cell lines, TNF-α activates NF-ҡB pathway through 
ubiquitin-mediated degradation of IҡBs (Machuca et al., 2006). This effect should 
be inhibited when TNF-α activity is blocked by inhibitory antibodies. In order to 
test whether TNF-α and its inhibitory antibodies were functional, MCF-7 cells were 
seeded in 12well plates and were incubated at 37ºC and 5%CO2 for 24hours. The 
medium was removed and replaced with fresh medium containing neutralizing or 
blocking antibody. The cells were incubated for one hour before adding 
recombinant h-TNF-α. After 30min, cell lysates were collected and tested for IҡB-α 
expression using western blot analysis. The data shown in Figure 5.3C indicated 
that TNF-α induced down regulation of IҡB-α in MCF-7. This downregulation was 
inhibited when the cells were pre-treated with the inhibitory antibodies. This 
confirmed the activity of rh-TNF-α and the inhibitory antibodies and supported our 
observations. 
In conclusion, the results obtained suggested that TNF-α could be a marker 
of Smac59 sensitivity and that TNF-α could be used to sensitise Smac59 resistant 
cells to Smac59 induced apoptosis. However, the exact mechanism by which 





unable to induce cell death as seen with Smac59. Furthermore, blocking TNF-α did 
not inhibit Smac59-induced apoptosis. Collectively, these results suggested that 
TNF-α was important for Smac59-induced apoptosis. The exact mechanism by 
























Figure 5.1  Effect of TRAIL and Smac59 treatment on TNF-α secretion in HNSCC cell lines 
Three Smac59 sensitive cell lines and three TRAIL sensitive cell lines were seeded in 12well plates 
and incubated at 37ºC and 5%CO2 for 24hours then the medium was replaced with fresh medium 
containing TRAIL (50ng/ml) or Smac59 (50nM). After 24 hours, the media were collected and were 
used to measure the secreted TNF-α using ELISA. A: standard curve created for the TNF-α standard 
used in ELISA. B: The level of secreted TNF-α in the tested cell lines. All experiments were 
performed in duplicate. The results shown are the average of the TNF-α concentration in the tested 
samples. Red rectangle encloses the Smac59 sensitive (TRAIL resistant) cell lines and the green 













































Figure 5.2  Effect of TNF-α addition on the viability of HNSCC cell lines  
A: HSC3M3 and UMSCC11B cells were seeded in 96 well plates and incubated at 37ºC and 5% CO2 
for 24hours then the medium was replaced with fresh medium containing rh-TNF-α, (10ng/ml), 
TRAIL (50ng/ml) or Smac59 (50nM). After 24hours the cell viability was measured using MTT 
assay. B: UMSCC11B cells were seeded in 96 well plate and incubated at 37ºC and 5% CO2 for 
24hours then the medium was replaced with fresh medium containing rh-TNF-α (10, 5, 2.5, 1.25, 
0.625, 0.3125, 0.15625 ng/ml) alone or with TRAIL 50ng/ml or Smac59 50nM. After 24 hours the 
cell viability was measured using MTT assay. The results are shown as the percentage of the viable 
cells after treatment with respect to viable untreated cells. All experiments were performed in 
triplicate, error bars indicate SD. 
UMSCC11B






















































































Figure 5.3  Effect of TNF-α inhibition on the HNSCC cell lines 
A,B: HSC3M3 cells were seeded in 96well plates and incubated at 37ºC and 5%CO2 for 24hours then the medium was replaced with fresh medium containing either 
neutralizing antibody (anti-h-TNF-α, 10ug/ml, InvivoGen) or blocking antibody (anti-TNF-R1, 20ug/ml, ABD Serotec). The cells were incubated with the antibody for 1hour 
before adding Smac59 (50nM). After 24 hours cell viability was measured using MTT assay. C: MCF-7 cells were seeded in 12well plates and were incubated at 37ºC and 
5%CO2 for 24hours. Then the medium was removed and replaced with fresh medium containing neutralizing or blocking antibody. The cells were incubated for one hour 
before adding recombinant h-TNF-α. After 30min, cell lysates were collected and tested for IҡB-α expression using western blotting analysis. The results are shown as the 
percentage of the viable cells after treatment with respect to viable untreated cells. All experiments were performed in triplicate, error bars indicate SD. 











































































































5.2 Role of Bcl-2 in TRAIL/Smac59 induced apoptosis 
Bcl-2 is an anti-apoptotic member of Bcl-2 family; it prevents membrane 
disruption of the mitochondria as part of intrinsic apoptosis pathway. 
Overexpression of Bcl-2 molecules has been shown to cause TRAIL resistance 
(Fulda et al., 2002). As shown in figure 5.5, Bcl-2 was overexpressed in four of our 
Smac59 resistant (TRAIL sensitive) HNSCC cell lines, while Smac59 sensitive 
(TRAIL resistant) cell lines had undetectable levels of Bcl-2 protein. The role of 
Bcl-2 up or downegulation in HNSCC cell lines and its connection to 
sensitivity/resistant to TRAIL and Smac59 were further investigated. 
5.2.1 Effect of Bcl-2 overexpression on Smac59 sensitivity in Smac59 
sensitive cell lines 
To investigate the role of Bcl-2 overexpression on Smac59 sensitivity in 
HNSCC cell lines, stable bcl-2 expressing mixed populations from the HSC3M3 
cell line were established for the purpose of this study (Figure 5.4C). HSC3M3 is a 
Smac59 sensitive cell line and it showed undetectable levels of endogenous Bcl-2. 
HSC3M3 and HSC3M3-Bcl-2 cells were seeded in 96well plates and incubated at 
37ºC and 5%CO2 for 24hours then the medium was replaced with fresh medium 
containing Smac59 at (2, 1, 0.5, 0.25, 0.125nM) concentrations. The cells were 
incubated for 24hours then the cell viability was tested with MTT assay. 
As illustrated in Figure 5.4A and Figure 5.4B, Bcl-2 overexpression in 
HSC3M3 cells did not protect the cells from Smac59-induced apoptosis. The 
cytotoxic effect of Smac59 was similar in both HSC3M3 and HSC3M3-Bcl-2 cells 
suggesting that bcl-2 may not be involved in the regulation of Smac59-induced 
apoptosis and that Smac59 may induce cell death by acting downstream or 





5.2.2 Effect of Bcl-2 overexpression on TRAIL sensitivity in TRAIL 
sensitive cell lines 
Four (UMSCC74A, UMSCC74B, UMSCC11B and UMSCC22B) out of six 
Smac resistant (TRAIL sensitive) HNSCC cell lines expressed high levels of Bcl-2 
(Figure 4.5) suggesting a possible role for Bcl-2 in TRAIL-induced apoptosis. 
While two (HN30, H357) had undetectable Bcl-2 expression. In order to investigate 
the role of Bcl-2 overexpression on TRAIL sensitivity in HNSCC cell lines, stable 
Bcl-2 expressing mixed populations from the H357 cell line were established in the 
department by Dr Marcella Flinterman (Figure 5.5D). H357 and H357-Bcl-2 cells 
were seeded in 96 well plates and incubated at 37ºC and 5%CO2 for 24hours then 
the medium was replaced with fresh medium containing TRAIL at (100, 50, 25, 
12.5, 6.25, 3.125, 1,65ng/ml) concentrations. The cells were incubated for 24hours 
then the cell viability tested with MTT assay. 
The results shown in Figure 5.5A and Figure 5.5B indicated that TRAIL 
induced 25% cell death in H357-Bcl-2 cell compared with 75% cell death induced 
in H357 cells. This difference in the level of cytotoxicity was statistically significant 
(p value <0.001) (Figure 5.5C). These findings suggested that Bcl-2 overexpression 
inhibited TRAIL-induced apoptosis in H357-Bcl-2 cells indicating that TRAIL-
induced apoptosis in this cell lines was regulated by Bcl-2. H357 cells had a lower 
caspase-8 level than other Smac59 resistant (TRAIL sensitive) cell lines (Figure 
4.7), which may indicate that TRAIL-induced cell death in H357 cell lines may be 
mediated through activation of both extrinsic and intrinsic pathways and that H357 















Figure 5.4  Effect of Bcl-2 overexpression in Smac59 sensitive cells 
A,B: HSC3M3  and HSC3M3-Bcl-2 cells were seeded in 96 well plates and incubated at 37ºC and 5%CO2 for 24hours then the medium was replaced with fresh medium 
containing Smac59 at (2, 1, 0.5, 0.25, 0.125nM) concentrations. The cells were incubated at 37ºC and 5% CO2 for 24hours then the cell viability tested with MTT assay. C: 
Western blotting showing Bcl-2 expression in the HSC3M3 and HSC3M3-Bcl-2 cells. The results are shown as the percentage of the viable cells after treatment with respect 








































































Figure 5.5  Effect of Bcl-2 overexpression in TRAIL sensitive cell lines 
A,B: H357 and H357-Bcl-2 cells were seeded in 96well plates and incubated at 37ºC and 5%CO2 for 
24hours then the medium was replaced with fresh medium containing TRAIL at (100, 50, 25, 12.5, 
6.25, 3.125, 1.65ng/ml) concentration. The cells were incubated for 24hours then the cell viability 
tested with MTT assay.  C: H357, H357-GFP and H357-Bcl-2 cells were treated with TRAIL 
(50ng/ml). Cell viability tested with MTT assay. D: Western blotting showing Bcl-2 expression in 
the H357 and H357-Bcl-2 cells. The results are shown as the percentage of the viable cells after 
treatment with respect to viable untreated cells. All experiments were performed in triplicate, error 






























































































5.3 Role of IAPs in the TRAIL/Smac59 induced apoptosis 
IAPs are efficient suppressors of apoptosis induced by variety of stimuli, 
including death receptor activation, growth factor withdrawal, ionizing radiation, 
viral infection and genotoxic damage (Hunter et al., 2007). Since IAPs function at 
the convergence of both the mitochondrial pathway and death receptor pathway, 
they are described as an apoptosis brake and IAP antagonists function to release the 
brake (Dai et al., 2009a). XIAP is the first well characterized IAP family member 
due to its potent anti-apoptosis activity. The importance of IAPs in the regulation of 
apoptosis induction by TRAIL and Smac59 in HNSCC cell lines was investigated. 
5.3.1 TRAIL and Smac59 induce Caspase dependant cell death 
In order to investigate the mechanism by which TRAIL and Smac59 induce 
cell death in HNSCC cells lines, HSC3M3 and UMSCC11B cells were seeded in 
12well plates, incubated for 24hours at 37ºC and 5%CO2. Then medium was 
replaced by a fresh medium containing TRAIL (50ng/ml) or Smac59 (50nM). After 
2, 4, 8 and 12hours of incubation, the cells were lysed and subjected to western blot 
analysis to investigate capase-3 activation and apoptosis induction as marked by 
caspase-3 mediated cleavage of Poly (ADP-ribose) polymerase (PARP). PARP is a 
family of several proteins involved in a number of cellular process mainly DNA 
repair and apoptosis. Activated caspase-3 induces PARP cleavage which results in 
its inactivation.  Detection of cleaved fragments of PARP (89 kDa) by western blot 
analysis indicates that the cells were undergoing apoptosis. 
The results shown in Figure 5.6 indicated that TRAIL induced caspase-3 
activation in TRAIL sensitive cell line UMSCC11B. Caspase-3 activation was 
observed at four hours after adding TRAIL to the cells; this activation reached the 
maximum level at 12hours. Cleavage of PARP was observed concurrently with 
caspase-3 activation at 4 hours. Similarly, Smac59 induced caspase-3 activation in 
HSC3M3 Smac59 cell line. However caspase-3, activation and PARP cleavage was 
observed after 8hours. This data suggested that TRAIL and Smac59 induced 





5.3.2 Effect of TRAIL and Smac59 on IAPs expression in HNSCC cell lines 
IAPs overexpression is a main cause of cancer cells evading apoptosis.  In 
order to induce apoptosis in these cells, IAPs activity could be inhibited either by 
endogenous Smac/DIABLO secretion or use of anti-IAPs reagents. The kinetics of 
the effect of TRAIL and Smac59 treatment on XIAP and cIAP-1 expression in 
HNSCC cell lines was investigated. UMSCC11B and HSC3M3 cells were seeded in 
12 well plates, incubated for 24 hours at 37ºC and 5%CO2. The medium was 
replaced with a fresh medium containing TRAIL (50ng/ml) or Smac59 (50nM). 
After 2, 4, 8 and 12hours of incubation, the cells were lysed and subjected to 
western blot analysis to investigate XIAP and cIAP-1 expression. 
The results shown in Figure 5.7 indicated that in the UMSCC11B cell line, 
TRAIL induced XIAP and cIAP-1 downregulation at 8 hours and Smac59 induced 
cIAP-1 depletion as early as 2hours after treatment. Smac59 had no noticeable 
effect on XIAP expression in UMSCC11B.  Similarly in the HSC3M3 line, Smac59 
induced cIAP-1 depletion as early as 2hours after treatment and downregulated 
XIAP at 8hours. TRAIL had no effect on XIAP or cIAP-1 expression in HSC3M3 
cell lines. Smac59 induced cIAP-1 depletion in both sensitive and resistant cell lines 
suggesting that cIAP-1 depletion may not be an indicator of Smac59 sensitivity. 
XIAP downregulation was observed in the sensitive cells when treated with the 
corresponding drug. Whether XIAP downregulation is a primary effect in 
TRAIL/Smac59 induced apoptosis or is a secondary event for apoptosis needs to be 
























Figure 5.6  TRAIL and Smac59 induce caspase dependant apoptosis 
HSC3M3 and UMSCC11B cells were seeded in 12 well plates, incubated for 24hours at 37ºC and 
5%CO2. The medium was replaced by a fresh medium containing TRAIL (50ng/ml) or Smac59 
(50nM). After 2, 4, 8 and 12hours of incubation, the cells were lysed and subjected to western blot 
analysis to examine capase-3 activation and Poly (ADP-ribose) polymerase (PARP) cleavage. β-
























Figure 5.7  Effect of TRAIL and Smac59 on XIAP and cIAP-1 expression in HNSCC cells 
HSC3M3 and UMSCC11B cells were seeded in 12 well plates, incubated for 24hours at 37ºC and 
5%CO2. The medium was replaced by a fresh medium containing TRAIL (50ng/ml) or Smac59 
(50nM). After 2, 4, 8 and 12hours of incubation, the cells were lysed and subjected to western blot 





5.3.3 Effect of Caspase inhibitor treatment on IAPs (XIAP and cIAP-1) 
expression  
The results obtained from the previous two experiments suggested that 
TRAIL and Smac59 induced caspase dependant apoptosis in HNSCC cell lines and 
that they induced downregulation of XIAP and cIAP-1. In order to investigate the 
nature of IAPs role in TRAIL and Smac59 induced apoptosis and whether the 
downregulation observed after TRAIL/Smac59 treatment is important for apoptosis 
induction or is a consequent event of apoptosis, UMSCC11B and HSC3M3 cells 
were seeded in 12well plates, incubated for 24hours at 37ºC and 5%CO2. The 
medium was replaced by a fresh medium containing Pan-caspase inhibitor ZVAD-
FMK (20µM). The cells were incubated for one hour. Then TRAIL (50ng/ml) or 
Smac59 (50nM) were added to the cells. The cells were then incubated for a further 
8hours. The cells were lysed and subjected to western blot analysis to investigate 
XIAP and cIAP-1 expression. 
The results shown in Figure 5.8 indicated that in the HSC3M3 cell line, 
caspase inhibitor was unable to block cIAP-1 depletion induced by Smac59 but it 
did inhibit XIAP downregulation. Similarly in the UMSCC11B cell line, pre-
treatment with caspase inhibitor blocked XIAP downregulation. This data suggested 
that Smac59-induced cIAP-1 depletion was caspase independent and did not 
correlate with the sensitivity of HNSCC cell lines to Smac59. XIAP downregulation 
in UMSCC11B and HSC3M3 cells following TRAIL and Smac59 treatment 
respectively seemed to be caspase dependent. However, it is not clear from these 
experiments whether initiator caspases or executioner caspases might be responsible 
for blocking XIAP downregulation. To determine this, the effect of caspase type-























Figure 5.8  Effect of caspase inhibitor on IAPs expression with TRAIL/Smac59 treatment 
HSC3M3 and UMSCC11B cells were seeded in 12well plates, incubated for 24hours at 37ºC and 
5%CO2. The medium was replaced by Pan-caspase inhibitor ZVAD-FMK (20µM). The cells were 
incubated for one hour. Then TRAIL (50ng/ml) or Smac59 (50nM) were added to the cells. The cells 
were then incubated for further 8 hours. The cells were lysed and subjected to western blot analysis 






5.3.4 Effect of XIAP knockdown on TRAIL and Smac59 induced apoptosis 
In order to understand the role of XIAP in TRAIL/Smac59 induced 
apoptosis, we investigated the effect of XIAP knockdown on TRAIL and Smac59 
sensitivity in HNSCC cell lines. This was performed using two different 
approaches. The first one was to inhibit XIAP using siRNA.  UMSCC11B and 
HSC3M3 cells were plated in 24 well plates and incubated for 24hours at 37ºC and 
5% CO2. The cells were transfected with XIAP-siRNA (5’ 
AUCCAUCCAUGGCAGAUUA 3’) using X-tremeGENE HP siRNA Reagent 
(Roche). The cells were incubated for 24 or 48hours. The cells were lysed and 
subjected to western blotting to test the gene knockdown (Figure 5.9A). The 
maximum XIAP knockdown was observed at 48 hours after transfection.   
UMSCC11B and HSC3M3 cells were plated in 96 well plates and incubated 
for 24hours at 37ºC and 5%CO2. Then the cells were transfected with XIAP-siRNA 
or scrambled siRNA. After 48hours the cells were treated with TRAIL (50ng/ml) or 
Smac59 (50nM) for 24hours and cell viability was tested using MTT assay. The 
results shown in Figure 5.9 B indicated that XIAP knockdown had undetectable 
effect on the sensitivity of UMSCC11B to Smac59 suggesting that XIAP 
knockdown is not sufficient to sensitise the resistant cells to Smac59. In HSC3M3 
cells, XIAP knockdown increased their sensitivity to Smac59 but it had no effect on 
their sensitivity to TRAIL. 
The second approach was to establish stable XIAP knockdown cells. 
UMSCC11B and HSC3M3 cells were plated in 24well plates and incubated for 
24hours at 37ºC and 5%CO2. Then the cells were transfected with PLenti6-sh-XIAP 
or PLenti6-sh-lacZ as an empty vector. The transfection was performed using X-
tremeGENE HP DNA Transfection reagent. After 24hours, the medium was 
replaced with fresh medium containing the selectable marker Blasticidin (10ug/ml 
for UMSCC11B and 5ug/ml for HSC3M3). The cells were incubated for 1-2 weeks 
and medium was changed every 2 days. Then the mixed population of cells were 





XIAP knockdown from UMSCC11B cells but not from HSC3M3 cells (Figure 
5.10). 
In order to investigate the effect of stable XIAP knockdown on HNSCC cell 
lines, UMSCC11B, UMSCC11B-sh-lacZ and UMSCC11B-sh-XIAP cells were 
plated in 96well plates and incubated for 24hours at 37ºC and 5%CO2. Then the 
cells were treated with TRAIL (50ng/ml) or Smac59 (50nM) for 24hours and cell 
viability was tested using MTT assay. The results shown in Figure 5.10 indicated 
that XIAP knockdown had no effect on the sensitivity of UMSCC11B to Smac59 
and that XIAP knockdown could not sensitise UMSCC11B cells to Smac59-
induced apoptosis. These data was consistent with the results obtained from the 





















Figure 5.9  Effect of XIAP knockdown using siRNA on TRAIL/Smac59 sensitivity 
A:  HSC3M3 and UMSCC11B cells were seeded in 24well plates and incubated for 24hours at 37ºC 
and 5%CO2. Then the cells were transfected with XIAP-siRNA using X-tremeGENE HP siRNA 
Reagent. The cells were incubated for 24 or 48hours and gene knockdown was tested using western 
blotting. β-actin was used as a loading control B: UMSCC11B and HSC3M3 cells were plated in 
96well plates and incubated for 24hours at 37ºC and 5%CO2. Then the cells were transfected with 
XIAP-siRNA or scrambled siRNA. After 48hours the cells were treated with TRAIL (50ng/ml) or 
Smac59 (50nM) for 24hours then cell viability was tested using MTT assay. The results are shown 
as the percentage of the viable cells after treatment with respect to viable non treated cells. All 
















































































Figure 5.10  XIAP knockdown stable clones 
Left:  UMSCC11B cells were plated in 24well plates and incubated for 24hours at 37ºC and 5%CO2. 
Then the cells were transfected with PLenti6-sh-XIAP or PLenti6-sh-lacZ using X-tremeGENE HP 
DNA Transfection reagent. The following day, the medium was replaced with fresh medium 
containing the selection antibiotic Blasticidin (10 and 5ug/ml). The cells were incubated for 1-2 
weeks and medium was changed every 2days. Then the cells were tested for XIAP knockdown using 
western blotting. β-actin was used as a loading control. Right: UMSCC11B-sh-XIAP cells were 
seeded in 96well plates, incubated for 24hours at 37ºC and 5%CO2. Then TRAIL (50ng/ml) or 
Smac59 (5 nM) were added to the cells, incubated for 24 hours then cell viability was tested using 
MTT assay. The results are shown as the percentage of the viable cells after treatment with respect to 









































In conclusion, the results of this chapter suggested that:  
 Smac59 increased TNF-α autocrine secretion in the Smac59 sensitive 
(TRAIL resistant) HNSCC cell lines. 
 Recombinant TNF-α was able to sensitise Smac59 resistant (TRAIL 
sensitive) HNSCC cells to Smac59. 
 TNF-α inhibition had no significant effect on Smac59 induced 
apoptosis in Smac59 sensitive HNSCC cells. 
 Bcl-2 overexpression increased resistance to TRAIL in HNSCC cell 
lines, however it showed undetectable effect on Smac59 sensitivity. 
 TRAIL and Smac59 induced a caspase dependent cell death in 
HNSCC cell lines. 
 TRAIL and Smac59 induced XIAP downregulation in sensitive 
HNSCC cell lines. This down regulation was inhibited with pan-
caspase inhibitor. 
 XIAP knockdown could not sensitise TRAIL or Smac59 resistant 








6 Results IV 
Biomarkers of treatment outcome in head and neck squamous 
cell carcinoma. 
Treatment of cancer patients with conventional therapies normally is 
successful only initially. However, in many patients tumour recurs and patients 
relapse, such tumours exhibit the resistant phenotype to various cytotoxic and 
apoptotic agents. Cancer cells can become resistant to radio-chemotherapy by 
developing mechanisms to repair DNA damage or decreasing the uptake of drugs 
across the cell membrane (Lee et al., 2007). To avoid the resistance and adverse 
effects of different therapeutics, it is essential to characterise individual tumour 
specimens to establish a genetic profile prior to each patient treatment which may 
predict response to a given treatment. For this to become possible in routine clinical 
practice, biomarkers and appropriate sensitivity assays need to be employed to 
reliably identify those patients who may benefit from a certain treatment. The need 
for specific and effective therapy is essential as the survival rate of HNSCC is low 
with high mortality rate and finding such therapy will be the optimum achievement. 
ERCC1, HIF-1α, Ku80, PTEN, Rad51 and XRCC1 proteins are involved in 
the DNA damage repair and tumour hypoxia. Their expression has been associated 
with resistance to radiotherapy and/or chemotherapy and with the survival of 
patients with different types of tumour as discussed in the introduction. HPV 
positive carcinomas showed better response to treatment and overall survival.  
In this chapter, we investigated the immuoexpression of ERCC1, HIF-1α, 
Ku80, PTEN, Rad51 and XRCC1 proteins in HNSCC tissues. Furthermore, we 
investigated the association between their levels of expression and patient survival 
and response to treatment. In addition, we investigated the HPV status in the tonsil 
and pharyngeal carcinomas and its association with survival and expression of the 





6.1 Patients and carcinomas 
Tissue biopsies from head and neck squamous cell carcinomas (HNSCC) 
were obtained from the pathology archives of the Oral Pathology Department, 
Dental Institute, King’s College London from patients treated in the period 1997 to 
2004. The cases were selected to be representative of a range of oral and pharyngeal 
sub-sites. Table 6.1 shows the number of cases for each sub-site. Details of clinical 
and histopathological features and the follow up information for each case were 
collected from pathology records, clinical notes and various hospital clinical 
management databases. Data were recorded in Excel spreadsheet before being 
exported to IBM SPSS statistics 20 program for analysis. The data recorded was site 
of origin, age at the time of diagnosis, gender, tumour differentiation, TNM stage 
(6
th
 edition), treatment (surgery or surgery followed by radiotherapy), disease free 
survival and overall survival. The overall survival was calculated in months from 
the date of initial surgery to the date of last follow-up or death, and the disease free 
interval was calculated from the date of initial surgery to the date of first recurrence 
or the date of last follow-up without evidence of recurrent or persistent disease. The 
ethics approval for this study was obtained from Guy’s Hospital Research Ethics 
Committee, reference 04/02/10). 
Table 6.1  Sub-site distribution of the study cases 
Site Number of cases 
Lateral tongue  
Buccal mucosa  
Retromolar, tuberosity  
Floor of the mouth and palate 
Alveolus  

















6.1.1 Clinical and pathological characterization 
The median age of the 150 patients at diagnosis was 60 years (range, 26 to 
91 years). 99 (66%) patients were male and 51 (34%) patients were female.  
Histologically, 23 (15.3%) cases were well differentiated carcinoma, 79 (52.7%) 
cases were moderately differentiated and 48 (32.0%) cases were poorly 
differentiated. Using the TNM staging system 6
th
 edition, 21 (14%) cases were stage 
I, 32 (21.3%) cases were stage II, 27 (18%) cases were stage III and 70 (46.7%) 
cases were stage IV. No metastasis was present in 85 (56.7%) cases while 65 
(43.3%) cases had metastasized to regional lymph nodes at diagnosis. 78 (52%) 
cases were treated by surgery only and 69 (46%) cases were treated with surgery 
followed by radiotherapy with curative intent, 3 (2%) cases had palliative therapy.  
This data broken down by sub-site is shown in Table 6.2. 
For all sites of origin, males were affected more frequently than females. 
Moderate tumour differentiation was most common except for tonsil and pharynx in 
which poorly differentiated tumours were more common, though in at least some 
cases the undifferentiated type may refer a differentiated carcinoma of tonsil crypt 
epithelium as HPV associated carcinoma of tonsil was not recognized at the time of 
original diagnosis. Metastasis to regional lymph nodes was observed in cases from 
all sites but was more frequent in lateral tongue cases. Carcinoma of the lip cases 
was the least likely to metastasize. TNM stage IV was predominant in carcinomas 
from the lateral tongue, alveolus, tonsils and retromolar region, tuberosity and 
palate. Stage I was predominant in lip cases. Stage III and stage IV were equally 
distributed in cases of floor of the mouth. Stage II and Stage IV were comparable in 
buccal mucosa cases. This data is summarised by site in Figure 6.1and Figure 6.2. 
The diagnostic tissue specimens from the 150 carcinomas were used to 
construct tissue microarray (TMA) blocks as described in the materials and methods 
section 2.2.14. 14 specimens were post-radiotherapy tissues. This was discovered 
after array construction and all data from these cases has been excluded from 





Table 6.2  Clinical and histopathological characteristics of the study cases and carcinomas 
 Number of cases (%) 
Characteristic Lateral  Tongue Buccal mucosa Retro-palate Floor of mouth Alveolus Lip  Tonsil Pharynx Total  

















































































































































































































































































































































































































































































































































































































































































































































































































6.2 Immunohistochemical staining 
Paraffin embedded formalin fixed (PEFF) tissue specimens from 150 cases 
were used to construct tissue microarray (TMA) blocks for immunostaining as 
described in materials and methods section 2.2.14. Immunohistochemical staining 
was performed to examine the expression of ERCC1, HIF-1α, KU80, PTEN, Rad51 
and XRCC1 using the appropriate antibody. Antigen retrieval, antibody 
concentration and incubation period and use of positive controls were optimised for 
each antibody. 
TMA blocks were sectioned at 4µm using routine histological procedures on 
a Leica-RM2235 microtome by staff in the KCL Department of Oral Pathology and 
stored for a maximum of three days before staining. Two sections from each TMA 
were stained as described in the material and methods section 2.2.15. Images of IHC 
staining were taken using a Zeiss microscope with an Olympus CV3 camera and 
Olympus Cell-D software. 
The expression of each antibody was scored by consensus between two 
pathologists (Odell E. and El-Attar R.H.) blind to clinical and pathological data. 
Two parameters were scored for each antibody, the intensity of the staining (1=no 
stain, 2=equivocal, 3=weak, 4=moderate or 5=strong) and the percentage of the 
stained cells (1=0-25%, 2=26-50%, 3=51-75% or 4=76-100%). Both assessments 
were subjective. Four carcinoma cores were scored in duplicate for each case and a 
final combined score was calculated as the average of the eight scores. 
The scores were recorded in the spreadsheet with the clinical and the 
histological data for each case and imported into the IBM SPSS statistics 20 
programme for statistical analysis. Due to limited number of cases in each band of 
the scoring system used and to increase statistical power, scores from each 
parameter were transformed into a binary score. Intensity of the staining was 
transformed to either negative (which included 1=no stain, 2=equivocal) or positive 
(which included 3=weak, 4=moderate and 5=strong). Percentage of cells stained 





2=26-50%, 3=51-75% and 4=76-100%). These combinations were selected on the 
basis of score distribution. When less than 25% of cells were positive, the number 
of cells positive was usually very low, so that there appeared to be a natural division 
into two groups. 
6.2.1 ERCC1 Immunostaining 
The immunostaining for ERCC1 was nuclear in normal, dysplastic and 
carcinoma tissue. ERCC1 positivity was variable in intensity and distribution in 
carcinoma tissues. When the staining was strong, it usually involved all carcinoma 
cells except the keratinizing ones. When the staining was weak, it was focally 
distributed involving mainly the immature cells. Suprabasal staining with little basal 
positivity was observed in normal and dysplastic epithelium. Stromal cells showed 
weak positive staining. Minimal background staining was observed in some cases, 
but the reaction overall appeared strong (Figure 6.3). 
6.2.2 HIF-1α immunostaining 
Staining for HIF-1α was nuclear with variable intensity and distribution. 
Mostly the maturing cells showed positive staining (Figure 6.3). Occasionally 
stromal cells showed positive staining. Normal epithelium and dysplasia showed 
suprabasal positivity. Background staining was observed in some cases. 
6.2.3 Ku80 immunostaining 
Ku80 staining was nuclear, well defined with no background staining. All 
carcinoma tissues expressed Ku80 to different degrees. Staining intensity was 
moderate to strong. Mature cells showed positive attaining. Stromal cells were 
positive for ku80 (Figure  6.4).  
6.2.4 PTEN immunostaining 
PTEN immunostaining was observed to be both nuclear and cytoplasmic, 





positive. Mature and keratinizing cells were negative. Stromal cells showed strong 
positivity. The overall carcinoma positive staining was weak with a few cases which 
showed strong staining intensity. PTEN expression was usually observed in small 
numbers of cells (Figure  6.4). 
6.2.5 Rad51 immunostaining  
Rad51 staining was nuclear with some cases showed strong cytoplasmic 
staining. Mostly suprabasal cells were positive. Stromal and muscle cells showed 
strong positivity. Background staining was observed in most of the cases when 
antibody was incubated overnight but staining was faint when incubated for 30 min 
as recommended by manufactures, so optimization for anti-Rad51 was modified to 
3 hours incubation period to balance staining intensity in carcinoma cells with 
minimal background staining (Figure 6.5). 
6.2.6 XRCC1 immunostaining 
XRCC1 staining was mainly nuclear but a few cases showed cytoplasmic 
staining. Almost all HNSCC tissues were positive to XRCC1 staining with strong 
intensities. Positive staining was confined to proliferating basal and suprabasal cells. 
Stromal cells showed positive staining in some cases. Minimal background staining 

























Figure 6.3  ERCC1 and HIF-1α expression in HNSCC tissues 
Photomicrographs showing representative immunostaining for ERCC1 and HIF-1α expression in 
HNSCC tissues. The staining was nuclear with variable intensity. Original magnification10x 



























Figure  6.4  Ku80 and PTEN expression in HNSCC tissues 
Photomicrographs showing representative immunostaining for Ku80 and PTEN expression in 
HNSCC tissues. Ku80 staining was nuclear with variable intensity and PTEN staining was nuclear 



























Figure 6.5  Rad51 and XRCC1 expression in HNSCC tissues 
Photomicrographs showing representative immunostaining for Rad51 and XRCC1 expression in 
HNSCC tissues. Rad51 showed both nuclear and cytoplasmic staining with different intensities and 
distribution. XRCC1 staining was only nuclear nuclear with variable intensities. Original 






6.3 Survival analysis 
Clinical and pathological features of the study cases as well as the 
expression levels of ERCC1, HIF-1α, Ku80, PTEN, Rad51 and XRCC1 genes were 
tested for their influence on overall survival and disease free survival. Overall 
survival was calculated in months from the date of surgery until the date of death or 
date of last follow up. Disease free survival was calculated in months from date of 
surgery to the date of first recurrence or date of last follow up. 
6.3.1 Clinical and histopathological features and survival 
Overall survival and disease free survival in relation to gender, carcinoma 
site, tumour differentiation, TNM stage, metastasis to regional lymph nodes and 
treatment was analysed using Cox Regression analysis. All 150 cases were included 
in this analysis. Detailed P values, Odds Ratio (OR) and 95% confidence intervals 
(CI) are listed in Table 6.3. 
 Males were approximately one and a half times more likely to die or 
develop recurrence than females (Figure 6.6A). 
 Cases that metastasized to regional lymph node were significantly 
more likely to die or recur than cases with no detectable lymph node 
metastasis at time of diagnosis. P values for overall survival was 
(P=0.026) and for disease free survival (P=0.034) (Figure 6.6B).  
 In relation to lateral tongue carcinomas, pharynx, floor of the mouth, 
lip carcinomas were more likely to kill the patient and tonsil, 
retromolar and palate, buccal mucosa and alveolus carcinomas were 
less likely to kill the patient. Carcinomas of floor of the mouth, lip 
and buccal mucosa were more likely to recur and tonsil, pharynx and 
alveolus carcinomas were less likely to recur. However, these 
differences was not significant statistically, except for disease free 





 Tumour differentiation did not affect the overall survival of the 
patient. However, moderately and poorly differentiated carcinomas 
were more likely to recur than well differentiated carcinomas (Figure 
6.7B). 
 In relation to TNM stage1, cases at TNM stage 3 and stage 4 were 
more likely to die and stage 2 cases were less likely to die. Stage 3 
carcinomas were more likely to recur and stage 2 carcinomas were 
less likely to recur (Figure 6.8A).  
 Cases treated with surgery followed by radiotherapy were 
significantly more likely to die (P=0.064) and to recur (P=0.003) 





Table 6.3  P values, Odds Ratios (OR) and 95% confidence interval (CI) for the 
survival analysis of the study cases 
 Overall survival Disease free survival 
Variable P value OR 95% CI P value OR 95% CI 










































































































L.N metastasis 0.026 1.708 1.06-2.74 0.034 2.423 1.06-5.5 































Figure 6.6  Cox Regression survival analysis graphs of the study cases 
***
***












































Figure 6.7  Cox Regression survival analysis graphs of the study cases 



























Figure 6.8  Cox Regression survival analysis graphs of the study cases 
 







6.3.2 DNA damage repair genes expression and survival 
Overall survival and disease free survival in relation to expression level of 
ERCC1, HIF-1α, Ku80, PTEN, Rad51 and XRCC1 genes in HNSCC tissues were 
tested using Cox Regression analysis. The 14 post-radiotherapy specimens were 
excluded from this analysis. Detailed P values, Odd Ratios (OR) and 95% 
confidence interval (CI) are listed in Table 6.4. 
 ERCC1 positive carcinomas were more likely to kill the patients and 
more likely to recur than ERCC1 negative carcinomas. Carcinomas 
with high percentage of ERCC1 expressing cells were more likely to 
recur than carcinomas with low percentage ERCC1 expressing cells 
(Figure 6.9). 
 HIF-1α positive carcinomas and carcinomas with high percentage of 
HIF-1α expressing cells were more likely to kill the patient than HIF-
1α negative or low expressing carcinomas. HIF-1α positive 
carcinomas and carcinomas with high percentage of HIF-1α 
expressing cells were significantly more likely to recur than HIF-1α 
negative or low expressing carcinomas (Figure 6.10).   
 PTEN positive carcinomas were more likely to kill patients and to 
recur than PTEN negative carcinomas. Carcinomas with high 
percentage of PTEN expressing cells were significantly more likely 
to kill the patients and more likely to recur than carcinomas with low 
percentage of PTEN expressing cells (Figure 6.11). 
 Carcinomas which expressed high Rad51were more likely to kill the 
patients and to recur than carcinomas with low Rad51expression 
(Figure 6.12). 
 Carcinomas which expressed high XRCC1were more likely to kill 






 Ku80 high expressing carcinomas were more to kill the patient and 
to recur than Ku80 low expressing carcinomas (Figure 6.14).  
 
Table 6.4  P values, Odds Ratios (OR) and 95% confidence interval (CI) for the 
survival analysis of the study cases 
 Overall survival Disease free survival 
Variable P value OR 95% CI P value OR 95% CI 
ERCC1 
intensity 
0.52 1.18 0.694-2.037 0.225 1.981 0.65-5.98 
ERCC1 % 0.94 0.47 0.389-2.423 0.175 2.35 0.68-8.07 
HIF-1α 
intensity 
0.40 1.23 0.753-2.032 0.011 4.997 1.45-17.16 
HIF-1α % 0.68 1.60 0.966-2.674 0.005 3.657 1.46-9.12 
Ku80 intensity   calculation of p value was not possible because all cases within the analysis were 
positive 
Ku80 % 0.20 3.55 0.49-25.65 0.492 21.848 0.003-
146532 
PTEN intensity 0.47 1.20 0.72-1.99 0.508 1.362 0.54-3.39 
PTEN % 0.042 1.72 1.02-2.41 0.305 1.665 0.62-4.4 
Rad51 intensity 0.80 0.94 0.57-1.54 0.488 0.993 0.39-2.47 
Rad51 % 0.25 1.35 0.8-2.29 0.752 1.169 0.44-3.00 
XRCC1 
intensity 
0.93 0.94 0.23-0.3.88 0.589 21.165 0.00- 
1364598 




















































Figure 6.10  Survival analysis in relation to HIF-1α expression in HNSCC 
***
***


























Figure 6.11  Survival analysis in relation to PTEN expression in HNSCC 
***







































































6.4 Association analysis 
The association between protein expression and response to treatment (all 
types, excluding prior radiotherapy, 136 cases) or surgery followed by radiotherapy 
(69 cases)) was tested using the Chi-square/Fisher exact test. Logistic regression 
analysis was carried out to identify the significant predictors of response. The main 
purpose of this analysis was to determine whether the expression of proteins 
involved in the DNA damage repair and tumour hypoxia could predict the outcome 
of treatment, in particular to radiotherapy. Disease free survival was used as an 
indicator of the treatment outcome. Response to treatment was reduced to a 
binomial score on the basis of survival distribution. A scatter plot of survival of the 
136 cases is shown in Figure 6.15 and it can be seen that survival naturally clusters 
into short and long term survivor with a natural division at 32-36 months. Patients 
who survived more than three years without developing any recurrence were 
considered good responders to treatment. Conversely patients who developed 
recurrence or died of carcinoma in less than three years were considered bad 





















































6.4.1 Association analysis in relation to treatment 
The variables tested were gender, site of origin, tumour differentiation, 
TNM stage, lymph node metastasis, expression level of ERCC1, HIF-1α, Ku80, 
PTEN, Rad51 and XRCC1 (intensity and percentage). The p values are listed in 
Table 6.5. 
 ERCC1 intensity, PTEN intensity, lymph node metastasis, TNM 
stage and site of origin, significantly associated with the response to 
treatment. 
 61.8% of ERCC1 negative carcinomas showed a better response to 
treatment. While only 41% of ERCC1 positive carcinomas were 
good responders to treatment (p=0.010).  
 71% of carcinomas which had a high percentage of PTEN positive 
cells were bad responders to treatment and 55% of low PTEN 
expressing tumours had good outcome to treatment (p=0.016). 
 66% of carcinomas with lymph node metastasis at diagnosis had 
poor outcome to treatment while 58.3% of carcinomas without 
lymph node metastasis had a better response to treatment (p=0.010). 
 Stage 3 and stage 4 tumours had a higher percentage of bad 
responders (78.9% and 55% respectively) than stage 1 and stage 2 
tumours (38.5% and 33.3% respectively) (p=0.022). 
Variables with (P<0.10) were included in the logistic regression analysis to 
identify the significant predictors of response. PTEN low expression was significant 
predictor of good response (p =0.018). Lip vermillion as a site of origin was also 





6.4.2 Association analysis in relation to surgery followed by 
radiotherapy treatment 
The same analysis was performed for the 69 cases treated by surgery 
followed by radiotherapy only. The p values are listed in Table 6.5. 
 ERCC1 intensity, HIF-1α intensity, percentage and gender 
significantly associated to the outcome.  
 73.3% of ERCC1 positive carcinomas had poor treatment outcome. 
While 65% of ERCC1 negative carcinomas responded well to 
treatment by surgery followed by radiotherapy (p=0.004). 
 71.9% of HIF-1α positive carcinomas and 85% carcinomas with high 
percentage of HIF-1α expressing cells didn’t respond well to 
treatment by surgery followed by radiotherapy (p=0.046   and 
p=0.005 respectively). 
 92.3% of females responded badly to treatment with surgery 
followed by radiotherapy (p=0.009). 
Variables with (P<0.10) were included in the logistic regression analysis to 
identify the significant predictors of response, none of the variables showed 






Table 6.5  Left: Chi-square/Exact test p values. Right: logistic regression results of response to 
treatment association analysis 
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6.4.3   HPV status in tonsil and pharyngeal carcinomas 
6.4.3.1  P16 immunostaining  
20 tonsil and 15 pharyngeal cases were selected for immunostaining by p16 
using TMA sections on the basis of site of origin. Out of the 35 carcinomas only 8 
cases were p16 positive (Figure 6.16A) using criteria of strong and diffuse staining 
in 95% of cells. Whole sections of these eight cases were subjected to DNA ISH for 
detection of HPV DNA. Six carcinomas were HPV positive (Figure 6.16B). 
6.4.3.2  HPV status and survival 
Survival analysis was performed for the 35 tonsil and pharyngeal 
carcinomas in relation to their HPV status using Cox Regression analysis. HPV 
negative carcinomas were more likely to kill the patient than HPV positive 
carcinomas (P value= 0.061, OR=6.8, 95% CI=0.92-51.4) (Figure 6.17). In relation 
to disease free survival, the number of cases in each category (HPV positive and 
negative) was not enough to perform the analysis. 
6.4.3.3  HPV status and response to treatment 
83.3% of HPV positive carcinomas were good responders to treatment and 
58.8% of HPV negative carcinomas were bad responders. However, it was not 
statistically significant (P value= 0.15). Association analysis between response to 
treatment and expression of ERCC1, HIF-1α, Ku80, PTEN, Rad51 and XRCC1 
protein were re performed after excluding the HPV positive carcinomas and the 
results were unchanged except for PTEN expression (staining intensity) which 
became significantly associated with response to treatment (P value= 0.04) and 
showed that 67% of PTEN positive carcinomas were bad responders. 
6.4.3.4  HPV status and expression of ERCC1, HIF-1α, Ku80, PTEN, Rad51 
and XRCC1  
Association between expression of ERCC1, HIF-1α, Ku80, PTEN, Rad51 





analysed using Chi-square/Fisher exact test. No significant association was found 
between HPV positivity and expression of these biomarker proteins (P values= 1.00 












Figure 6.16  P16 immunostaining and HPV ISH in tonsil carcinomas 
Photomicrographs showing representative immunostaining for p16 (A) and HPV in situ 



















In summary, in this chapter, the expression of proteins involved in DNA 
damage repair and tumour hypoxia was investigated. Furthermore, this expression 
level was correlated with overall survival, disease free survival and treatment 
outcome in the study cases. The main findings in this chapter are: 
 Lack of, or low, expression of HIF-1α was associated with better 
disease free survival and was significant predictor of good response 
to treatment by surgery followed by radiotherapy. 
 ERCC1 expression was associated with bad response to all treatment 
types.  
 Low expression of PTEN was a predictor of better overall survival 
and a significant predictor of good response to treatment. 
 Ku80, Rad51 and XRCC1 expression were not associated with 
response to treatment by any modality or combination. 
 Metastasis to lymph node was a significant factor in relation to 
overall survival and disease free survival. Cases without lymph node 
metastasis showed better survival than cases with lymph node 
metastasis at time of diagnosis. Furthermore, lack of metastasis to 
lymph node was a predictor of good response to treatment. 
 TNM stage 3 and 4 were associated with poor outcome to treatment. 
 Tumour differentiation had no effect on survival or response to 
treatment  
 In multivariate analysis, only low percentage of PTEN expressing 
cells and lip as a site of origin were predictors of good response to 
treatment. 
 In tonsil and pharyngeal carcinomas, patient with HPV positive 
oropharyngeal carcinomas had better overall 3 years survival rates 






 Expression of ERCC1, HIF-1α, Ku80, PTEN, Rad51 and XRCC1 








Head and neck cancer is the 6
th
 most common cancer with high morbidity 
and mortality rates worldwide. Despite advances in the treatment of head and neck 
cancer over the last several years, its survival rates remain poor so there is an urgent 
need for specific and effective treatments. Surgery alone or combined with 
radiotherapy and/or chemotherapy is currently the main type of treatment for head 
and neck cancer. Other treatment modalities based on better understanding of the 
molecular nature of these tumours have emerged in the last few years but have had 
limited success.  
TRAIL and Smac mimetics have shown anti-cancer activity in several types 
of cancer cell lines as well as in mouse tumour models. TRAIL based therapeutics 
have entered phase I and Phase II clinical trials for the treatment of advanced solid 
and haematological cancers. Little is known about the effect of TRAIL and Smac 
mimetics on head and neck cancer. In this study we investigated the cytotoxic effect 
of TRAIL and Smac mimetics on a panel of HNSCC cell lines. The underlying 
molecular mechanisms of TRAIL and Smac mimetics induced cell death were also 
investigated. Furthermore, this study sought to identify the biomarkers which could 
predict the response of HNSCC cell lines to TRAIL and Smac mimetic treatment. 
The main pitfall of treatment with chemo-radiotherapy is that a high 
percentage of patients develop resistance to radiotherapy and or chemotherapy, 
which results in poor treatment outcome as well as undesirable side effects. For 
such patients, new and alternative therapeutic agents are necessary. Therefore, 
identifying those patients who will not benefit from a certain treatment modality can 
spare patients suffering as well as cost. 
In this study we investigated the expression of a number of genes involved 
in the DNA damage repair process in primary carcinoma tissues of 150 HNSCC 
patients. Association between protein expression profile and survival as well as the 





7.1 TRAIL and Smac59 killed HNSCC cell lines effectively 
Recombinant IZ-TRAIL has been shown to induce apoptosis in leukaemia, 
multiple myeloma, neuroblastoma, lung, liver, colon, breast, prostate, pancreas, 
kidney and thyroid cancer cell lines (Newsom-Davis et al., 2009). IZ-TRAIL was 
not toxic to primary human hepatocytes (Ganten et al., 2006). These findings 
promoted TRAIL as a promising anticancer drug and it entered into clinical trials. 
Smac mimetics have been shown to induce apoptosis as a single agent in 
glioblastoma (Li et al., 2004), leukaemia (Sun et al., 2007) as well as breast cancer 
cell lines (Lu et al., 2008). Smac mimetics as a single agent induced cell death in 
NSCLC cell lines as well as tumour regression in lung xenograft model. 
Furthermore, Smac mimetics were safe to normal cells (Petersen et al., 2007). The 
effect of TRAIL and Smac mimetics on HNSCC cell lines or normal keratinocytes 
has been tested and the results were shown in section 3.1. 
In this study we have shown that IZ-TRAIL and Smac59 effectively kill 
HNSCC cell lines as a single agent at low concentrations.  HNSCC cell lines were 
found to be sensitive either to TRAIL or Smac59; out of the nine HNSCC cell lines 
tested, five were sensitive to IZ-TRAIL and three were resistant indicating that 
HNSCC cells are more sensitive to TRAIL than most other primary cancer cell lines 
which are found to be TRAIL resistant. This may be due to an inherent 
susceptibility of HNSCC cell lines to TRAIL. 
Only three out of the nine HNSCC cell lines tested were Smac59 sensitive, 
however their sensitivity was remarkable. Smac59 was able to induce cell death at 
fractions of nanomolar concentration. Smac59 is a bivalent Smac mimetic and is 
known for its high activity, however it was not able to induce cell death as a single 
agent in our resistant cells even at high concentrations up to 1µM (data not shown). 
Similarly, Sun et al. found that Smac164 (same as Smac59) could not induce cell 
death as a single agent in 1483, 1640, JHU HNSCC cell lines (Sun et al., 2011).  
However, using both TRAIL and Smac59 was able to kill all tested cell lines at low 
concentrations. These data suggested that TRAIL and Smac59 could be potential 





The pattern of sensitivity observed in our HNSCC cell lines provided a good 
model for studying the cellular mechanisms that determine the differences between 
sensitive and resistant cells as well as identifying biomarkers that might allow the 
prediction of response of different cells to TRAIL and Smac mimetics prior to 
treatment. 
7.1.1 Smac59 sensitised TRAIL resistant cell lines to TRAIL 
In this study we have used Smac59 at non toxic concentrations to sensitise 
TRAIL resistant cell lines (HSC3, HSC3M3 and HN5) and although Smac59 was 
able to sensitise HSC3, HSC3M3 cells to TRAIL, the resultant effect was 
significantly less than the effect of Smac59 alone when used at toxic concentration 
in these cell lines. Furthermore, Smac59 was not able to sensitise HN5 cells to 
TRAIL suggesting that this sensitisation effect may be cell type specific.  
Smac mimetics have been used to sensitise several cancer cell lines to 
TRAIL (Fandy et al., 2008; Li et al., 2004; Sun et al., 2011). In these studies Smac 
mimetics were not able to induce cell death alone but in our study Smac59 was 
highly toxic to the sensitive cells suggesting that using Smac59 as a single agent is 
more effective than being used as a sensitiser to TRAIL. Our findings therefore 
suggest that single treatment with either Smac59 or TRAIL is sufficient in killing 
different HNSCC cell lines. However, to select specific cases for treatment with 
suitable drug, understanding the molecular mechanisms that determine the response 
to this targeted therapeutics is important.  
7.1.2 TRAIL but not Smac59 was toxic to normal human keratinocytes  
TRAIL was shown to be effective in killing most of the cancer cell lines 
tested in this study but it was also toxic to normal oral keratinocytes and a non-
transformed, immortalised epidermal keratinocytes, which may limit its use in 
patients. On the other hand Smac59 had no effect on the viability of normal oral 
keratinocytes suggesting it as a safe therapeutic in patients.  A previous study by 





days of their culture but they develop resistance to TRAIL with time during culture 
in vitro (Ganten et al., 2006) Furthermore, the toxicities observed for some forms of 
recombinant TRAIL were suggested to represent either cell culture artefacts or are 
related to the specific recombinant protein used (Newsom-Davis et al., 2009). In 
this study it was not possible to keep primary normal cells in culture for long 
enough to test if they will develop resistant to TRAIL, however the HaCat cells 
were sensitive to TRAIL even during long period of culture. IZ-TRAIL used in this 
study was shown to be safe in normal hepatocytes (Ganten et al., 2006). In vivo 
studies are necessary to further investigate the cytotoxic effect of TRAIL and 
Smac59 on normal and non-transformed tissues including oral keratinocytes. 
7.1.3 Protein biomarkers could predict response of HNSCC to TRAIL and 
Smac59 
The observed pattern of sensitivity of HNSCC cell lines triggered further 
investigation into the underlying genetic causes, particularly the expression level of 
proteins that play a role in pathways involved in TRAIL and Smac mimetics-
induced apoptosis. IAPs (XIAP, cIAP-1 and cIAP-2), caspases (-3 and -8), Bcl-2, 
Mcl-1, Smac/DIABLO, cFLIP and EGFR expression levels were investigated using 
western blot analysis. TNF-α level was investigated using ELISA. TRAIL death 
receptors (DR4 and DR5) levels were investigated using flow cytometry. 
Additionally, the mRNA and microRNA expression profile of the cells grouped 
based on their resistance/sensitivity to these drugs was carried out and the 
followings are proteins which showed differential expression in TRAIL/Smac59 
sensitive/ resistant cell lines. 
7.1.3.1  Inhibitor of apoptosis proteins (IAPs) 
In this study, XIAP level was higher in Smac59 sensitive (TRAIL resistant) 
cell lines than in Smac59 resistant (TRAIL sensitive) cell lines (Figure 4.1and 
Figure 4.2) while cIAP-2 expression was higher in Smac59 resistant (TRAIL 
sensitive) cell lines (Figure 4.3). XIAP is known to be overexpressed in many 





normal human keratinocytes (NHK) used in this study were found to express high 
levels of XIAP, however HaCat cells had a very low XIAP. In general, all HNSCC 
cells expressed high levels of XIAP which was in accordance with previous findings 
in other tissues for example in chronic lymphocytic leukaemia cells, XIAP 
expression level was significantly higher than normal cells (Frenzel et al., 2011). 
Why our normal cells expressed high level of XIAP could be due to temporary 
upregulation of XIAP expression as a protective mechanism in early days of culture 
and that could be changed overtime. It was not possible for us to test this hypothesis 
because of difficulties in maintain NHK in culture for long periods as mentioned 
above.  
High levels of XIAP are believed to result in apoptosis resistance of cancer 
cells to a wide variety of therapeutic agents. In melanoma cells, TRAIL resistance 
was correlated with the ratio of XIAP and caspase-3 levels of the cells 
(Thayaparasingham et al., 2009), and XIAP expression has been proposed as an 
important adverse biomarker for chemoresistance in cancer patients (Kashkar, 
2010). All the cell lines tested here expressed high levels of XIAP yet showed high 
sensitivity to either TRAIL or Smac59 suggesting either that these drugs were 
successful in overcoming inhibitory effect of XIAP in the sensitive cells or that 
XIAP is not involved in TRAIL or Smac59 resistance in HNSCC cell lines.  Seeger 
et al. found that elevated XIAP expression alone cannot serve as a predictive marker 
of chemoresistance (Seeger et al., 2010).  
cIAP-2 was less expressed in Smac59 sensitive (TRAIL resistant) cell lines 
than Smac59 resistant (TRAIL sensitive) cell lines indicating that maintaining low 
levels of cIAP-2 may be essential for Smac mimetic sensitivity. Knowing that some 
cancer cell lines evade Smac mimetic-induced apoptosis via upregulation of cIAP-2 
expression (Petersen et al., 2010) is supporting this conclusion. 
7.1.3.2  Smac/DIABLO  
In this study we have shown that Smac/DIABLO expression level was 





(TRAIL sensitive) had moderate levels of Smac/DIABLO (Figure 4.4). Expression 
of Smac/DIABLO has been shown to be important in determining the response of 
HNSCC cell lines to different chemotherapeutics that function through 
mitochondrial pathway activation (Sun et al., 2011). Smac/DIABLO promotes 
apoptosis through binding to XIAP in order to relieve its inhibitory effect on 
caspases. In Smac59 sensitive (TRAIL resistant) cell lines, XIAP and 
Smac/DIABLO levels were higher than in Smac59 resistant (TRAIL sensitive) cell 
lines which may indicate that these cell lines induce apoptosis mainly through the 
intrinsic apoptotic pathway. 
7.1.3.3  Bcl-2 family members (Bcl-2 and Mcl-1) 
Bcl-2 expression was detected in four out of six Smac59 resistant (TRAIL 
sensitive) cell lines and was undetectable in two out three Smac59 sensitive (TRAIL 
resistant) cell lines (Figure 4.5).  Mcl-1 expression was observed in all tested cell 
lines but its level was higher in Smac59 sensitive (TRAIL resistant) cell lines 
(Figure 4.6). Anti-apoptotic activity of Bcl-2 and Mcl-1 is mediated through 
inhibition of mitochondrial pathway activation and release of cytochrome c, so 
overexpression of these proteins could be responsible for resistance of cell lines to 
drugs that work through the mitochondrial pathway.  Whether Bcl-2 and Mcl-1 
overexpression could be used as a biomarker for TRAIL and Smac mimetic 
sensitivity is controversial.  Some studies have shown that overexpression of Bcl-2 
protein mediates resistance to TRAIL induced apoptosis in neuroblastoma, 
glioblastoma and breast carcinoma cell lines (Fulda et al., 2002). Similarly, 
inhibition of Mcl-1 upregulation was shown to be able to sensitise neuroblastoma 
cells to TRAIL (Ammann et al., 2009) and that sensitisation of transformed and non 
transformed cells to TRAIL-induced apoptosis was associated with reduction in 
Mcl-1 expression levels (Martin-Perez et al., 2012). On the other hand, no 
difference in the expression level of Bcl-2 and Mcl-1 was found between primary 
colon carcinoma cell line SW480 (TRAIL sensitive) and the metastatic cell line 





7.1.3.4  Caspases (caspase-8 and caspase-3) 
Initiator caspase-8 activation is the first step in response to extrinsic 
apoptosis pathway activation; according to the level of caspase-8, cells decide 
whether or not to activate the intrinsic pathway to execute apoptosis (Scaffidi et al., 
1998). The HNSCC cell lines tested here had clear differences in caspase-8 
expression levels between Smac59 sensitive (TRAIL resistant) cell lines and 
Smac59 resistant (TRAIL sensitive) cell lines (Figure 4.7). Caspase-8 level was 
clearly lower in Smac59 sensitive (TRAIL resistant) cells, which suggests this as 
one of the mechanism responsible for resistance to TRAIL-induced apoptosis. 
Caspase-3 was expressed in all HNSCC cell lines and showed no correlation with 
sensitivity or resistance to these drugs. 
7.1.3.5  Cellular FLICE-inhibitory protein (c-FLIP) 
c-FLIP was expressed in almost all HNSCC cell lines as well as normal 
human keratinocytes and HaCat cells. Smac59 sensitive (TRAIL resistant) cell lines 
had lower levels of c-FLIP than Smac59 resistant (TRAIL sensitive) cell lines 
(Figure 4.9). The level of c-FLIP was directly correlated with the caspase-8 level, 
which suggests that cells produce c-FLIP at such levels to antagonize caspase-8 
activation and apoptosis induction. Interestingly, normal human keratinocytes and 
HaCat cells had high levels of c-FLIP despite having low caspase-8 expression. c-
FLIP inhibits caspase-8 auto-proteolysis at DISC which results in apoptosis 
inhibition (Krueger et al., 2001). Level of c-FLIP protein has been shown to 
influence the sensitivity of cell lines to TRAIL induced apoptosis and  that 
sensitisation of transformed and non-transformed cells to TRAIL-induced apoptosis 
was related to reduction in the levels of FLIP (Martin-Perez et al., 2012).  
7.1.3.6  Epidermal growth factor receptor (EGFR)  
EGFR expression pattern in HNSCC cell lines was interesting as all Smac59 
resistant (TRAIL sensitive) cell lines had low or undetectable level of EGFR in 
comparison to Smac59 sensitive (TRAIL resistant) cell lines which had high EGFR 





mechanisms including cell growth, angiogenesis, inhibition of apoptosis, cell 
adhesion, cell motility and invasion (Lui and Grandis, 2002). Whether and how 
EGFR expression is involved in determining sensitivity or resistance of TRAIL and 
Smac59 is not clear. One possibility is that high EGFR expression may affect the 
binding of TRAIL to its receptors on cell membrane, or that activation of EGFR 
downstream pathways might be involved in blocking TRAIL induced apoptosis 
pathway leading to apoptosis inhibition, as seen in TRAIL resistant cells. 
7.1.3.7  Tumour necrosis factor-alpha (TNF-α) 
One of the mechanisms by which Smac mimetics induce apoptosis is 
through the activation of the TNF-α pathway (Dai et al., 2009a). Therefore the level 
of secreted TNF-α in HNSCC cell lines was measured using ELISA. Additionally 
TNF-α mRNA level was tested using gene expression profiling. Interestingly, 
Smac59 sensitive (TRAIL resistant) cells secreted higher levels of TNF-α than 
Smac59 resistant (TRAIL sensitive) cell lines (Figure 4.11). TNF-α mRNA level 
was also higher in Smac59 sensitive (TRAIL resistant) cell line (Figure 4.14). These 
findings suggested that TNF-α level strongly correlates with Smac59 sensitivity. 
This is in agreement with previous finding in other cancer cell lines, in which 
autocrine TNF-α secretion was a strong predictor of sensitivity to JP1201 Smac 
mimetics in non-small cell lung carcinoma cell lines (Greer et al., 2011).  
7.1.3.8  TRAIL receptors 
TRAIL death receptors DR4 and DR5 expression on HNSCC cell membrane 
was measured using flow cytometric analysis and gene expression profiling. Results 
from flow cytometry showed that DR4 and DR5 expressed in all cell lines tested 
regardless of the type of response to TRAIL (Figure 4.12). The results of gene 
expression profiling showed that Smac59 sensitive (TRAIL resistant) cell lines 
expressed higher mRNA levels for DR5 than Smac59 resistant (TRAIL sensitive) 
cell lines (Figure 4.14). Level of TRAIL death receptors expression and its 
importance for TRAIL-induced apoptosis is different according to cell lines tested. 





TRAIL was in part due to upregulation of DR5 (Martin-Perez et al., 2012). 
However other studies have shown that sensitisation to TRAIL in malignant human 
glioma cells was not associated with overexpression of TRAIL receptors DR4 and 
DR5 (Jane et al., 2011).  
Previous reports attributed resistance to TRAIL to overexpression of TRAIL 
decoy receptors DcR1 and DcR2 by competing with DR4 and DR5 for TRAIL 
binding (Newsom-Davis et al., 2009). In this study, gene expression profiling 
showed that DcR1 and DcR2 expression was not different between TRAIL sensitive 
and TRAIL resistant cell lines. 
7.1.4 miRNA biomarkers could predict response of HNSCC to TRAIL and 
Smac59 
Analysis of miRNA expression profile in HNSCC cell lines revealed a 
significant difference in the expression of a number of miRNAs between Smac59 
sensitive (TRAIL resistant) cell lines and Smac59 resistant (TRAIL sensitive) cell 
lines (Figure 4.15). These could be potential biomarkers for predicting sensitivity to 
TRAIL or Smac59. 15 miRNA were upregulated and 7 miRNA were downregulated 
in Smac59 resistant (TRAIL sensitive) cell lines. The validation of these biomarkers 
needs further investigations. However, miR-9 as the most upregulated miRNA in 
Smac59 resistant (TRAIL sensitive) cells is an important candidate. NF-κB is one of 
the validated targets of miR-9 and NF-κB is a transcription factor for many proteins 
including TNF-α  (Pahl, 1999).  
We have shown that TNF-α level is higher in Smac59 sensitive (TRAIL 
resistant) cell lines (Figure 4.11) which indicates that NF-κB transcriptional activity 
may be higher. This assumption is consistent with previous findings which showed 
that blocking NF-ҡB activation reduced TNF-α production and protected cells to 
Smac mimetic induced cell death (Ahn et al., 2007) and that activated NF-ҡB 
enhanced the ultraviolet B radiation induced apoptosis via NF-ҡB dependant 
increased secretion of TNF-α (Barisic et al., 2008). It is tempting to speculate that 





negative regulation through miR-9-mediated inhibition of NF-κB activity in these 
cell lines. However, these observations are preliminary and further investigations 
are in progress to validate these findings.  
7.1.5 Smac59 increased the levels of secreted TNF-α in sensitive cell 
lines and TNF-α sensitised resistant cells to Smac59 
Since the endogenous level of TNF-α correlated with Smac59 sensitivity and 
since one mechanism of Smac mimetics induced apoptosis is to induce autocrine 
TNF-α production (Lu et al., 2007), the effect of Smac59 and TRAIL on the level of 
TNF-α in HNSCC cell lines was tested.  Smac59 was found to effectively increase 
the level of secreted TNF-α in the sensitive cell lines but not in the resistant cell 
lines (Figure 5.1), which suggested that Smac59 induced apoptosis in these cell 
lines is probably mediated by activation of the TNF-α pathway. To further 
investigate the role of TNF-α in Smac59 induced apoptosis in HNSCC cell lines, 
rhTNF-α was added to the cells alone or in combination with TRAIL or Smac59. 
Furthermore, TNF-α was inhibited by both blocking and neutralising antibody and 
its effect on cell sensitivity to Smac59 was measured. 
Adding rh-TNF-α to Smac59 sensitive cell lines did not induce a similar 
level of apoptosis to that obtained with Smac59. Consistent with this, inhibiting 
TNF-α could not protect the sensitive cell lines from Smac59 induced apoptosis. 
Our findings are in agreement with Petersen and co-workers who found that adding 
Smac mimetics to sensitive non-small cell lung carcinoma cell lines activated TNF-
α secretion whereas this effect was not observed in resistant cells. But by contrast to 
our results, using TNF-α neutralizing antibodies protected their cells from Smac 
mimetics induced apoptosis (Petersen et al., 2007). In their study 1-2 µg/ml of 
neutralizing antibody was used compared to 10µg/ml in our study. Therefore, it is 
unlikely that our finding is due to insufficient amount of neutralizing antibody used. 
We also used blocking antibody (20µg/ml) to inhibit TNF-α activity and the results 
were the same. Taken together, this part of the study suggests that in HNSCC cell 





secretion of TNF-α. A previous study by Wagner and co-workers found that Smac 
mimetics sensitisation of glioblastoma cells was not associated with TNF-α 
production and that use of TNF-α blocking antibody could not inhibit this 
sensitisation (Wagner et al., 2012). 
Interestingly, combining TNF-α with Smac59 sensitised Smac59 resistant 
cells suggesting that lack of TNF-α in this cell line may be the reason of their 
Smac59 resistance. This finding is in agreement with Li et al. studies which showed 
that combining TNF-α and Smac mimetic (compound 3) successfully induced 
apoptosis in HeLa cells which were resistant to either TNF-α or Compound 3 alone 
(Li et al., 2004).  The exact mechanism by which TNF-α sensitised UMSCC11B to 
Smac59, and how TNF-α and NF-κB are involved in this mechanism needs further 
investigation.  
In conclusion, the results obtained in our study suggest that TNF-α could be 
a marker of Smac59 sensitivity and that TNF-α could be used to sensitise Smac59 
resistant cells to Smac59 induced apoptosis. However, the exact mechanism by 
which Smac59 utilizes the TNF-α pathway is not clearly understood. TNF-α alone 
was unable to induce cell death at levels that were achieved with Smac59. 
Furthermore, blocking TNF-α did not inhibit Smac59 induced apoptosis. 
Collectively, these results suggest that TNF-α is important for Smac59 induced 
apoptosis but that it was not the only factor involved in this process.  
7.1.6 Bcl2 overexpression induced TRAIL resistance in TRAIL sensitive 
cells but could not protect Smac59 sensitive cells against Smac59-
induced apoptosis 
The pattern of Bcl-2 expression in HNSCC cell panel tested showed that 
most of Smac59 resistant (TRAIL sensitive) cells had high Bcl-2 levels while most 
of the Smac59 sensitive (TRAIL resistant) cells had undetectable levels. To further 
investigate the role of Bcl-2, overexpression experiments were performed. 
Treatment of a Bcl-2 overexpressing mixed population of HSC3M3 cell line 





suggesting that Smac59 induced apoptosis may be independent or downstream of 
Bcl-2. To further understand the role Bcl-2 in Smac59 induced apoptosis, Bcl-2 
knockdown in Smac59 resistant cell lines needs to be performed. 
Conversely, Bcl-2 overexpression in H357 (TRAIL sensitive) cells mediated 
significant resistance to TRAIL treatment compared to parent cells suggesting, that 
in this cell line TRAIL induced apoptosis is at least partly regulated by Bcl-2 
expression and that Bcl-2 overexpression could protect cells against TRAIL induced 
apoptosis. Our results are in agreement with the finding that overexpression of bcl-2 
conferred protection against TRAIL in neuroblastoma, glioblastoma or breast cancer 
cell lines (Fulda et al., 2002).  
As mentioned before most Smac59 resistant (TRAIL sensitive) cell lines 
expressed high levels of Bcl-2 protein though they were highly sensitive to TRAIL. 
This finding is not compatible with the overexpression experiments results. This 
could be explained as follows, H357 cells express undetectable or low levels of Bcl-
2 and caspase-8 compared with other TRAIL sensitive cell lines. This suggests that 
TRAIL may induce apoptosis through different mechanisms in different cell lines; 
in H357 with low caspase-8, activation of the extrinsic pathway may not be 
sufficient to accomplish apoptosis and the involvement of mitochondrial pathway 
may be necessary and this may be why Bcl-2 overexpression protected H357 
against TRAIL-induced cell death. Whilst in other cell lines with high levels of 
caspase-8, TRAIL activation of extrinsic pathway may be sufficient to accomplish 
apoptosis without the need for mitochondrial involvement and this could explain 
why Bcl-2 overexpression in these cells did not affect their sensitivity to TRAIL.  
Therefore to understand the role of Bcl-2 in TRAIL induced apoptosis, it is 
important to identify whether the cells are type I or type II and which apoptotic 
pathway is activated to execute apoptosis. 
7.1.7  TRAIL and Smac59 depleted XIAP and cIAP-1 in HNSCC 
Understanding the underlying mechanisms of TRAIL and Smac59 induced 





drugs. One of the main mechanisms by which cancer cells evade apoptosis is the 
overexpression of inhibitor of apoptosis proteins and in particular XIAP. We 
investigated the role of XIAP and cIAP-1 in TRAIL and Smac59 induced apoptosis 
and the effect of TRAIL and Smac59 treatment on XIAP expression in HNSCC cell 
lines. 
We have shown that all our HNSCC cells expressed relatively high levels of 
XIAP and cIAP-1 though all of them were highly sensitive to either TRAIL or 
Smac59. This suggested that in these cell lines high endogenous IAPs expression 
did not inhibit apoptosis induced by TRAIL or Smac59. Furthermore, we have 
shown that Smac59 sensitive (TRAIL resistant) cell lines had slightly higher XIAP 
levels than Smac59 resistant (TRAIL sensitive) cell lines.  
Treatment with Smac59 resulted in the depletion of cIAP-1 in both Smac59 
sensitive and resistant cell lines early after treatment (Figure 5.7), before caspase-3 
activation and PARP cleavage (Figure 5.6). Smac mimetics are known to induce 
ubiquitination of cIAPs by direct binding which results in cIAPs degradation and 
consequently caspase activation (Chen and Huerta, 2009). In the HNSCC cell lines 
tested here, Smac59-mediated, cIAP-1 depletion did not result in caspase activation 
or apoptosis induction in Smac59 resistant cells indicating either that cIAP-1 
depletion is not the determining factor of Smac59 induced apoptosis or that cIAP-1 
upstream targets in these cell lines are blocked. Recently it has been shown that 
Smac mimetics induce rapid degradation of cIAP1 and cIAP2 and this requires the 
binding of TNF-α to its receptor (TRAF2) (Darding et al., 2011). It is unlikely that 
the same mechanism applies in HNSCC cell lines because Smac59 did not stimulate 
TNF-α secretion in Smac59 resistant (TRAIL sensitive) cells. TRAIL treatment 
induced cIAP-1 depletion in TRAIL sensitive cell line UMSCC11B at 8 hours 
which suggests that this depletion is a product of apoptosis and that cIAP-1 is not 
involved in apoptosis initiation by TRAIL in this cell line.  
In this study, we have shown that both TRAIL and Smac59 induced XIAP 
depletion in their sensitive cells. The downregulation was observed at 8 hours after 





observed at 4 hours after treatment, which suggests that XIAP downregulation is a 
consequence rather than the cause of apoptosis. However, an important role of 
XIAP in TRAIL or Smac59 induced apoptosis cannot be ruled out as interactions 
could have taken place early during caspase-3 activation. Yang and co-workers 
showed that in HeLa cells, despite Smac/DIABLO promoting the auto-
ubiquitination of XIAP, it did not result in XIAP degradation (Yang et al., 2004). In 
our cell lines, Smac59 could have induced ubiquitination of XIAP releasing its 
inhibitory effect on caspases and promoted apoptosis induction while XIAP 
degradation occurred late after apoptosis execution, such hypothesis need further 
investigation of the interaction between Smac59 and XIAP. 
7.1.8 TRAIL and Smac59 mediated XIAP depletion was Caspase 
dependent, while Smac-59 mediated depletion of cIAP-1 was 
caspase independent.  
Caspase inhibitor Z-VAD-fmk was used to investigate the effect of caspase 
inhibition on XIAP downregulation induced by TRAIL and Smac59 in sensitive 
cells. Pre-treatment with pan caspase inhibitor completely abolished both the 
TRAIL and Smac59 mediated downregulation of XIAP suggesting that XIAP 
depletion is caspase dependent. To determine which caspase was responsible for 
this effect, specific caspase inhibitors need to be used to clarify the exact 
mechanisms underlying TRAIL and Smac59 induced XIAP depletion. It has been 
shown that TRAIL induced depletion of XIAP and cIAP-1 required caspase activity 
and that caspase-8 knockdown stabilized both XIAP and cIAP-1, while caspase-9 
knockdown prevented only XIAP, but not cIAP-1 degradation (Guicciardi et al., 
2011).  
In this study, results showed that Smac59 mediated cIAP-1 depletion was 
not affected by treatment with caspase inhibitor suggesting that Smac59 induced 
cIAP-1 degradation was independent of caspase activity in HNSCC cell lines. This 





degradation via direct binding to their E3 motif which results in their ubiquitination 
(Chen and Huerta, 2009).  
7.1.9 XIAP knockdown could not sensitise TRAIL and Smac59 resistant 
cell lines 
In TRAIL resistant cell line HSC3M3, XIAP knockdown using siRNA did 
not sensitise the cells to TRAIL. Slight loss of cell viability was observed in the 
knockdown cells but this was the same with the control siRNA transfected cells 
(Figure 5.9) indicating that this was due to the transfection process itself. These 
results suggested that XIAP overexpression is not responsible for resistance to 
TRAIL-induced apoptosis.  
Our data is different from some previous studies that showed that 
knockdown of XIAP and cIAP-1 increased sensitivity of prostate cancer cells to 
TRAIL (Dai et al., 2009b),  and that XIAP knockdown using siRNA was able to 
sensitise chronic lymphocytic leukaemia resistant cells to TRAIL-mediated 
apoptosis (Frenzel et al., 2011).  However, our results are in agreement with the 
finding that chemotherapeutics that induce cell death through the mitochondrial 
pathway required only inhibition of XIAP for sensitisation, whereas 
chemotherapeutics that induce cell death through multiple apoptotic pathways 
required inhibition of cIAP-1, cIAP-2 and XIAP  (Greer et al., 2011). Furthermore, 
Smac mimetics enhanced TRAIL activity in breast, prostate and colon cancer cell 
lines by targeting XIAP and cIAP-1 (Lu et al., 2011). Combined knockdown of 
XIAP and cIAPs would be a logical next step to understand how IAPs are involved 
in TRAIL and Smac mimetics induced apoptosis in HNSCC cell lines.  
In the HSC3M3 cell line, XIAP knockdown was able to increase sensitivity 
to Smac59 (Figure 5.9) suggesting that XIAP plays a role in Smac59 induced 
apoptosis.  It is notable that we were not able to establish XIAP knockdown stable 
cells from this cell line which may indicate that XIAP expression in this cell line is 





In the Smac59 resistant UMSCC11B cell line, XIAP knockdown using 
siRNA or by establishing stable XIAP knockdown cells could not sensitise the cells 
to Smac59. Which member of the IAPs family is essential for Smac mimetic-
induced apoptosis remains controversial. Some studies have shown that XIAP plays 
a critical role in inhibiting apoptosis induction by Smac mimetics and that removal 
of cIAP1/cIAP2 by Smac mimetics is not sufficient for TNF-α-dependent apoptosis 
induction (Lu et al., 2008). Other studies however showed that some cancer cells 
(NSCLC) mediate resistance to Smac mimetic by up-regulating cIAP2 (Petersen et 
al., 2010). We suggest that the mechanism of TRAIL and Smac mimetic induced 
apoptosis is cell type dependent and is affected by which apoptotic machinery is 
active in each cell. Understanding the biology and the genetic phenotype (using 
gene and miRNA expression profiling) of each cell could help to predict how each 
cell responds to a specific therapeutics.  
In summary, this study showed that, TRAIL and Smac59 were effective in 
killing all HNSCC cell lines tested suggesting potential value in treatment of head 
and neck cancers. Caspase-8 expression seemed to be an important factor in 
predicting sensitivity of HNSCC cell lines to TRAIL. TNF-α expression was a 
predictor for Smac59 sensitivity in HNSCC cell lines and was able to sensitise the 
Smac59 resistant cells. Bcl-2 overexpression was able to protect the TRAIL 
sensitive cells against TRAIL induced apoptosis. Caspase-8, TNF-α, EFGR and 
Bcl-2 are potential biomarkers for TRAIL and Smac mimetic sensitivity in HNSCC 
cell lines. Further investigations including more HNSCC cell lines as well as animal 
studies are necessary to take these two agents towards clinical trials for treating 
HNSCC patients. 
7.1.10   Biomarkers for response of HNSCC to treatment 
Surgery alone or combined with radiotherapy and/or chemotherapy is the 
most common treatment modality for HNSCC patients. Many patients fail these 
treatments and develop recurrences or metastases as well as suffering the unpleasant 





respond to such treatments before starting the treatment would spare unnecessary 
suffering and achieve more successful outcome. Radiotherapy and chemotherapy 
induce cell death by causing damage to DNA that cannot be repaired and this 
activates apoptotic pathways in cancer cells and results in their elimination. Some 
cancer cells escape this process either by escaping check point for DNA damage 
repair or by activating DNA damage repair machinery.  
In this project the expression of a number of genes involved in DNA damage 
repair and tumour hypoxia was investigated in tissues from 150 HNSCC patients 
using immunohistochemical staining.  Expression of these genes was tested for 
association with survival and treatment outcome. In this patient cohort, males were 
more frequently affected than females and age range was from 29 to 91 years with 
median of 60 years. This finding is in accordance with the previous reports about 
United Kingdom patients (Bonner et al., 2006). 
Moderate tumour differentiation was predominant in carcinomas of all sites 
except tonsil and pharynx carcinomas in which poor differentiation was more 
common. TNM stage 4 was common in carcinomas of lateral tongue, retromolar 
region, alveolus, tonsils and pharynx. Stage 3 and stage 4 were equally prevalent in 
patients with floor of the mouth carcinomas. Stage II and stage IV were comparable 
in buccal mucosa cases. This lack of stage 3 may be because buccal carcinomas 
involve skin early and this makes them T4 at a small diameter. Stage 1 was common 
in patients with lip carcinomas.  
7.1.11  TNM stage, lymph node metastases, site of tumour and treatment 
were associated with survival and patient’s outcome.  
In this study, cases with lymph node metastases at diagnosis and high TNM 
stage had poorer overall survival and disease free survival than cases without. These 
findings are in agreement with previous reports of head and neck carcinomas which 
showed that the most important prognostic factors are site and TNM stage and that 
patients with tumours that have spread to lymph nodes have poorer survival and that 





2010). Furthermore, other studies showed that the number of positive lymph nodes 
and total number of excised lymph nodes was the only significant predictor of 
outcome in patient receiving adjuvant radiotherapy and was the only independent 
predictor of overall and disease free survival (Gil et al., 2009). All these findings 
demonstrate the importance of proper screening of lymph nodes involvement and 
importance of radical treatment decisions and confirm our series as representative. 
Site of origin may also affect the survival of the patients due to proximity to 
vital organs or inaccessibility to radical treatment. In this study, overall survival was 
not affected by site of origin however; floor of mouth carcinomas had the least 
disease free survival. Carcinoma of base of the tongue is known to have low 
survival rates (Zhen et al., 2004), and lip carcinomas to have the best survival rates 
(Mehanna et al., 2010). 
Patients treated with surgery followed by radiotherapy had shorter disease 
free survival than patients treated only with surgery while there was no difference in 
the overall survival of both groups. This is likely to be because adjuvant 
radiotherapy is usually used in more advanced tumours or in tumours with positive 
margins and such tumours will have more chances to develop recurrence and 
metastases.   
7.1.12   ERCC1 expression was not associated with patients survival but 
was significantly associated with treatment outcome 
ERCC1 expression (staining intensity or percentage of positive cells) had no 
significant association with overall survival or disease free survival in the study 
patients despite those carcinomas with low percentage of ERCC1 expressing cells 
achieving a better disease free survival than cases with high percentage of ERCC1 
expressing cells. Our data was in accordance with previous reports which showed 
that ERCC1 expression was not correlated with survival in HNSCC (Lima et al., 
2012) but differ with  the finding that ERCC1 expression correlated with long 





chemotherapy (Lee et al., 2008). However, non small cell carcinoma is different 
than HNSCC in pathogenesis presentation and prognosis. 
Our results showed ERCC1 expression (staining intensity) was significantly 
associated with patient’s response to treatment as ERCC1 negative cases showed 
better outcome than ERCC1 positive cases. ERCC1 is involved in both recognition 
of the damage and excision of the damaged part of DNA (Hoeijmakers, 2001) and 
its expression has been correlated with resistance of HNSCC patients to cisplatin-
based chemotherapy (Handra-Luca et al., 2007). Furthermore, our results showed 
that ERCC1 expressing cases recurred more frequently than ERCC1 negative cases 
suggesting that ERCC1 enhances the survival of cancer cells. These findings imply 
the role of ERCC1 in the repair of radiotherapy induced DNA damage and suggest 
that ERCC1 could be used as a prognostic marker for response to radiotherapy. 
However, our study did not have sufficient power to maintain ERCC1 as 
independent prognostic factor in multivariate analysis. 
7.1.13   HIF-1α expression in HNSCC tissues was significantly associated 
with disease free survival and patients response to treatment 
Under normoxic conditions HIF-1α degrades rapidly but under hypoxic 
conditions, HIF-1α accumulates in the nucleus, dimerizes with HIF-1β subunit and 
activates transcription of more than 100 target genes that are responsible for 
inducing cell proliferation, angiogenesis, local invasion and metastasis. Increased 
levels of HIF-1α in tumours has been associated with poor clinical outcome in 
different types of cancers including breast, cervical and endometrial cancers 
(Semenza, 2010).  
In this study, HIF-1α was found to be expressed in HNSCC tissues and its 
expression (staining intensity or percentage of positive cells) was significantly 
associated with disease free survival as HIF-1α positive cases had poorer disease 
free survival suggesting that HIF-1α promotes the survival characteristics of cancer 
cells leading to tumour survival. Our data is in agreement with previous findings 





oral tongue cancer (Roh et al., 2009) and that HIF-1α expression was a significant 
adverse prognostic factor, locoregional control and cancer specific survival of 
HNSCC treated with primary radiotherapy (Silva et al., 2007).  
In our study, HIF-1α expression (staining intensity or percentage of positive 
cells) was significantly associated with poor outcome of the patients treated with 
surgery followed by radiotherapy in univariate analysis but it did not retain its 
significance in multivariate analysis, may be because our patient group is 
retrospective and heterogeneous for treatment.  These findings suggested that HIF-
1α could be a marker for survival and for outcome of patients to treatment. 
However, other studies found that basal HIF-α expression levels are not predictive 
of radiosensitivity of human lung cancer and HNSCC cell lines (Schilling et al., 
2012).  
7.1.14   PTEN expression in HNSCC tissues was significantly associated 
with overall survival and response of patients to treatment 
In this study, PTEN expression was generally weak and was identified as 
both cytoplasmic and nuclear but only nuclear expression was scored. Cytoplasmic 
PTEN expression was previously correlated with histological grade and biological 
behaviour of oral squamous cell carcinoma; PTEN expression was stronger and 
more frequent in well differentiated carcinomas,  reduced in less differentiated 
tumours and was completely absent at the invasive front (Squarize et al., 2002).  
In our study PTEN expression (percentage of positive cells) cases was 
significantly associated with overall survival as cases with high percentage of PTEN 
expressing cells had poorer overall survival than cases with low percentage of 
PTEN expressing cells. It was also significantly associated with patient’s outcome 
to treatment as 55% of low PTEN expressing carcinomas responded better to 
treatment and 71% of high PTEN expressing tumours had a poorer response to 
treatment. PTEN plays a critical role in the DNA damage repair and cells deficient 





carcinoma cells with low PTEN will not be able to repair radiotherapy-induced 
DNA damage and will lead to cell death and tumour elimination. 
The roles of PTEN expression in patient survival and response to treatment 
have been discussed in previous studies. Ming and He showed that PTEN 
expression played an important role in the response of cancers to radiotherapy as 
reduced levels of PTEN were associated with radioresistance and hence poor 
treatment outcome (Ming and He, 2012). Snietura and co-workers found that 
patients with high PTEN expression had a favourable outcome after accelerated 
postoperative radiotherapy, compared to patients with low PTEN expression 
(Snietura et al., 2012).  
Our results seems to contradict  these previous findings, however, all 
previous studies scored tested expression of PTEN as a simple positive or negative, 
which in our study was not significantly associated with treatment outcome. In our 
study we tested the percentage of positive cells within the PTEN expressing 
tumours which provide a more informative measure in PTEN expression analysis in 
relation to survival and response outcome. Testing these findings at a larger scale 
study in patients treated with radiotherapy alone is necessary to further determine 
the role of PTEN expression in HNSCC response to radiotherapy as the numbers in 
our study was relatively small and our patient group was heterogeneous to 
treatment. 
7.1.15   Ku80, Rad51 and XRCC1 expression in HNSCC tissues were not 
significantly associated with survival or response of patients to 
treatment  
Ku80, Rad51 and XRCC1 are important proteins involved in DNA damage 
repair and their expression has been extensively studied and they have been 
correlated with survival, locoregional control and response to different treatments in 
different tumour types. 
Ku80 overexpression in HNSCC was highly predictive of loco-regional 





overexpression correlated with radiation resistance in HNSCC cell lines (Chang et 
al., 2006) and that silencing Ku80 using small interfering RNA enhanced radiation 
sensitivity in lung, pancreas, oesophageal, prostate and breast cancer cell lines 
(Nimura et al., 2007). In our study Ku80 was expressed in all HNSCC cases at 
different levels so associations between its expression and survival or patient’s 
outcome could not be determined. However, carcinomas with high percentage of 
Ku80 expressing cells had poorer overall survival and disease free survival than 
carcinomas with low percentage of Ku80 expressing cells.  
Rad51 overexpression has been reported to increase resistance of 
mammalian cells to ionizing radiation (Vispe et al., 1998). Antisense inhibition of 
mouse Rad51 enhanced radio-sensitivity of mouse embryos to ionizing radiation. 
(Bernstein et al., 2002). Head and neck cancer patients with high Rad51 protein 
level in their pre-treatment tumour biopsies demonstrated poor cancer-specific 
survival rates than patients with lower Rad51 levels (Connell et al., 2006). 
Similarly, elevated expression of Rad51 was associated with poor prognosis in 
esophageal squamous cell carcinoma (Li et al., 2011). In this study, overall survival 
and disease free survival in both Rad51 positive and negative carcinomas were not 
significantly different. However, carcinomas with high percentage of Rad51 
expressing cells had poorer overall survival and disease free survival than 
carcinomas with low Rad51 expressing cells in consistent with previous studies. 
Rad51 expression (staining intensity or percentage) was not associated with 
patient’s response to treatment.  
High levels of XRCC1 mRNA has been detected in the blood of HNSCC 
patients (Schena et al., 2012). However, other studies showed that XRCC1 
expression is lower in HNSCC patient in North India than healthy controls (Kumar 
et al., 2012). High XRCC1 protein expression in HNSCC is associated with poor 
survival, especially in patients receiving chemoradiation (Ang et al., 2011). In our 
study, XRCC1 was highly expressed in almost all HNSCC tissues and it was not 






In summary, this study show that expression of DNA damage repair genes 
and tumour hypoxia affect patient survival and response to treatment in particular to 
radiotherapy. ERCC1, HIF-1α and PTEN are promising biomarkers for HNSCC 
survival and treatment outcome. In this study, Ku80, Rad51 and XRCC1 were not 
significantly associated with patient survival or response to treatment. 
7.1.16   HPV status was associated with patient survival and response to 
treatment 
In this study, eight out of 35 tonsil and pharyngeal carcinomas were p16 
positive and six of these were HPV positive indicating that not all carcinomas 
arising in oropharyngeal areas are HPV related and that p16 is a good predictor of 
HPV positivity. P16 is commonly silenced in HPV negative carcinomas by multiple 
mechanisms, including mutation, deletion, and hypermethylation. In contrast, p16 is 
overexpressed in HPV positive oropharyngeal carcinomas because of E7-mediated 
pRb loss of feedback control leading to a paradoxical upregulation of p16  (Howard 
and Chung, 2012).  
As expected, patients with HPV positive carcinomas had a better overall 
survival than patients with HPV negative carcinomas and HPV positivity was 
associated with better response to treatment. This finding is in consensus with the 
previous findings about oropharyngeal carcinomas. In 2010, Ang et al. in their 
retrospective study of patients treated with fractionation radiotherapy, found that of 
63.8% of patients with oropharyngeal cancer had HPV-positive tumours; 
these patients had better 3 year rates of overall  survival  among  patients with HPV 
negative tumours and that HPV status was a strong and independent prognostic 
factor for  survival  among  patients  with  oropharyngeal cancer (Ang et al., 2010).  
In another prospective study on oropharyngeal carcinomas treated with 
chemotherapy, HPV was detected in tissues of 40% of patients with HNSCC of the 
oropharynx or larynx by in situ hybridization and PCR and that patients with HPV 
positive tumours had higher response rates after induction chemotherapy than HPV 





There is a growing interest in understanding the underlying mechanisms that 
make HPV positive tumours more sensitive to treatment. Among these interests is 
the effect of HPV infection on the expression of DNA damage repair genes. In a 
previous study by Moeller et al., Ku80 expression was found to be a DNA repair-
related biomarker of radiation treatment failure particularly in HPV negative 
HNSCC  (Moeller et al., 2011). Another study by Mani et al. in 2011, showed that 
HIF-1α as a marker of hypoxia was less expressed in HPV positive tumours 
indicating that HPV positive tumours are less hypoxic and this could be a 
mechanism to explain their radiosensitivity (unpublished data). In our study, no 
association was detected between HPV status and expression of ERCC1, HIF-1α, 
Ku80, PTEN, Rad51 and XRCC1 proteins. Unfortunately the small number of HPV 
positive carcinomas included in the study series prevents definitive analysis and 
further work to explore potential associations will require many more cases 
specifically selected to test this hypothesis.  One area of interest and related to this 
work is that HPV infection modulates apoptosis in HPV positive tumours (Lagunas-
Martinez et al., 2010). How HPV would affect the expression of DNA damage 
repair genes which in turn will affect the apoptosis induction following radiotherapy 
treatment need to be investigated in a prospective study including large number of 





7.1.17   Conclusions  
In conclusion, biomarkers predicting response of HNSCC to treatment are 
essential to improve curability. Biomarkers that could determine preoperative 
prognosis and treatment response through routine tumour biopsy is the ultimate 
achievement. In this study we have investigated the response of HNSCC cell lines 
to two novel therapeutic drugs (TRAIL and Smac59) and we investigated candidate 
biomarkers which could predict response of HNSCC cell lines to these novel 
targeted agents. Furthermore, we investigated the expression of genes involved in 
DNA damage repair and tumour response to hypoxia in tissues of HNSCC patients 
in a trial to find whether the expression profile of these genes could be correlated to 
the response of the patients to treatment.  
The main findings of the apoptosis study:  
 TRAIL and Smac59 was effective in killing HNSCC cell lines 
suggesting them as potential therapeutics for HNSCC treatment. 
Head and neck cancer cell lines can be grouped based on 
sensitivity/resistance to TRAIL and Smac59. 
 Protein and mirRNA biomarkers could predict response of HNSCC 
cell lines to TRAIL and Smac59. 
 Importantly an association was found between TNF-α expression 
and sensitivity to Smac59, adding rhTNF-α to Smac59 sensitised 
Smac59 resistant cells suggesting TNF-α as a strong predictive 
marker for Smac59 sensitivity. 
 Caspase-8 overexpression was associated with sensitivity to 
TRAIL and could be a marker for TRAIL sensitivity in tumour 
cells that use the extrinsic pathway for apoptosis induction. 
 Several miRNAs were differentially expressed in 





TRAIL and Smac59 sensitivity, mir-9 seemed to be a promising 
predictor for Smac59 resistance. 
 Bcl-2 overexpression protected HNSCC cell lines from TRAIL 
induced apoptosis but it could not protect them from Smac59 
induced apoptosis. 
 TRAIL and Smac59-mediated depletion of XIAP seems to be a 
consequence rather than the cause of caspase dependent induction of 
apoptosis. 
The main findings of our clinical series: 
 Lymph node metastasis was associated with poor overall survival 
and disease free survival as well as bad response to treatment in 
HNSCC patients. 
 ERCC1 expression was significantly associated with treatment 
outcome in HNSCC patients suggesting that ERCC1 expression 
could be a biomarker for response of patients to treatment. 
 Low HIF-1α expression was significantly associated with disease 
free survival and response of patients to combined surgery and 
radiotherapy treatment making HIF-1α a strong candidate as a 
prognostic biomarker.  
 High PTEN expression indicated reduced overall survival and worse 
response of patients to treatment and this has potential as a 
prognostic biomarker in HNSCC. 
 Patients with HPV positive carcinoma had a better overall survival 
and responded better to treatment. 
 No association was detected between HPV positivity and expression 





7.1.18   Future work 
Future in vitro and in vivo studies will determine the potential of TRAIL and 
Smac mimetics and their modulators alone or in combination with radiotherapy 
and/or chemotherapy for personalised treatment of head and neck cancers. 
 Investigate the role of miR9 in Smac59 sensitivity and the 
involvement on NF-κB in this process. 
 Investigate the underlying mechanisms of TNF-α sensitisation of 
Smac59 resistant cells to Smac59. 
 Investigate the effect of specific caspase inhibitors on IAPs 
expression following TRAIL and Smac59 treatment. 
 Caspase-8, Smac/DIABLO, Mcl-1 and cFLIP have shown 
differential expression in TRAIL and Smac59 sensitive and resistant 
cell lines. Further validation of these agents and their potential use as 
biomarkers is needed. 
 Investigate the effect of combined XIAP and cIAPs knockdown on 
TRAIL and Smac59 sensitivity.  
 Animal studies to test the in vivo effect of TRAIL and Smac59 on 
viability of HNSCC xenograft. 
 Validation of ERCC1, HIF-1α, Ku80, Rad51, PTEN and XRCC1 as 
biomarkers for radiosensitivity via a prospective study with patient 
treated with radiotherapy alone. 
 Validation of these candidate biomarkers, including testing 
overexpression/knockdown effect on response to radiotherapy using 
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